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Summary 
 
SUMMARY 
The aim of my thesis was the optimization, characterization and application of a new, 
innovative drug carrier system which can be used to target pharmaceuticals to diseased 
tissues and organs. In the present study, a non-covalent biotin-streptavidin coupling 
procedure for the preparation of pegylated immunoliposomes is presented which 
simplifies the attachment of targeting vectors to sterically stabilized liposomes. The 
OX26 monoclonal antibody against the rat transferrin receptor was used as a targeting 
vector.  
 
Immunostaining experiments with the OX26 monoclonal antibody followed by 
fluorescent confocal microscopy revealed immunofluorescence labeling of the 
transferrin receptor on muscle and on glioma cells. Uptake experiments with these cells 
demonstrated cellular uptake and accumulation of small molecules (daunomycin, 
fluorescent probes) or macromolecules such as fluorescent oligonucleotides, within an 
intracellular compartment.  
 
Cellular uptake of liposomal daunomycin by multidrug-resistant cells was dose- and 
time-dependent and was associated with a clear pharmacological (i.e. cytotoxic) effect. 
Cytotoxic effects of liposomal formulations of daunomycin, in contrast to the free drug, 
were apparent only after prolonged incubation periods being indicative of a slow 
intracellular unpacking and release of liposomal daunomycin. With respect to 
expression plasmids (i.e. gene targeting), only marginal levels of gene expression were 
observed in vitro. 
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Pharmacokinetics and tissue distribution studies in the rat revealed a substantially 
increased plasma half-live of liposomal drug compared to free drug. Brain accumulation 
of daunomycin in OX26-immunoliposomes occurred in higher levels as compared to 
brain uptake of free daunomycin or daunomycin incorporated within pegylated 
liposomes or unspecific IgG2a isotype control immunoliposomes. Such OX26-mediated 
effects were not observed in other tissues such as spleen, liver, muscle or kidney.  
Our experiments indicate that immunoliposomes can be used to target small drug 
molecules as well as macromolecules, such as oligonucleotides and expression 
plasmids, to cells and tissues.  
 
These findings demonstrate that immunoliposomes are a versatile and promising tool 
for future drug development in regard to both, galenic and therapeutical research. For 
clinical administrations, a better understanding of cellular uptake and release 
mechanisms are needed. 
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Introduction 
1 INTRODUCTION 
Drug targeting is an innovative and challenging topic in contemporary drug 
development and galenic research. The use of immunoliposomes offers a promising 
approach to improve controlled drug delivery. The molecule of interest is thereby 
incorporated into immunoliposomes that are directed by a coupled antibody against a 
defined target that is present in diseased tissues or organs. The ideal vector antibody 
exhibits specificity for one sole antigen. Therewith, liposomal drug is delivered only to 
the targeted, diseased tissue or organs and not to unintentional, not diseased sites. 
Adverse side effects are a major drawback in drug development and pharmaceutical 
research. By using immunoliposomes as a specific drug delivery system, adverse 
reactions can be circumvented or reduced. It presents an enhancement of efficacy as 
the drug is delivered completely to the sites of disease, yielding in lower required doses. 
Thus, immunoliposomes, the topic of present work, describe a promising tool for the 
targeted delivery of small drugs to organs or tissues. 
1.1 LIPOSOMES 
1.1.1 Structure 
Liposomes are vesicles in which an aqueous volume is entirely enclosed by a 
membrane composed of lipid molecules, usually phospholipids (Figure 1). 
Spontaneously formed upon dispersion in aqueous media, the size of such vesicles can 
range from tens of nanometres to tens of microns in diameter (New, 1990). In 
pharmaceutical sciences, liposomes have been used traditionally as formulation 
ingredients to assist in formulation of poorly soluble therapeutic agents for oral or 
parenteral administration. The antibiotic amphotericin B is an example of a marketed 
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drug that makes use of this formulation principle for intravenous infusion (Gulati et al., 
1998). 
 
 
Figure 1: Schematic representation of membranes: Liposome structure (left panel) and 
human cell membrane (right panel). Both of them are formed by phospholipid molecules 
that have arranged themselves to form a membrane. Under certain physical conditions 
they will spontaneously form liposomes (left panel) whose walls are very similar in 
construction to the actual cell membrane shown on the right side. 
 
 
Liposomes can contain large amounts of small molecules either within their aqueous 
interior or dissolved in the lipophilic region of their membrane bilayers (Cerletti et al., 
2000). Enzymes have no longer access to the encapsulated substance which is hence 
protected from degradation and metabolism. This is one of the reasons why such 
liposomal delivery systems acquired much attention during the last years (Storm and 
Crommelin, 1998).  
Liposomes can be made of natural constituents. Their membrane is very similar to 
natural cell membranes (Figure 1) and provides great convenience as models for 
membrane systems (New, 1990). Such naturally occurring constituents are cholesterol, 
phospholipids or fatty acids that make them a biocompatible and safe vehicle for 
medical in vivo applications. Those favourable properties can be adjusted by chemical 
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modifications of the phospholipid-bilayer membrane of the liposome. Chemical 
modifications, such as saturation or pegylation of phospholipids are well established 
and numerous possibilities are described, which results in a vast versatility and 
flexibility of such phospholipid-bilayer membrane liposomes.  
1.1.2 Pegylation of liposomes 
Pharmacokinetics of conventional liposomes, i.e. liposomes that consist of naturally 
occurring phospholipids and cholesterol, are characterized by a very high systemic 
plasma clearance. After intravenous administration, such vesicles are rapidly removed 
from the circulation by macrophages of the reticuloendothelial system, namely the liver, 
the spleen, and the bone marrow (Frank, 1993). The liposome half-life in the circulation 
can considerably be prolonged by incorporation of gangliosides (such as 
monosialoganglioside GM1 derived from bovine brain (Allen and Chonn, 1987)) or 
polyethylene glycol (PEG) derivatized lipids within the phospholipid bilayer of 
conventional liposomes (Papahadjopoulos et al., 1991; Woodle et al., 1992; Uster et al., 
1996). Conventional liposomes coated with the inert and biocompatible polymer PEG 
are often referred to as ‘sterically stabilized’ liposomes. The PEG coating is believed to 
prevent binding of opsonins from physiological fluids such as plasma, which in turn 
avoids the recognition by phagocytotic cells (Moghimi and Patel, 1992). PEG 
phospholipids are safe and can be prepared synthetically at high purity and in large 
quantities, which has led to their acceptance for clinical applications. Animal and human 
studies (Gabizon et al., 2003) have demonstrated pronounced differences with respect 
to pharmacokinetic parameters between conventional and sterically stabilized PEG-
liposomes: in humans, pegylation of liposomes resulted in a 50-fold decrease in plasma 
volume of distribution to a value similar to the plasma volume (from 200 to 4.5 liters), a 
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200-fold decrease in systemic plasma clearance (from 22 to 0.1 l/hour) and a nearly 
100-fold increase in area under the time-concentration curve (Allen, 1994a). The 
apparent terminal half-life of PEG-liposomes reached up to 90 h in humans (Gabizon et 
al., 2003). The extended circulation half-life of sterically stabilized liposomes in 
combination with an increased permeability of tumor vasculature results in passive 
accumulation of PEG-liposomes in solid end-stage tumors (Gabizon and 
Papahadjopoulos, 1988). This principle of passive targeting to tumor tissue has been 
applied to commercial formulations of doxorubicin used for the chemotherapy of 
malignant Kaposi’s sarcoma or breast cancer (Gabizon, 2001). 
Aside from the effects described above, pegylation of liposomes offers an additional 
advantage. As it has been shown several times, incorporation of PEG derivatized lipids 
within the phospholipid bilayer provides liposomes with an enhanced stability (Allen, 
1994b; Kirpotin et al., 1996; Mori et al., 1991). The underlying mechanism is in 
particular inhibition of membrane fusion, whereat PEG acts on three independent 
levels: First, inhibition of phospholipase C-induced liposome fusion, second, prevention 
of membrane apposition and third, stabilization of the lamellar phase (Basanez et al., 
1997). These effects may act together and lead, along with formerly discussed items, to 
a remarkably enhanced lifetime of liposomal carrier systems in vivo.  
1.2 IMMUNOLIPOSOMES 
1.2.1 Targeting using immunoliposomes: a new technology 
Long-circulating, sterically stabilized PEG-liposomes show minimal interactions with 
cells in vitro and not diseased tissues and organs in vivo and can be considered to be 
neutral and inert carriers for encapsulated molecules. They therefore provide a 
biologically inert and safe platform for the design of drug delivery systems. The organ 
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and tissue distribution of sterically stabilized liposomes can be modulated by 
conjugation of an appropriate targeting vector. Examples of such vectors include 
proteins, peptides, and small molecules such as the vitamin folate, which was used to 
target folate-receptor overexpressing tumor cells (Goren et al., 2000; Lee and Low, 
1994). Pharmacokinetics therefore largely depend on the nature of the coupled 
targeting vector. Only the attachment of certain specific ligands makes liposomes 
targeted. Protein-conjugated liposomes have attracted a great deal of interest, 
principally because of their potential use as targeted drug delivery systems (Heath et 
al., 1983; Leserman et al., 1981) and in diagnostic applications (Kung et al., 1986; 
O'Connell et al., 1985). Examples of vectors include proteins such as Staphylcocus 
aureus protein A (Leserman et al., 1981), plant lectins and enzymes (Shek and Heath, 
1983). However, the most commonly conjugated proteins are antibodies that lead to the 
denomination of “immunoliposomes”, represented schematically in Figure 2.  
 
Linker
 
Figure 2: Schematic representation of an immunoliposome-based delivery system for 
in vitro and in vivo drug targeting. The design of immunoliposomes combines four 
different functional units responsible for steric stabilization in vivo, encapsulation of 
drug, targeting and linkage of a receptor-specific monoclonal antibody. 
Immunoliposomes are prepared by attachment of monoclonal antibodies via linker 
molecules to pegylated liposomes. PEG, polyethylene glycol. 
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Immunoliposomes consist of four different functional units:  
a) The inert and biocompatible PEG derivatized lipids incorporated in the 
phospholipid bilayer membrane of the liposome which provide steric stabilization 
or coating of the liposome surface.  
b) The liposome itself, acting as a container for several thousand molecules that 
can be incorporated.  
c) The linker molecule in order to combine steric stabilization of liposomes with 
efficient immuno-targeting by attaching a cell-specific ligand to the distal end of 
a few lipid-conjugated and in liposome bilayer anchored PEG molecules. 
d) The vector itself, responsible for the specific delivery. 
With respect to brain drug delivery vectors, modified proteins or antibodies are used 
that undergo absorptive-mediated or receptor-mediated transcytosis through the blood-
brain barrier. Examples of brain targeting vectors include cationized albumin, the OX26 
monoclonal antibody to the rat transferrin receptor, or monoclonal antibodies to the 
insulin receptor (Pardridge, 1993; Wu et al., 1997). 
Site-specific delivery of drugs to diseased cells can lead to increased therapeutic 
effects and to significant reductions of toxicity. Drug targeting by antibody-conjugated 
liposomes or immunoliposomes (Heath et al., 1980) represents a technology which has 
been applied for the targeting of specific sites of drug action such as the brain (Huwyler 
et al., 1996), lungs (Maruyama et al., 1990a), cancer cells (Allen et al., 1995; Emanuel 
et al., 1996; Kirpotin et al., 1997; Moradpour et al., 1995; Nassander et al., 1992; 
Suzuki et al., 1995a), HIV-infected cells (Gagne et al., 2002; Zelphati et al., 1993) or 
cells of the immune system (Dufresne et al., 1999). Site-specific targeting is in particular 
mediated by the high affinity binding of monoclonal antibodies, i.e. the targeting vectors, 
to their specific antigens. The efficacy of the method depends first, on the target 
specificity of the vector and, second, on the cellular uptake and intracellular delivery of 
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the liposomal load. In addition, a sufficient stability in the circulation is in equal measure 
an essential requirement of those methods.  
1.2.2 Targeting of small molecules – state of the art 
Immunoliposome-based drug delivery systems are of special interest for targeting of 
molecules that can not be coupled directly to a transport vector. This can be small 
drugs that have to achieve micromolar concentrations in a target tissue to reach a 
pharmacological effect (Carlsson et al., 2003; Wang and Low, 1998). Possible 
indications are the chemotherapy of neoplastic diseases as liposomal formulations of 
anthracycline antibiotics are often characterized by quantitative encapsulation and 
retention in liposomes (Lasic, 1996). The first clinical application of antibody-conjugated 
liposomes was a recent phase I trial in oncology (Matsumura et al., 2004). Doxorubicin 
encapsulated in long-circulating PEG-immunoliposomes was administered by 1-h 
infusions every 3 weeks in raising dose levels to 23 patients with metastatic or recurrent 
stomach cancer. The duration of the treatment period was between 48 and 135 days. 
The used targeting vector was a F(ab’)2 fragment of a cancer-reactive human 
monoclonal antibody (GAH), which showed high binding (with a positive ratio of > 90 %) 
to cells obtained from cancerous stomach tissues (Hosokawa et al., 2003). The 
antibody was grafted by a post-insertion method to the surface of PEG-liposomes. 
Stable disease (but no antitumor response) was observed in 10 out of 18 evaluable 
patients with a tolerance similar to Doxil, a doxorubicin formulation based on pegylated 
liposomes (Gabizon et al., 1994). This study is an impressive demonstration of the 
technical feasibility of the clinical application of antibody-conjugated liposomes. 
However, the pharmacological efficacy of this particular design of immunoliposomes 
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(where the antibody was conjugated to the surface of the liposome and not to the tip of 
the PEG chains) remains to be shown.  
In addition to therapeutic applications, a possible future application of 
immunoliposomes might include their use as diagnostic tools to localize, for example, 
tumor tissue (Gabizon et al., 1994) or amyloid plaques in Alzheimer’s Disease (Kurihara 
and Pardridge, 2000; Lee et al., 2002). Such applications rely on brain delivery of 
quantitative amounts of contrast agents such as magnetoferritin (Bulte et al., 1994) or 
gadolinium (Arnold and Matthews, 2002). Recent in vivo studies using a C6 glioma rat 
brain tumor model indicate that liposomal gadolinium might indeed be used for the 
visualization of tumor tissue by in vivo magnetic resonance imaging (MRI) (Saito et al., 
2004). In these studies, gadolinium loaded liposomes were delivered to tumor tissue by 
convection-enhanced delivery, an invasive technique where drugs are infused under 
pressure into brain white matter (Bobo et al., 1994). 
1.2.3 OX26 and the transferrin receptor 
The murine monoclonal antibody to the rat transferrin receptor, the OX26 mAb, 
conjugated to pegylated liposomes, was used in first attempts to use liposomes for 
brain targeting (Huwyler et al., 1996). OX26 is shown to trigger receptor-mediated 
transcytosis through the blood-brain barrier upon binding to its target, the transferrin 
receptor, which mediates endocytosis of iron bound to the plasma glycoprotein 
transferrin. The transferrin receptor is a cell membrane-associated glycoprotein that 
serves as a gatekeeper in regulating cellular uptake of iron from transferrin, a plasma 
protein which transports iron in the circulation (Richardson and Ponka, 1997). Cellular 
iron uptake from transferrin is reasonably well understood, and involves the binding of 
transferrin to the transferrin receptor, internalization of transferrin within an endocytotic 
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vesicle by receptor-mediated endocytosis, and the release of iron from the protein by a 
decrease in endosomal pH (Ponka and Lok, 1999). It is a frequent statement in 
literature that only proliferating cells express the transferrin receptor excessively. 
However, there are many examples of non-proliferating cells that show high transferrin 
receptor expression, such as endothelial cells of the blood-brain barrier, Sertoli cells of 
the blood-testis barrier, hepatocytes, and trophoblast cells of the hemochorial type of 
placenta (Ponka and Lok, 1999).  
The model of how transferrin receptors function in mediating cellular uptake of iron from 
transferrin is reproduced from Ponka and Lok (Ponka and Lok, 1999) and shown in   
Figure 3. 
 
Figure 3: Schematic representation of iron uptake from transferrin via receptor-
mediated endocytosis in mammalian cells. Tf, transferrin; TfR,l transferrin receptor. 
 
 
(1) In the first step, transferrin (Tf) attaches to the receptors on the cell surface by a 
physicochemical interaction. Bound transferrin receptor (TfR) complexes then cluster 
into clathrin-coated pits; (2) the transferrin receptor complexes, enclosed within 
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endocytic vesicles, are internalized by the cells. Transferrin receptor containing 
endosomes are diverted from lysosomes and this deflection prevents receptor 
degradation; (3) iron is released from transferrin within the endocytic vesicles. The low 
pH in endosomes (approximately 5.3) is conductive to iron release; (4) iron released 
from transferrin is then transported through the endosomal membrane; (5) the iron free 
apotransferrin, which remains attached to the receptor at pH ~5.5, returns to the cell 
surface, where the apotransferrin is released from the cells. Iron that is taken up by the 
cell can be used for metabolic functioning or it can be stored in ferritin.  
Transferrin receptors are expressed in all cells, but their expression levels vary greatly 
(Ponka and Lok, 1999). On cells such as RBE4 cells, a receptor density of 
approximately 70000 receptors per cell has been described (Huwyler et al., 1999). 
Receptor mapping studies using different antibodies to the human transferrin receptor 
have demonstrated binding to different organs and tissues in cynomolgus monkeys 
(Friden et al., 1996). The highest percentage of the injected dose of antibody was found 
in the brain where it bound almost exclusively to the parenchyma, indicating 
transcytosis over the blood-brain barrier. Quite interestingly, skeletal muscle as well 
showed a very high accumulation of antibody, compared to other tissues (Friden et al., 
1996).  
The OX26 monoclonal antibody was shown before to achieve a high degree of brain 
delivery. Following a single intravenous injection, 0.26 % of the injected dose per gram 
can be found in brain tissue at 60 min (Bickel et al., 1993) as a result of both a high 
blood-brain barrier PS product (i.e. blood-brain barrier permeability) as well as high 
plasma AUC (area under the curve) of the antibody. Using the internal carotid artery 
brain perfusion and capillary depletion technique (Triguero et al., 1990), it could be 
shown that the OX26 monoclonal antibody is transported across the blood-brain barrier 
by receptor-mediated transcytosis (Friden et al., 1996; Pardridge et al., 1991). In vivo, 
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brain uptake of the OX26 monoclonal antibody is not inhibited by endogenous 
transferrin despite the saturation of the BBB transferrin receptor (which has a KD of 6 
nM) by the micromolar transferrin concentrations in plasma (Pardridge et al., 1987). 
This is due to the fact that the antibody recognizes a binding site on the transferrin 
receptor which is distant to the one of the natural ligand transferrin (Pardridge, 1995b).  
 
Based on these findings, we decided to explore if the OX26 mAb to the rat transferrin 
receptor would bind to rat skeletal muscle, and if this antibody subsequently could serve 
as a targeting vector in a novel design of biotinylated immunoliposomes. 
1.2.4 Antibody conjugation 
Different types of coupling strategies have been developed to attach proteins to 
phospholipids or pegylated phospholipids while preserving their biological activity. 
Covalent coupling to phospholipids can be achieved using amino-reactive 
homobifunctional cross-linkers (Hermanson, 1996; Torchilin et al., 1978) for example. 
Water-soluble carbodiimides can be used to catalyze the formation of an amide linkage 
between amines of the phospholipid headgroups and carboxyl moieties of proteins 
(Dunnick et al., 1975). Thiolated F(ab’)2 fragments and maleimidated 
phosphatidylethanolamine (Martin and Papahadjopoulos, 1982; Suzuki et al., 1995b) 
can be linked by disulfide bonds. A major drawback of the direct coupling of proteins to 
the liposome surface is the observation that the PEG chains may have a strong 
shielding effect that prevents the interaction between the bound receptor ligand and its 
receptor (Kaasgaard et al., 2001). In a liposome agglutination assay, as little as 0.72 
mol % of PEG5000-phosphatidylethanolamine (PEG molecular mass 5000 Da) 
completely abolished the interaction between phospholipid-bound biotin and 
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streptavidin (Klibanov et al., 1991). The shielding effect also reduced target binding in 
vivo of immunoliposomes by up to 50 % and was highly dependent on PEG chain 
length (Mori et al., 1991). The effect of pegylation was less pronounced or not present 
for PEG molecular masses of 2000 or 750 Da.  
As opposed to direct coupling to the phospholipid headgroup region on the liposome 
surface, ligands can be attached at the terminus of the PEG chains (Figure 4 A and 3 
C). Thus, PEG is used as a spacer that results in a better accessibility and flexibility of 
the vector (Allen et al., 1995; Maruyama et al., 1995; Shahinian and Silvius, 1995). By 
this strategy, the immunoliposome target binding efficiency increases by a factor of two 
to three as well in vitro (Bendas et al., 1999) as in vivo (Maruyama et al., 1995). The 
PEG interactions associated with different coupling strategies and the dimensions of an 
immunoliposome are visualized in Figure 4.  
 
 
Figure 4: Schematic representation of a pegylated immunoliposome where the 
antibody is bound directly to the liposome surface (A) or to the distal tip of the PEG 
chains (C). The relative sizes are representative for a 80 nm liposome decorated with 
PEG2000 (PEG of molecular weight 2000 Da). When attached to the liposome surface, 
steric hindrance between the PEG chains in their coiled (A) as well as extended (B) 
conformation and the antigen-recognition site of the antibody can be expected. 
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The minimal size of a unilamellar liposome is determined by the maximal tolerated 
proximity of the phospholipid headgroups imposed by the curvature of the inner leaflet. 
This minimal size is approximately 80 nm for liposomes that have as main constituents 
lecithin-analogs and cholesterol (New, 1990). Approximately 30 % of the inner volume 
of a 80 nm liposome are occupied by the phospholipid bilayer which thickness 
represents 4 - 5 nm. The hydrophilic PEG2000 corona has a thickness of 5 nm as shown 
by electron microscopy (Bendas et al., 1999). By the same technique, the apparent 
dimensions of an antibody are determined to be in the range of 10 - 15 nm. Direct 
measurement of PEG tethered ligand-receptor interaction potentials confirms a 
thickness of 5 nm for PEG2000 in its coiled state (Figure 4 A) and an overall length of an 
extended PEG2000 chain of 15 nm (Wong et al., 1997) (Figure 4 B). These 
considerations emphasize that a corona of PEG2000 substantially blocks the access of a 
surface-bound antibody to its epitope. This steric hindrance will further increase using 
PEG molecules of higher molecular weights. 
Different techniques have been developed for the covalent binding of proteins to 
pegylated phospholipids by cleavable (i.e. disulfide) or metabolically stable (i.e. 
thioether, amide, or imide) linker strategies (Hansen et al., 1995; Huwyler et al., 1996; 
Maruyama et al., 1995; Shahinian and Silvius, 1995). In general, the choice of a specific 
coupling procedure is guided by practical considerations such as coupling efficiency 
and the need to retain the antigenicity of the coupled antibody despite the introduced 
chemical modifications. The target recognition by the coupled antibody may also 
depend on the orientation (i.e. random or defined) of the antibody or a Fab’ on the 
liposome surface and the resulting accessibility of the antibody binding sites to their 
respective epitopes (Allen et al., 2002).  
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Covalent binding protocols rely generally on chemical reactive PEG phospholipid 
derivatives which are part of the phospholipid/cholesterol mix used for the synthesis of 
the PEG-liposomes. The liposomes are loaded with the drug, reduced in size and 
purified before the actual coupling procedure is performed by addition of the vector. The 
latter may undergo a chemical modification (i.e. chemical introduction of functional 
groups) before use. The disadvantage of such protocols is the observation that the 
efficiency of the coupling procedure is very difficult to control due to competing 
(hydrolytic) reactions. 
In attempts to develop more reproducible and flexible coupling procedures that may be 
used for the large-scale production of immunoliposomes, alternative methods have 
been recently introduced (Iden and Allen, 2001; Tan et al., 2003).  
Iden et al. (Iden and Allen, 2001) developed a postinsertion technique that involves the 
coupling of ligands to the terminus of PEG lipid derivatives in a micellar phase. At a 
later time point, the ligand-coupled PEG lipids are transferred into the bilayers of 
preformed liposomes during a simple incubation step (1 hour at 60°C). The final product 
is purified by size exclusion chromatography (SEC). Therapeutic effect, cytotoxicity and 
binding of immunoliposomes prepared by the postinsertion technique were comparable 
to the ones of immunoliposomes made by a conventional coupling technique (Allen et 
al., 2002).  
In the present work the OX26 murine monoclonal antibody (mAb) to the rat transferrin 
receptor (Jefferies et al., 1985) has been used as vector. As mentioned, this antibody 
has been shown to bind to an extracellular epitope on the receptor, at a site removed 
from the transferrin binding site (Pardridge, 1995b). In cultured cells, such as the RG2 
rat glioma cell line, the immortalised rat brain capillary endothelial RBE4 cell line, and 
the L6 cell line derived from rat skeletal muscle, receptor mediated endocytosis and 
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thus intracellular accumulation of the OX26 mAb as well as OX26 conjugated liposomes 
is observed (Huwyler et al., 1997).  
We presented in this work a new coupling procedure for the preparation of pegylated 
immunoliposomes. A biotinylated PEG phospholipid (bio-PEG-DSPE) is used for a non-
covalent (biotin-streptavidin) method of attachment of the OX26 mAb to sterically 
stabilized liposomes (Schnyder et al., 2004). 
 
1.3 NON-COVALENT STREPTAVIDIN-BIOTIN BINDING METHOD  
 
We have designed a linker lipid, DSPE-PEG-biotin (distearoylphosphatidylethanolamin-
PEG-biotin), based on a common phospholipid with two (saturated) fatty acids 
(stearoyl). The phosphatidyl moiety was linked to a PEG molecule and a biotin 
molecule, being attached on its tip (Figure 5 B). This biotinylated linker lipid was 
introduced into the liposome lipid-bilayer during fabrication. Preformed and purified 
biotin-PEG-liposomes are subsequently simply mixed with the streptavidin-conjugated 
antibody to result immediately in a quantitative coupling. The biotin-streptavidin 
interaction is among the strongest non-covalent affinities known and is characterized by 
a dissociation constant of about 1.3 x 10-15 M. One streptavidin molecule has four biotin 
binding sites. Consequently, excess binding sites on the streptavidin molecule need to 
be blocked by free biotin to avoid cross-linking and thus aggregation of the biotinylated 
immunoliposomes. The biotin is coupled at the PEG terminus that allows optimal target 
recognition of the bound mAb (Figure 5 A). Coupling of a streptavidin-conjugated 
antibody is simple, rapid and highly reproducible. Streptavidin conjugated OX26 mAb 
was used since streptavidin has a much lower isoelectric point (pI 5 - 6) as compared to 
the highly basic pI of 10 of avidin.  
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In addition, streptavidin is not a glycoprotein and that reduces its potential for binding to 
carbohydrate receptors (Hermanson, 1996). Both factors reduce the amount of 
nonspecific binding and thereby the systemic clearance in vivo (Kang and Pardridge, 
1994). 
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Figure 5: Preparation of OX26-immunoliposomes by coupling of streptavidin-
conjugated OX26 mAbs to biotinylated PEG-liposomes (A), and chemical structure of 
bio-PEG-DSPE, the biotinylated linker phospholipid (B). There are approximately 5500 
strands of PEG of molecular mass 2000 Da attached to the liposome surface, of which 
approximately 30 carry a biotin group at their distal end. SA, streptavidin. 
 
1.4 LOADING OF LIPOSOMES 
 
The use of immunoliposomes as drug delivery systems requires adequate techniques 
for the generation of unilamellar vesicles and for the encapsulation of drugs and 
macromolecules. With respect to drug loading, several methods have been described. 
Whereas first attempts relied on passive entrapment methods with low loading 
efficiencies. Recent methods make use of more efficient strategies such as loading by 
transmembrane ion gradients (i.e. a pH or specific salt gradient).  
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Passive entrapment can be done by hydration of dried phospholipids. Liposomes are 
prepared in presence of the molecule of interest followed by purification of the 
liposomes and their separation from nonincorporated material by gel-filtration 
chromatography (Torchilin and Weissig, 2003). Lipophilic or amphiphilic drugs will 
thereby partition into the lipid bilayer which leads to a quantitative and efficient loading 
of the liposomes.  
 
 
 
Figure 6: Nomogram relating theoretical captured volume, diameter, number, area, and 
lipid weight of unilamellar liposomes. To read the nomogram, two known parameters 
are connected by a straight line and the unknown parameter where this line intersects 
the third scale is read off. The calculation is based on the assumption that the 
phosphatidyl choline headgroup occupies an area of the membrane bilayer of 42 Ǻ2. 
Note: the smallest possible diameter for an unilamellar liposome is on theoretical 
grounds 25 nm. 
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For water-soluble compounds, which partition into the aqueous phase of the lumen of 
the liposome, the amount of entrapped drug is directly proportional to the initial drug 
concentration used in the incubation mix and the total inner volume of the resulting 
liposomes. The latter depends on liposome diameter, and lipid concentration and can 
be related to these parameters using a nomogram (Figure 6) (New, 1990). Because the 
inner volume of liposomes represents only a small percentage of the whole liposome 
suspension, the efficiency of this method is low and a considerable amount of 
(expensive) material is not incorporated and therefore lost. This can be illustrated based 
on theoretical considerations with the help of the nomogram in Figure 6: liposomes with 
a diameter of 100 nm that are prepared using 4 mg of lecithin will have an outer surface 
of 1.2 m2. These 6 x 1013 liposomes will capture a theoretical volume of as little as 15 µl. 
One single 100-nm liposome will be made up of approximately 150000 phospholipid 
molecules assuming that the phosphatidyl choline headgroup occupies an area of the 
membrane bilayer of 42 Ǻ2. 
 
The loss of hydrophilic biological macromolecules such as proteins, plasmids and 
enzymes during the passive loading process can be reduced using highly concentrated 
liposomal solutions. Solutions of preformed liposomes are thereby concentrated by 
ultrafiltration or partial lyophilization. The molecule of interest is added and incorporated 
into the liposomes by several freeze-thaw cycles. The freezing and thawing is used to 
rupture and re-fuse the liposomes, during which time the solute equilibrates between 
the inside and outside. This method has been used recently. For example, to 
incorporate DNA into neutral liposome formulations (Shi and Pardridge, 2000). 
Disadvantages of this method are the poor entrapment stability (i.e. leakage of the 
encapsulated molecules after dilution and purification of the liposomes) and influences 
on size and heterogeneity of the preformed liposomes (Lasic et al., 1995).  
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The remote (active) loading of drug molecules into preformed liposomes is generally a 
very efficient loading technique and can result in a sustained incorporation of small 
molecules. The underlying principle is the use of pH or ion gradients to create an 
electrochemical potential across the phospholipid-bilayer of the liposome that in turn 
leads to active uptake and entrapment of a given drug within the liposome. The gradient 
is generated by a two-step process: after preparation of liposomes in a buffer of a 
certain pH and ion strength, the external medium is exchanged by size exclusion 
chromatography (Goren et al., 2000; Hwang et al., 1999; Lasic et al., 1995). This 
method has been applied with success to small, weakly basic molecules such as 
doxorubicin and vincristine. Under appropriate conditions, they precipitate as a gel 
within the liposome (Lasic et al., 1995). This leads to quantitative uptake with 
incorporation efficiencies approaching 100 % as well as a stable retention within the 
liposome. It is important to note that the use of such liposomal formulations greatly 
enhances the carrying capacity of the coupled vector. For example, approximately 
28000 small molecules of daunomycin can be packed within a single 100-nm liposome 
and can be directed to a target tissue using just a few conjugated antibodies (Huwyler 
et al., 1996). Thus, antibody to drug ratios of 1000 are possible using 100-nm 
immunoliposomes. This value is in sharp contrast to the 1:1 ratios obtained by 
individual attachment of drugs to a targeting vector (Pardridge, 1995b). 
In general, the choice, the optimization, and the validation of a specific loading 
technique may be a complex problem depending on the physico-chemical properties of 
a given drug. To assess suitability of a liposome-based drug delivery system for in vivo 
use, careful in vitro tests should be performed to evaluate loading efficiency, loading 
capacity and stability of entrapment upon large dilutions in physiological fluids. 
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1.5 CLINICAL USE OF IMMUNOLIPOSOMES 
 
Recent phase I clinical trials with immunoliposomes (Matsumura et al., 2004) 
demonstrate that liposome-based targeting technologies have the potential to find their 
way from the bench to the bedside. Formulations of pegylated liposomes have been on 
the market for many years. We now have the technologies at hand (using efficient 
coupling strategies for vectors such as post-insertion techniques (Allen et al., 2002) and 
biotin-streptavidin coupling strategies (Schnyder et al., 2004)) to expand the use of 
such liposomal formulations to the targeted delivery of drugs to organs and tissues. 
Once produced, liposomal formulations should be applied immediately or within short 
periods of time to minimize leakage of the liposomal content. As discussed earlier, 
remote loading techniques are available for selected drugs which are characterized by 
high loading efficiencies and a stable retention of the transported drug within the 
liposomal carrier. However, loading of peptides, plasmids and DNA is in general still 
problematic and expensive due to the low efficiency of entrapment.  
Lyophilization may be an alternative to stabilize liposomal formulations and to minimize 
storage in a dissolved and diluted state. A formulation kit for doxorubicin composed of 
lyophilized liposomes was developed recently by Stevens et al. (Stevens and Lee, 
2003), providing a strategy to expand the shelf-life of liposomal formulations. 
With respect to any targeting of liposomes, the success of this as well as any other 
physiological and non-invasive targeting strategy will depend on the availability of 
efficient and specific targeting vectors. For instance in the field of brain targeting, there 
does not exist an ‘ideal’ brain vector to date. Such a molecule would have to recognize 
a target which is expressed exclusively at the brain capillary endothelium, would not 
compete with endogenous ligands, and would be transported with high efficiency across 
the blood-brain barrier by receptor-mediated transcytosis. The transferrin receptor, to 
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name a well characterized example, is expressed in several other organs than the 
brain. As a consequence, targeting of immunoliposomes coupled to anti-transferrin 
receptor antibodies is not confined solely to the brain. Other organs such as the liver 
(Huwyler et al., 1997) or skeletal muscle (Schnyder et al., 2004) are recognized as well. 
It is therefore tempting to speculate that in the future the design of immunoliposomes 
using alternative brain delivery vectors (such as antibodies directed at the insulin 
receptor) (Slepushkin et al., 1997; Stevens and Lee, 2003) might allow for higher 
targeting efficiencies bringing this technology to its full potential. 
 
1.6 GENE TARGETING 
 
Gene therapy is a promising technique for correcting defective genes responsible for 
certain diseases. This technique has attracted more and more attention in the last few 
years. One of the most challenging difficulties dealing with this advanced therapeutic 
strategy is how to bring a certain gene to the desired site of action and, within the target 
tissue to the nucleus of a diseased cell. However, due to limits of current technology, 
this is a very ambitious goal. Above all, it is very difficult to deliver a gene exclusively to 
the site of disease in order to reduce side effects and exposure to healthy tissue. This is 
of special importance when it comes to the treatment of CNS diseases.  
Past strategies have often used direct intracerebral implantation of a therapeutic gene 
by means of a viral vector, such as adenovirus or herpes simplex virus. However, this 
provokes an inflammatory response and demyelination in many animals and virtually all 
humans (Herrlinger et al., 1998; Kajiwara et al., 2000). The incorporation of DNA in the 
interior of stealth immunoliposomes would therefore inhibit such immune reactions due 
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to viral antigens and, additionally, prevent supercoiled plasmid DNA from degradation 
by ubiquitous nucleases in vivo.  
Complexes between cationic lipids and DNA are often used to transfect cultured cells or 
tissues. An application of this technology for in vivo gene delivery is problematic 
because DNA-cationic liposome form micrometer-scale aggregates, particularly at lipid 
to DNA ratios where the overall charge of the complex is neutral (Radler et al., 1997). 
As a consequence, their pharmacokinetics and tissue distribution is characterized by a 
very short plasma half-live (i.e. a few minutes in a mouse) and an unspecific 
accumulation in different organs (Osaka et al., 1996). Microautoradiography of tissue 
samples at 24 h after injection of cationic lipid-DNA complexes revealed uptake of 
expression-plasmid DNA in cells of the reticuloendothelial system, i.e. alveolar 
macrophages, hepatic Kupffer cells, and macrophages of the spleen. DNA uptake per 
tissue occured in this, as well as in other studies, significantly higher in the lung (up to 
1000 fold) than in the liver or spleen (Liu et al., 1997). It is tempting to speculate that 
the efficient transfection of lung tissue might be a direct consequence of quantitative 
first-pass filtration of particulate DNA-lipid aggregates in the lung. 
An alternative to DNA/cationic liposome complexes is the use of neutral liposome 
formulations. The DNA is thereby encapsulated within the liposome. The neutral 
liposome can be pegylated and subsequently coupled to a targeting vector. Such a 
targeted gene delivery system is characterized by a high stability of the encapsulated 
DNA under physiological conditions and a prolonged circulation half-life in vivo (Shi and 
Pardridge, 2000; Zhang et al., 2002a). Several studies have demonstrated that 
exogenous gene expression in the brain can be achieved using such a gene-delivery 
system: Shi et al. (Shi et al., 2001a; Shi and Pardridge, 2000) incorporated an 
expression plasmid coding for either β-galactosidase or luciferase in the interior of 
pegylated OX26-immunoliposomes. In vivo gene expression was shown at 2 - 6 days 
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after a single intravenous administration. Similar expression plasmids were 
incorporated into PEG-immunoliposomes which were targeted to the rhesus monkey 
brain in vivo with a monoclonal antibody to the human insulin receptor (HIR) by Zhang 
et al. (Zhang et al., 2003b). Widespread neuronal expression of the β-galactosidase 
gene in primate brain was demonstrated after 48 hours (Figure 7).  
 
 
Figure 7: β-galactosidase histochemistry of brain removed from either the HIRmAb-
immunoliposomes injected rhesus monkey (A and C) or the control, uninjected rhesus 
monkey (B). The plasmid DNA encapsulated in the immunoliposomes is the pSV-β-
galactosidase expression plasmid driven by the SV40 promoter. (A) Reconstruction of 
the 2 halves of a coronal section of the forebrain. (C) Half-coronal sections through the 
primate cerebrum and a full coronal section through the cerebellum; the sections from 
top to bottom are taken from the rostral to caudal parts of brain. All specimens are β-
galactosidase histochemistry without counter-staining. The magnification in panels A 
and B is the same and the magnification bar in panel A is 3 mm; the magnification bar 
in panel C is 8 mm. HIRmAb, monoclonal antibody to human insulin receptor. 
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The tissue specificity of gene expression in a given target tissue can be further 
enhanced by the combined use of such a gene targeting technology and tissue-specific 
gene promoters. In a recent study (Shi et al., 2001b), β-galactosidase exogenous 
expression plasmids under the control of either the unspecific simian virus 40 (SV40) 
promoter or by a brain-specific promoter (taken from the 5’ flanking region of the GFAP 
gene), were incorporated in pegylated immunoliposomes and injected intravenously into 
mice. The used targeting vector was a monoclonal antibody against the mouse 
transferrin receptor (8D3 mAb). The expression in mice of the β-galactosidase gene 
was restricted to brain tissue in experiments where the β-galactosidase gene was under 
the control of the brain-specific GFAP promoter.  
In contrast, immunoliposomes loaded with expression plasmids controlled by the 
unspecific SV40 promoter caused β-galactosidase expression in all transferrin receptor 
rich organs, i.e. brain, liver, spleen and lung. Several studies indicate that gene 
expression in the brain following immunoliposome-based gene therapy may translate to 
pharmacological effects in vivo. OX26-immunoliposomes were used to normalize 
tyrosine hydroxylase activity in an animal model of Parkinson’s disease (Zhang et al., 
2003a), which did result in reversal of apomorphine-induced rotation behavior in 6-
hydroxydopamine-lesioned rats.  
In another study, the immunoliposome-mediated gene targeting technology was used 
for brain delivery of a therapeutic gene in a human brain tumor model consisting of scid 
mice implanted with intracranial U87 human glial brain tumors (Zhang et al., 2004). The 
expression plasmid did encode a short hairpin RNA directed at a nucleotide sequence 
within the human epidermal growth factor receptor (EGFR). The used targeting vectors 
were the murine 83-14 mAb to the human insulin receptor and the rat 8D3 mAb to the 
mouse transferrin receptor. This intravenous RNA interference gene therapy resulted in 
silencing of EGFR expression in tumor cells both in vitro as well as in vivo leading to a 
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significant increase in survival time of mice with implanted brain tumors. The 
pharmacological effect on brain cancer cells in vivo provides evidence that 
macromolecules such as plasmid DNA can be delivered across consecutive series of 
biological barriers that included in the discussed gene therapy studies the blood-brain 
barrier, the plasma membrane of the target cells within the brain tissue and the nuclear 
membrane (Zhang et al., 2003b). 
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2 AIMS OF THE THESIS 
Specific drug delivery using immunoliposomes is an innovative promising approach to 
target pharmaceuticals to diseased tissues and organs. It was the aim of the work 
presented here:  
 
1. To optimize and characterize an immunoliposome based drug delivery system using 
a novel antibody linker technology.  
 
2. To test in vitro uptake of drugs incorporated within immunoliposomes by specific 
target cells, such as rat muscle cells or rat glioma cells. The transported drugs can be 
small molecules or macromolecules such a DNA plasmids for gene therapy.  
 
3. To investigate uptake, intracellular fate and endosomal release of the liposomal 
carrier system, using technologies such as confocal microscopy, ESR spectroscopy, 
molecular biological and biochemical methods.  
 
4. To determine if such a delivery translates to a pharmacological effect in vitro by 
incorporating a cytotoxic substance (daunomycin) or an expression plasmid into the 
immunoliposomal carrier system. 
 
5. To characterize in vivo the pharmacokinetics and tissue distribution of this 
immunoliposome based drug delivery system after i.v. injection into the rat. 
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3 MATERIALS AND METHODS 
3.1 MATERIALS 
 
Dioleoylphosphatidylethanolamin (DOPE), Cholesteryl hemisuccinate (CHEMS), 1-
palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (POPC), Cholesterol, and Distearoyl-
phosphatidylcholine (DSPC) were from Sigma (St. Louis, MI). Pegylated distearoyl-
phosphatidylethanolamine (PEG-DSPE) was purchased from Avanti Polar Lipids 
(Alabaster, AL). Didodecyldimethylammoniumbromide (DDAB), was from Fluka Chemie 
(Buchs, CH). For conjugation of the OX26 mAb to the liposome, a biotin-derivatized 
linker lipid was used which consists of a bifunctional 2000-Da polyethylene-glycol 
(PEG) that contains a lipid on one end (distearoylphosphatidylethanolamine (DSPE)) 
and a biotin molecule at the other end. Biotinylated PEG-DSPE (bio-PEG-DSPE) was 
custom synthesized by Shearwater Polymers (Huntsville, AL). 5(6)-Carboxyfluorescein 
was purchased from Acros Organics (Geel, Belgium), Sephadex G-75 and Sephacryl S-
200 High Resolution were from Amersham Pharmacia Biotech (Uppsala, Sweden). 
Cy2-conjugated secondary antibody was from Jackson Laboratories (West Grove, PA). 
Biotin-labeled with flourescein was from Pierce (Rockford, IL). The IgG2a anti-rat 
transferrin receptor OX26 monoclonal antibody (MRC OX-26) (Jefferies et al., 1985) 
was harvested from cell-culture supernatants of the OX26 hybridoma cell line and was 
purified by protein G Sepharose affinity chromatography as described (Kang and 
Pardridge, 1994). The OX26 mAb was thiolated using 2-iminothiolane (Traut's reagent) 
(Sigma) as described previously (Huwyler et al., 1996) by conversion of one primary 
amine per mAb and then linked to streptavidin (Sigma) by activation of the latter with m-
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) (Pierce, Rockford, IL). Unspecific 
mouse IgG2a isotype monoclonal antibody was from Sigma. (Yoshikawa and Pardridge, 
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1992). The protein concentration was quantified by the Pierce BCA Protein Assay 
(Pierce, Rockford, IL) using bovine serum albumin (Sigma, St. Louis, MO) as reference. 
Equipment for electrophoresis, such as Novex® 4 - 20 % Tris-Glycine polyacrylamide 
gels, pre-stained protein standard SeeBlue Plus2, running buffer, reducing and non-
reducing buffer and the XCell II Mini Cell electrophoresis apparatus were from 
Invitrogen (Carlsbad, CA). The GelCode® Blue Stain Reagent was from Pierce 
(Rockford, IL). Centrifree® MPS micropartition devices for separation of biotin bound to 
OX26 mAb from free biotin, were from Millipore (Bedford, MA) and [3H]Biotin was from 
Amersham Pharmacia Biotech. [3H]Daunomycin (16 Ci/mmol) was from PerkinElmer 
Life Sciences (Wellesley, MA). Daunomycin was from Merck (Darmstadt, FRG). The 
Bright-Glo™ Luciferase Assay System and luciferase expression vectors were from 
Promega (Madison, WI). β-galactosidase plasmid DNA, pcDNA™3.1/myc-His/lacZ, was 
purchased from Invitrogen (Carlsbad, CA), phosphorothioate oligonucleotides-labeled 
at the 5′-end with Cy3 was synthesized by Microsynth AG (Balgach, CH). DNAse I for 
digestion of not incorporated DNA was from Roche Diagnostics (Rotkreuz, CH). 
Lipofectamine for gene transfection was from Gibco-BRL (Paisley, Scotland), PlusTM 
reagent was purchased from Invitrogen (Carlsbad, CA). Sulforhodamine for 
sulforhodamine B assay was from Fluka (Buchs, CH). For tissue solubilization, 
Soluene-350 was purchased form Packard (Meriden, CT). The spin labels 4-Amino-
2,2,5,5,-tetramethyl-3-imidazoline-1-yloxy (AT) and 2-Heptadecyl-2,3,4,5,5,-
pentamethylimidazolidine-1-yloxy (HP) and were purchased from Magnettech GmbH 
(Berlin, FRG). 
All other chemicals were of analytical grade and were obtained from commercial 
sources.  
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3.2 METHODS: PREPARATION AND CHARACTERIZATION OF A 
NOVEL LIPOSOMAL CARRIER SYSTEM  
3.2.1 Synthesis of streptavidin-conjugated OX26 mAb 
The OX26 mAb (1.65 mg, 11.2 nmol) was thiolated by using a 20:1 molar excess of 2-
iminothiolane (Traut’s Reagent) as described previously (Huwyler et al., 1996). By this 
procedure a single thiol reactive group is introduced into the OX26 mAb. In parallel with 
the antibody thiolation, streptavidin (2 mg, 33 nmol) was dissolved in 200 µl 0.1 M 
phosphate bufferet saline (PBS) (100 mM phosphate, 150 mM sodium chloride, pH 7.4) 
and activated by using a 20:1 molar excess of m-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS, Pierce, Rockford, IL) (Hermanson, 1996). After 
incubation for 1 h at room temperature with gentle shaking, the reaction mix was 
purified by Sephadex G-75 gel filtration chromatography and UV detection at 280 nm. 
The thiolated antibody was conjugated to the activated streptavidin at a molar ratio of 
1:3 (OX26:streptavidin) by incubation over night at room temperature and gentle 
shaking. The reaction products were purified by Sephacryl S-200 gel filtration 
chromatography and OX26-containing samples were detected by absorbance 
measurements at 280 nm. The protein concentration was quantified by the Pierce BCA 
Protein Assay (Pierce, Rockford, IL) using bovine serum albumin (BSA) as reference. 
OX26-streptavidin was stored in 0.01 M PBS (10 mM phosphate, 150 mM sodium 
chloride, pH 7.4) at -20°C.  
3.2.2  Gel electrophoresis 
Purified peak samples of OX26 mAb conjugated to streptavidin were prepared for 
electrophoresis under reducing and non-reducing conditions. 5 µl of samples were 
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mixed with 10 µl of reducing or non-reducing buffer, respectively, and denaturized at 
90°C for 5 min. A Novex® 4 - 20 % Tris-Glycine polyacrylamide gel (Invirtogen, 
Carlsbad, CA) was loaded with two concentrations (2 µl and 10 µl) of each sample and 
with a pre-stained protein standard (SeeBlue Plus2, Invitrogen, Carlsbad, CA) to 
determine molecular mass and consequently identify the reaction products. One-
dimensional vertical gel electrophoresis was performed according to the method of 
Laemmli (Laemmli, 1970) by using the XCell II Mini Cell apparatus (Invitrogen, 
Carlsbad, CA). Novex® Tris-Glycine Running Buffer from Invitrogen (Invitrogen, 
Carlsbad, CA) was used for electrophoresis (2 h, 34 mA, 200 V), to identify fractions 
that contain streptavidin-coupled, uncoupled, and aggregated antibody fractions. The 
gel was stained for 1 hour in (Coomassie) GelCode® Blue Stain Reagent (Pierce, 
Rockford, IL) and washed.  
3.2.3  Biotin binding assay 
Binding of [3H]biotin to the neutral streptavidin-OX26 conjugate was determined by an 
ultrafiltration method using Centrifree® MPS micropartition devices (Millipore, Bedford, 
MA) containing a low-adsorptive hydrophilic membrane with a 30 kDa exclusion. The 
binding measurements were performed in a final volume of 1 ml of 10 mM PBS 
containing 0.1 µCi of [3H]biotin and unlabeled biotin at concentrations ranging from 16 
to 500 nM. The assay was initiated by the addition of neutral streptavidin-OX26 to a 
final concentration of 32 nM. Samples were incubated for 15 min at 37°C and unbound 
biotin was separated from the bound fraction by centrifugation (10 min at 1250 x g, 3 
times). The percentage of unbound biotin in the filtrates was determined by liquid 
scintillation counting (Packard beta counter, Downers Grove, IL).  
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3.2.4 Preparation of liposomes 
DSPC (4.2 µmol), cholesterol (1.8 µmol), PEG-DSPE (0.24 µmol) and linker lipid (bio-
PEG-DSPE, 0.66 nmol) were dissolved in chloroform. A lipid film was prepared by 
vacuum evaporation using a Rotavapor (Büchi, CH). Dried lipid films were hydrated at 
40°C in PBS or, in case of drug loading by pH gradient, in 0.1 M citrate buffer 
respectively, such that a final lipid concentration of 4.4 mM was achieved. Lipids were 
dispersed by addition of glass beads and gentle agitation. Lipids were subjected to 5 
freeze-thaw cycles followed by extrusion (6 times) at room temperature through a 200 
nm pore-size polycarbonate membrane employing an extruder (Avestin, Ottawa, 
Canada). Extrusion was repeated 9 times using a 100 nm polycarbonate membrane.  
Mean vesicle diameters were 150 nm as determined by dynamic light scattering using a 
Zetasizer 4 Particle Analyzer (Malvern Instruments, Worcestershire, UK). 
3.2.5 Loading of immunoliposomes by pH gradient 
Loading of liposomes with [3H]daunomycin was done via a pH gradient (Mayer et al., 
1986) as described elsewhere (Huwyler et al., 1996). Dried lipids were rehydrated in  
0.1 M citrate buffer pH 4.0 (4.4 µmol of lipid). By addition of NaOH, the pH of the 
external buffer was raised to at least pH 7.1. [3H]daunomycin (5 µl, 1 µCi/µl) and 
Daunomycin (880 nmol) was added and the incubation mix was incubated for 10 min at 
53°C. External buffer was exchanged by passing the liposomes over a Sephadex G-75 
column and eluting with 0.001 M PBS (0.001 M Na-phosphate, 0.15 M NaCl, pH 7.4). 
Aliquots of column eluates were analyzed by scintillation counting. Efficiency of 
entrapment of daunomycin was determined by analysis of the column elution profiles. 
Fractions containing daunomycin loaded biotinylated liposomes were used immediately 
for conjugation with streptavidin-linked OX26 mAb by addition of antibody (using a 
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molar ratio of bio-PEG-DSPE:OX26-streptavidin of 1:1). Excess biotin-binding sites on 
the OX26-streptavidin vector were blocked before coupling to the biotinylated 
liposomes, using free biotin (in a molar ratio of OX26-streptavidin:biotin of 1:1) in order 
to minimize cross-linking and thus precipitation of immunoliposomes as described 
earlier (Schnyder et al., 2004). In cases of IgG2a-coupled immunoliposomes, the same 
procedure was performed with a streptavidin-linked IgG2a mAb.  
The average number of bio-PEG-DSPE molecules and thus mAb bound per liposome, 
was calculated to be 30, assuming that one 100 nm liposome contains 100000 
phospholipid molecules (Hansen et al., 1995).   
3.2.6  Passive loading of immunoliposomes 
The passive entrapment method was performed for DNA, fluorescent markers and all 
other drugs. Dried lipids were hydrated in 0.01 M or 0.001 M PBS pH 7.4 containing the 
corresponding material to be incorporated. Lipids were subjected to five freeze-thaw 
cycles, followed by extrusion through a 200 nm and 100 nm pore-size membrane, as 
described before (3.2.4).  
3.2.7 Preparation of pH-sensitive liposomes 
pH-sensitive liposomes were prepared following the protocol as for conventional 
liposomes. DOPE (7 µmol), CHEMS (3 µmol) and linker lipid (bio-PEG-DSPE, 3.15 nmol) 
were dissolved in chloroform. A lipid film was prepared by vacuum evaporation using a 
Rotavapor (Büchi, CH). Dried lipid films were hydrated at 40°C in PBS such that a final 
lipid concentration of 10 mM was achieved. Lipids were dispersed by addition of glass 
beads and gentle agitation. Lipids were subjected to 5 freeze-thaw cycles followed by 
extrusion (6 times) at room temperature through a 200 nm pore-size polycarbonate 
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membrane employing an extruder (Avestin, Ottawa, Canada). Extrusion was repeated 9 
times using a 100 nm polycarbonate membrane.  
3.2.8 Preparation of fluorescent biotinylated OX26-immunoliposomes 
DSPC (5.2 µmol), cholesterol (4.5 µmol), PEG-DSPE (0.3 µmol) and linker lipid (bio-
PEG-DSPE, 0.015 µmol) were dissolved in chloroform. A lipid film was prepared by 
vacuum evaporation using a Rotavapor (Büchi, CH). Dried lipid films were hydrated at 
40°C in 0.01 M PBS, such that a final lipid concentration of 10 mM was achieved. For 
the preparation of carboxyfluorescein filled immunoliposomes, the dried lipids were 
hydrated in 0.01 M PBS containing 0.1 mM 5(6)-carboxyfluorescein. Lipids were 
subjected to 5 freeze-thaw cycles followed by extrusion (5 times) at room temperature 
through a 100 nm pore-size polycarbonate membrane employing an extruder (Avestin, 
Ottawa, Canada). Extrusion was repeated 9 times using a 50 nm polycarbonate 
membrane. Mean vesicle diameters were 150 nm as determined by dynamic light 
scattering using a Zetasizer 4 Particle Analyzer (Malvern Instruments, Worcestershire, 
UK). 
Buffer was exchanged for 10 mM PBS by applying the liposome suspension to a 1.6 x 
20 cm Sephadex G-75 column. Aliquots of column eluates were analyzed by on-line 
absorbance measurements at 280 nm. Fractions containing fluorescent biotin-
liposomes were used immediately for conjugation with streptavidin linked OX26 mAb by 
addition of antibody (bio-PEG-DSPE:OX26-streptavidin = 1:1, molar ratio). Excess 
biotin binding sites on the OX26-streptavidin vector were blocked prior to coupling to 
the biotinylated liposomes using free biotin (OX26-streptavidin:biotin = 1:1, molar ratio) 
in order to minimize cross-linking and thus precipitation of immunoliposomes. The 
average number of biotin-PEG-DSPE and thus bound mAb per liposome was 
 45
Materials and methods  
calculated to be 30 assuming that one 100 nm liposome contains 100000 phospholipid 
molecules (Hansen et al., 1995). 
 
3.3 METHODS: IN VITRO ASSAYS AND RESULTS   
3.3.1 Cell-cultures  
Early passages of L6 cells (ATCC catalog No. CRL-1458) (Mandel and Pearson, 1974) 
were obtained from ATCC (Manassas, VA) and were grown using Dulbecco's Modified 
Eagle Medium (DMEM, Gibco-BRL) supplemented with 4 mM L-glutamine, 1.0 mM 
sodium pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, 10 % heat-inactivated 
fetal calf serum (FCS), 100 µg/ml streptomycin and 100 units/ml penicillin G (all Gibco-
BRL, Paisley, Scotland). They were characterized with respect to transferrin receptor 
expression by Hyde et al.(Hyde et al., 2002) and others.  
 
Passages between 30 and 40 of the immortalised rat brain capillary endothelial RBE4 
cell line were used for toxicology experiments. The immortalized rat brain microvessel 
endothelial cell line was kindly provided by Neurotech SA (Orsay, France). RBE4 cells 
were cultured as described (Huwyler et al., 1999). They were characterized with respect 
to transferrin receptor (Huwyler et al., 1999) and P-glycoprotein (Begley et al., 1996) 
expression. The cells were grown in a culture medium consisting of α-minimal essential 
medium (αMEM) and Ham’s F-10 (1:1 vol/vol), supplemented with 2 mM glutamine,    
10 % heat-inactivated FCS, 1 ng/ml bFGF (basic fibroblast growth factor), 100 µg/ml 
streptomycin and 100 units/ml penicillin G (all Gibco-BRL, Paisley, Scotland). The 
experiments were conducted 2 - 4 days after seeding when the cells reached 70 - 100 
% confluence.  
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RG2 cells (ATCC catalog No. CRL-2433) expressing the transferrin receptor (Nakano et 
al., 1996) were grown using Ham’s F-12 medium supplemented with 10 % heat-
inactivated fetal calf serum FCS, 100 µl/ml streptomycin and 100 units/ml penicillin G 
(Gibco-BRL, Paisely, Scotland). This cell line does not reach a confluence of 100 %, 
cells start to detach at approximately 60 % confluence. 
3.3.2 Immunohistochemistry 
For immunohistochemistry of skeletal rat muscle tissue, fresh rat muscle tissue 
fragments were transferred to plastic moulds (Tissue-Tek Cryomould, Miles, Torrance, 
CA),  embedded in Tissue-Tek OCT reagent and were frozen immediately in a mixture 
of isopropanol and dry ice. Samples were kept at -70°C until use. Sections (6 µm) of the 
frozen OCT-embedded tissue samples were made using a HM560 cryostat (Microm, 
Volketswil, CH), mounted on uncoated coverslips, dried for 24 hours at room 
temperature, fixed with ice-cold 4 % paraformaldehyde for 20 min and washed with 
PBS. All subsequent incubations were done using PBS containing 3 % FCS to reduce 
unspecific binding. Sections were incubated with mAb OX26 (125 µg/ml) for 30 min at 
room temperature, washed with PBS containing 3 % FCS and incubated with rabbit Cy2 
secondary anti-mouse antibody (Jackson Laboratories,West Grove, PA) for 1 hour 
(1:200 dilutions of antibody). Fluorophor protector (FluorSafe Reagent, Calbiochem, 
San Diego, CA) was added to the sections, slides were sealed and analyzed by 
confocal microscopy using a Zeiss LSM 510 confocal microscope. Control experiments 
done in parallel did include incubations with secondary antibody only. Alternatively, the 
primary OX26 mAb was substituted by an unspecific mouse monoclonal IgG2a isotype 
control antibody.  
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3.3.3 Immunocytochemistry and uptake experiments 
Cell surface expression of the transferrin receptor as well as intracellular accumulation 
of the OX26 mAb by L6 and RG2 cells was visualized by immunostaining experiments: 
L6 and RG2 cells were grown on chamber slides (Nalge Nunc, Naperville, IL). In order 
to visualize surface expression of the transferrin receptor, cells were incubated on ice 
for 30 min with the OX26 mAb (50 µg/ml). Cellular uptake and intracellular accumulation 
of the OX26 mAb was visualized by incubations for 30 min at 37°C under cell-culture 
conditions with OX26 mAb (30 µg/ml). Cells were washed and fixed for 20 min with ice-
cold 4 % paraformaldehyde, permeabilized by incubation for 5 min at room temperature 
with 0.5 % Triton X-100 in PBS, transferred for 15 min at room temperature to PBS 
containing 3 % FCS and incubated with rabbit Cy2 secondary anti-mouse antibody 
(Jackson Laboratories) for 1 hour (Cerletti et al., 2000). All incubations with antibody 
were done using PBS containing 3 % FCS to reduce unspecific binding. Cells were 
mounted in FluorSafe Reagent (Calbiochem, San Diego, CA) and analyzed by confocal 
microscopy (Leica TCS NT confocal microscope). Control experiments performed in 
parallel did include incubations with secondary antibody only, or the use of an 
unspecific mouse monoclonal IgG2a isotype control antibody.  
 
Uptake experiments with OX26-conjugates (i.e. OX26 conjugated to streptavidin or not 
pH-sensitive OX26 immunoliposomes) were performed with L6 and RG2 cells grown on 
chamber slides (Nalge Nunc). Fluorescent OX26-immunoliposomes (carrying 70 µg/ml 
of bound OX26 mAb) or biotin-fluorescein bound to OX26-streptavidin (70 µg/ml) in 10 
mM PBS were diluted with one volume of cell-culture medium. Incubations with cells 
were done for 1 hour at 37°C. Competition experiments were done in presence of     
200 µg/ml of OX26 after 15 min pre-incubation of the cells with the free OX26. Cells of 
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control experiments were incubated with normal growth medium, representing 
background fluorescence of the cells. Cells were washed four times with ice-cold 10 mM 
PBS and fixed (20 min at 4°C) using 200 µl of 4 % paraformaldehyde. Cells were 
washed and mounted using FluorSafe Reagent (Calbiochem). Slides were sealed and 
analyzed by confocal fluorescence microscopy (Leica TCS NT confocal microscope). 
3.3.4 Endosomal release of propidium iodide 
Confocal microscopy studies using RG2 cells were performed to investigate endosomal 
release and accumulation of propidium iodide to the cytosol. Cells were grown onto 
chamber slides (Nalge Nunc) until they reached a confluence of 50 %. Cells were 
incubated with not pH-sensitive immunoliposomes consisting of DSPC and linker lipid 
only, or pH-sensitive immunoliposomes (33.3 µg/ml OX26-streptavidin). Liposomes 
were filled preliminary with propidium iodide by the freeze-thaw technique and mixed 
1:1 with cell-culture medium. Cells were incubated for 1, 3 or 24 hours at 37°C, 
liposomes were either removed after 3 hours or left on cells till the end of the 
experiment. Cells were washed, fixed for 20 min at 4°C using 4 % paraformaldehyde as 
described before and were mounted in FluorSafe Reagent (Calbiochem). Confocal 
microscopy was performed with a Leica TCS NT inverted fluorescent microscope 
(Leica). (Excitation = 544 nm; emission = 603 nm).  
3.3.5 Microscopy 
Tissue sections and L6 cells of Figure 13 were analysed with a Zeiss LSM 510 inverted 
scanning confocal microscope using 20 x and 40 x Zeiss Plan-Neofluor lenses with a 
numerical aperture of 0.5 and 1.3, respectively. A 488 nm argon laser was used in 
combination with fluorescein bandpass filters. Optical sections of 5.3 µm (muscle 
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tissue) or 1.4 µm (L6 cells) were aquired and processed on a silicon graphics 
workstation (Silicon Graphics, Mountain View, CA, USA) using Zeiss software.  
 
All other confocal microscopy images were recorded with a Leica TCS NT confocal 
microscope (Leica) using 25 x and 40 x Plan Fluotar or 63 x Plan Apochromat oil 
immersion objectives with numerical apertures of 0.75, 1.0 and 1.32, respectively. 
Optical sections of 0.7 - 1 µm were analyzed using the Imaris software (Bitplane AG, 
Zurich, CH) and processed using Photoshop software (Adobe Systems, Mountain View, 
CA). 
3.3.6 DNA incorporation into immunoliposomes 
Immunoliposomes were synthesized by using a total of 40 µmol of lipids, including   
37.6 µmol of 1-palmitoyl-2-oleoyl-snglycerol-3-phosphocholine (POPC), 0.8 µmol of 
didodecyldimethylammoniumbromide (DDAB), 1.2 µmol of distearoylphosphatidyl-
ethanolamine (DSPE-PEG), and 12 nmol of DSPE-PEG-maleimide, as described by 
Shi et al. (Shi et al., 2001b) with minor modifications: 400 µg DNA (pGL3-Basic 
Luciferase Vector (Promega), β-galactosidase plasmid DNA (pcDNA™3.1/myc-
His/lacZ, Invitrogen, Carlsbad, CA) or Cy3-labeled phosphorothioate oligonucleotides 
(Microsynth AG, Balgach, CH) were encapsulated in the pegylated liposomes by the 
passive freeze-thaw method. Dried lipid film was resuspended in PBS containing the 
DNA to be incorporated, following the same protocol as for fabrication of 
carboxyfluorescein-filled immunoliposomes (3.2.8). There are two methods to remove 
not incorporated DNA from liposomes. That is the enzymatic method where exteriorized 
DNA is degraded by nuclease digestion, and the mechanic, more gentle method of 
purification by size exclusion chromatography (SEC). If not mentioned otherwise, 
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exteriorized DNA was removed by the mechanic SEC method, using a 1.6 cm x 20 cm 
Sephadex G-75 column. Fractions containing biotinylated liposomes were used 
immediately for conjugation with streptavidin-linked OX26 mAb by addition of antibody 
(using a molar ratio of bio-PEG-DSPE:OX26-streptavidin of 1:1). Excess biotin-binding 
sites on the OX26-streptavidin vector were blocked, before coupling to the biotinylated 
liposomes, using free biotin (in a molar ratio of OX26-streptavidin:biotin of 1:1) in order 
to minimize cross-linking and thus precipitation of immunoliposomes. The average 
number of OX26 mAbs conjugated to one liposome was 30 as described before. 
3.3.7 Confirmation of DNA incorporation into liposomes 
To confirm the presence of DNA in the liposome fraction, original DNA liposome 
samples were analyzed by agarose gel electrophoresis prior and after to size exclusion 
chromatography. Experiments were done with a pGL3-Basic Luciferase Vector 
(Promega). Biotinylated PEG-immunoliposomes were formulated in a total volume of    
1 ml Tris/HCl pH 8.5 prior to gel purification, using 20 µmol of lipids and 200 µg of 
plasmid DNA. 650 µl were subjected to DNAse I (Roche Diagnostics, CH) treatment to 
digest not incorporated DNA. DNAse I treatment was done in the presence of 68 µl 50 
mM MgCl2 and 10 U RNAse free DNAse I (10 U/µl), during 1 hour at 37°C and stopped 
by addition of EDTA at a final concentration of 7 mM. As control for the DNAse I digest, 
10 µg of not liposomal plasmid DNA (pCDNA3.1-lacZ plasmid, 8.5 kb) in an equal 
volume of Tris/HCl pH 8.5 were treated under identical conditions. Liposome samples 
were analyzed directly or purified by SEC with or without DNAse I digest. For DNA 
extraction, pCDNA3.1-lacZ plasmid and pGL3 containing immunoliposomes were 
subjected to phenol/chloroform extraction and precipitated with ethanol/acetate using 
glycogen as a carrier in order to achieve maximal DNA recovery. In the case of SEC 
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purified samples, as well peak fractions, as post-peak fractions were analyzed. The 
DNA pellets were resuspended in 17 µl of 10 mM Tris/HCl pH 7.5 and linearized by 
restriction digest with Xho l. The restriction digest was supplemented with 25 % gel 
loading buffer, and aliquots of the DNA were analyzed by electrophoresis on a 0.8 % 
agarose gel with subsequent ethidium bromide staining.   
3.3.8 Liposomal administration of pGL3 expression vector 
pGL3 expression experiments were carried out according to Shi et al. (Shi et al., 2001b) 
with minor modifications: Liposomes were composed of POPC, DDAB, DSPE-PEG and 
DSPE-PEG-biotin and prepared according to the standard protocol (3.3.6). The DNA 
content of the liposomes was calculated as approximately 10 % of the initial amount of 
DNA added to the suspension (assumption of internal unpublished data), that is about 
40 µg per 40 µmol lipid, according to published data (Shi et al., 2001b; Zhang et al., 
2002a). 40 µg plasmid DNA in a liposome volume of 1 ml before column purification 
results in approximately 0.01 µg/ml after column purification (estimated dilution factor). 
RG2 and L6 cells were cultured in a 24-well plate (2.0 cm2/well) and incubated with 
approximately 0.4 µg of liposomal DNA per well for 24 and 48 hours prior to analysis 
with the bright glow reagent (Promega, Madison, WI) according to manufacturer’s 
protocol (Bright-Glo™ Luciferase Assay System, Promega). Lipofectamine transfected 
cells were used as positive controls which were transfected with 5 µg of the plasmid 
and 2 µl of lipofectamine (Gibco-BRL, Paisley, Scotland). In brief, 5 µg of plasmid were 
diluted to a total volume of 25 µl DMEM. 8 µl of PlusTM reagent (Invitrogen) for pre-
complexing DNA was added and incubated 15 min at room temperature before mixing 
with 2 µl lipofectamine in 50 µl DMEM that was incubated likewise 15 min at room 
temperature. After another 15 min incubation at room temperature, 300 µl of 
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transfection mix and 500 µl of opti-Mem (Gibco-BRL) per well were placed on cells for 6 
hours at 37°. Transfection mixture was replaced with 1.5 ml complete growth medium 
supplemented with 150 µl PBS per well. Transfected cells were harvested 24 and 48 h 
after transfection for analysis of cellular luciferase activity by the Bright-Glo™ 
Luciferase Assay System (Promega), according to manufacturer’s protocol. Cell were 
lysed for 2 hours with Glo Lysis Buffer and 20 µl of the lysate were transferred on a 96-
well plate and mixed with 100 µl Bright-GloTM Assay Regent (n = 2 for each well). 
Plates were immediately placed in a TECAN fluorescence and luminescence plate 
reader (Spectrafluor plus, TECAN, Männedorf, CH), and peak light emission was 
measured at 20°C for 2 s and recorded as relative light units.  
3.3.9 Expression of β-galactosidase in RG2 cells 
Gene expression experiments were performed with a β-galactosidase exogenous 
expression plasmid under the control of the unspecific SV40 promoter 
(pcDNA™3.1/myc-His/lacZ, invitrogen, Carlsbad, CA). RG2 cells were grown on 
purified coverslips placed in 12-well cell-culture plates in the normal cell growth 
medium. The surface area was 3.8 cm2/well. The experiments were conducted 2 - 3 
days after seeding when cells reached a confluence higher than 50 %. RG2 cells were 
incubated for 24 or 48 hours with β-galactosidase expression plasmid filled 
immunoliposomes, medium or, the negative control, with unconjugated liposomes 
loaded with plasmid. The amount of liposomes per well was 13.3 pmol, and accordingly 
399 pmol OX26-streptavidin (30 antibodies per liposome). In order to confirm 
experimental proceeding, RG2 cells were transfected with β-galactosidase expression 
plasmid DNA using lipofectamine (Gibco-BRL, Paisley, Scotland) according to the 
manufacturer's protocol. In brief, 5 µg of the plasmid was diluted to a total volume of 25 
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µl DMEM. 8 µl of PlusTM reagent (Invitrogen) for pre-complexing DNA and enhancing 
cationic lipid-mediated transfection of DNA into cultured adherent eukaryotic cells, was 
added and incubated 15 min at room temperature before mixing with 2 µl lipofectamine 
in 50 µl DMEM that was incubated likewise 15 min at room temperature. After another 
15 min incubation at room temperature, 300 µl of transfection mix and 500 µl of opti-
Mem (Gibco-BRL) per well were placed on cells for 6 hours at 37°. Transfection mixture 
was replaced with 1.5 ml complete growth medium supplemented with 150 µl PBS per 
well. The transfected cells were harvested 24 and 48 h after transfection for analysis of 
mRNA expression and newly synthesized protein.  
Cells were washed 3 times with PBS, fixed and incubated overnight at 37°C in X-Gal 
solution (1 mg/ml X-gal, 2 mM MgCl2, 5 mM K4Fe(CN)6 and 5 mM (K3Fe(CN)6 in PBS 
pH 7.3). When lipofectamine transfected control cells reached sufficient staining 
intensity (after 2 - 24 h), cells were washed again 2 x with PBS.  
3.3.10 Uptake of liposomal, labeled oligonucleotides by RG2 cells 
In order to confirm gene uptake and intracellular distribution of administered liposomal 
cargo in RG2 cells, fluorescent Cy3-labeled phosphorothioate oligonucleotides ((Cy3)5'-
CAGATCCTCTTCTGAGATGAGTTTTTGTTC-3', Microsynth AG, Balgach, CH)  were 
incorporated into OX26-conjugated immunoliposomes and incubated with RG2 cells. 
RG2 cells were grown in 12-well cell-culture plates in normal growth medium. The 
surface area was 3.8 cm2/well. The experiments were conducted 2 - 3 day after 
seeding, when cells reached a confluence higher than 50 %. RG2 cells were incubated 
for 1, 24 or 48 h either with liposomes that were filled with labeled oligonucleotide or 
with medium only, as negative control. Liposomes were coupled to OX26 mAb 
(immunoliposomes) or, as additional negative control, kept in unbound, unspecific 
 54
Materials and methods  
original state alternatively. The amount of liposomes per well was 13.3 pmol, and 
accordingly 399 pmol OX26-streptavidin (30 antibodies per liposome). The transfected 
cells were washed 1, 24 and 40 h after transfection, fixed for 30 min at 4°C using 4 % 
paraformaldehyde and stored in 0.1 % sodium azide until fluorescent microscopy 
analysis. In order to visualize every cell, 4′,6-Diamidino-2-phenylindole (DAPI) was 
used. DAPI staining is one of the most frequently used nucleic acid stains; it binds to 
the minor groove of DNA at AT-rich sequences.  
Microscopy was performed with a Zeiss Axioplan fluorescent microscope with common 
epifluorescence equipment. Excitation at 565 nm and emission at 552 nm was provided 
by optics intended for Cy3.  
3.3.11 In vitro IC50 determination of daunomycin 
LD50 were defined as the concentration of daunomycin deleting 50 % of the cells. LD50 
were determined for RG2 and for RBE4 cells. Serial dilutions of daunomycin in normal 
cell growth medium were used at 0.001, 0.01, 0.1, 1, 10 and 100 µM daunomycin. All 
cell lines were seeded in 96-well microplates and experiments were performed when 
cells reached 50 – 70 % confluency and divided into control and treatment groups (n = 6). 
Controls were treated with same volumea of solvents without any treatment. RG2 cells 
between passage 35 and 40 and RBE4 cells between passages 25 and 35 respectively, 
were incubated for 3, 6 and 24 hours with according serial daunomycin dilutions. After 
indicated incubation times, cells were washed with PBS and kept in normal growth 
medium until analysis. When all incubation times were performed (24 h), cell viability (% 
of control) was determined by the sulforhodamine B (SRB) assay.  
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3.3.12 Cellular uptake of liposomal [3H]daunomycin 
The immortalized rat brain microvessel endothelial cell line RBE4 was kindly provided 
by Neurotech SA (Orsay, France). For uptake experiments, cells between passages 25 
and 35 were seeded at a density of 104 - 105 cells/cm2 into 24-well cell-culture plates. 
The surface area was 2 cm2 per well. The cells were grown in culture medium 
described above for 3 - 4 days until they reached confluence. For uptake assays, cells 
were incubated for one or three hours respectively with [3H]daunomycin (free drug,  
0.375 µCi/well) or [3H]daunomycin loaded immunoliposomes (5.5 pmol liposomes, 165 
pmol OX26-streptavidin. 0.2 µCi/well). Where pre-incubation is indicated, cells were 
incubated preliminary with 200 µg free OX26 per well for 15 min. Cells were washed 
after the incubation using ice-cold PBS, detached from the cell-culture plate by 
incubation with 250 µl trypsin-EDTA (0.05 % and 0.02 % (w/v)) and subsequently 
transferred to scintillation vials. 2 ml of scintillation fluid (Ultima Gold by Packard 
BioSciences, Meriden, CT) were added, cells were solubilized overnight and the 
amount of radiolabeled substrate taken up by the cells was quantified by scintillation 
counting.  
3.3.13 Pharmacological effects of daunomycin loaded immunoliposomes on 
RBE4 cells 
Toxicology experiments were performed using the immortalised rat brain capillary 
endothelial RBE4 cell line. RBE4 cells were cultured as described (Huwyler et al., 
1999). For pharmacological effect studies, cells between passages 30 and 40 were 
seeded into 96-well plates. The cells were grown in a culture medium as described 
above. The experiments were conducted 2 - 4 days after seeding when the cells 
reached 70 - 100 % confluence. For pharmacological effect experiments, cells were 
incubated 45 min at 37°C with free OX26 where pre-incubation is indicated. Pre-
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incubated and other cells were incubated for 1 or 3 hours respectively with 1 or 5 µM of 
free or liposomal daunomycin (1 µM and 5 µM). Cells were washed two times with PBS 
and incubated for another 48 h in fresh culture medium, before sulforhodamine B assay 
was conducted.  
3.3.14 Sulforhodamine B assays for determination of daunomycin cytotoxicity 
The protocol used for the SRB assay was similar to that previously described by 
Skehan et al. (Skehan et al., 1990). Cell layers were washed and fixed to the well 
bottoms by adding 20 µl of cold 50 % trichloroacetic acid (TCA) to the 200 µl of medium 
in each well (final concentration 5 %) and incubating the plate at 4°C for 1 h. The wells 
were then drained, rinsed five times with pure water, and air dried at 37°C. 0.4 % (w/v) 
sulforhodamine B (SRB) in 1 % glacial acetic acid was then added (100 µl/well), and the 
plate incubated for 15 min. Unbound dye was drained and removed by washing four 
times with 1 % glacial acetic acid. After air drying the plate, the dye was solubilized by 
adding 100 µl/well of 10mM Tris base, pH 10.5, and swirling for 5 min. Absorbance at 
562 nm was measured on a microtiter plate reader (SOFTmax Pro, Molecular devices, 
California).  
 
3.4 METHODS: IN VIVO ASSAYS AND RESULTS  
3.4.1 Pharmacokinetics and tissue delivery of (immuno) liposomes in the rat 
Pharmacokinetic experiments were performed as described (Bittner et al., 2003) by 
cannulating the right jugular vein of male Wistar rats for blood sampling. Surgery was 
performed under 10 mg/kg xylazin and 90 mg/kg ketamine anaesthesia two days before 
the experiment. During the study, the freely moving animals were kept individually in 
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plastic metabolism cages. All rat experiments were performed in accordance with the 
current Swiss legislation on the welfare of experimental animals.  
In brief, the right jugular vein of male rats was cannulated and injected with 0.001 M 
PBS containing 20 µCi/kg (specific activity: 16 Ci/mmol) of free [3H]daunomycin, 
[3H]daunomycin loaded pegylated liposomes (biotinylated or not) and [3H]daunomycin 
loaded OX26- or IgG2a-immunoliposomes. The injected dose of monoclonal antibodies 
and lipids was always ≤ 100 µg per rat and ≤ 2 µmol per rat, respectively. Blood 
samples were collected via the jugular vein catheter at 2, 5, 10, 15, 30 and 60 min after 
intravenous injection of the isotope. After 60 min, the animals were anesthetized with 
isofluorene, decapitated and brain, lung, spleen, heart, liver, kidney, testes and muscle 
tissue was collected. The plasma (50 µl aliquots) and organ samples (approximately 0.2 g) 
were weighted, solubilized with Soluene-350 (Packard, Meriden, CT) and neutralized 
with glacial acetic acid before liquid beta-scintillation counting. Pharmacokinetic 
parameters such area under the plasma concentration curve (AUC0-t), clearance (CL) or 
half-live (T½) were calculated by non-compartmental data analysis of plasma 
concentrations (percent injected dose (%ID) per ml plasma) using WinNonlin 4.1 
software (Pharsight, Mountain View, CA).  
The tissue volume of distribution (VD) of the [3H]daunomycin sample at 60 min after i.v. 
injection is defined as the amount of drug in tissue (%ID per g tissue) divided by the 
concentration of drug (%ID/ml) in terminal phase. The tissue clearance (i.e. organ 
permeability surface area (PS) product) was determined as:  
 
where Cp(T) = the terminal plasma concentration and V0 = the organ volume 
distribution of a plasma volume marker, i.e. sterically stabilized liposomes (biotinylated 
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PEG-liposomes) (Huwyler et al., 1996). Organ uptake was expressed as %ID/g tissue 
and was calculated from: %ID/g(t) = PS x AUC0-t (Pardridge, 1995b). It is important to 
note that tissue levels of [3H]daunomycin were solely determined by radiolabel analysis. 
We can thus not distinguish between the parent drug and possible metabolites.  
3.4.2 Statistics 
Statistical tests were performed using excel software (Microsoft). Multiple groups at the 
same time point were compared using ANOVA. The difference between two groups 
was tested using Student’s t test for single comparison. The level of significance was 
set at p < 0.05. 
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4 RESULTS 
4.1 CHARACTERIZATION AND OPTIMIZATION OF A NOVEL 
LIPOSOMAL CARRIER SYSTEM  
4.1.1 Synthesis of streptavidin-conjugated OX26 mAb 
A novel design of biotinylated immunoliposomes was tested, where a streptavidin-
conjugated targeting vector, OX26 mAb, is attached to the surface of the liposome 
using a PEG spacer (Figure 5). PEG-liposomes containing in addition pegylated 
phospholipids with a biotin molecule coupled to the top (bio-PEG-DSPE), can be used 
for the non-convalent conjugation of a streptavidin-conjugated ligand. In the present 
study, streptavidin was chemically combined with the OX26 mAb by using MBS as a 
hetero-bifunctional cross-linker reactive for primary amines in streptavidin. 
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Figure 8: Coupling reaction by the use of MBS as cross-linker reactive and introduction 
of a single thiol group into the antibody via Traut’s reagent (2-iminothiolane). 
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The amine-containing streptavidin is first modified via the N-hydroxysuccinimide ester 
end of MBS (its most reactive functional group) to create a stable amide bond. The 
derivative at this point contains reactive maleimide groups able to couple with the 
available sulfhydryl groups of a second molecule (New, 1990). A single thiol group was 
introduced into the OX26 mAb by thiolation with Traut’s reagent (2-iminothiolane) to 
achieve this reaction and complete the coupling of OX26 to streptavidin. The three 
steps of the coupling reaction with MBS and Traut’s reagent are shown in Figure 8. 
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Figure 9: (A) Elution pofile by fluorescence detection (excitation wavelength of 485 nm; 
emission wavelength of 535 nm) of OX26-streptavidin (I) labeled with an excess of 
fluorescein-labeled biotin (II). (B) Chromatographic separation after synthesis of OX26-
streptavidin (210 kDa; I) and unconjugated OX26 (150 kDa; II). (C) Elution profile of 
molecular-mass markers: thyroglobulin (of 670 kDa; void volume; I), γ-globulin (of 158 
kDa; II), ovalbumin (of 44 kDa; III), and myoglobin (of 17 kDa; IV), Vitamin-B12 (of 1.3 
kDa, V). OD, absorbance. 
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The OX26-streptavidin conjugate was purified and analysed by gel-filtration 
chromatography (Figure 9). The conjugate was identified by a shift in molecular mass 
as compared to unconjugated OX26 mAb, and its ability to bind the fluorescent label 
biotin-fluorescein (Figure 9 A). A separation was achieved between the cross-linked 
precipitates OX26-streptavidin (Figure 9 B, peak I), and unbound OX26 mAb (Figure 9 
B, peak II). This was confirmed as well by calibration of the used column with a set of 
molecular-mass markers (Figure 9 C) and comparison of the elution profiles, as by gel 
electrophoresis (4.1.2). The approximate yield of streptavidin-conjugated OX26 
recovered after purification was 40 %.  
4.1.2 Gel electrophoresis 
One-dimensional gel electrophoresis was performed on a Novex® 4 - 20 % Tris-Glycine 
polyacrylamide gel (Invirtogen, Carlsbad, CA), to resolve molecular weights of proteins 
in peak fractions. Figure 10 shows the coomassie stained protein pattern of peak 
samples before and after purification by SEC, shown in Figure 9 B. Under reducing 
conditions (lanes IV-VII), the interchain disulfide bonds of the antibody are cleaved, 
resulting in decomposition into heavy and light chains of the antibody. Lane IV is the 
positive control, OX26 which shows a staining pattern characteristic for this antibody 
which shows the heavy chain at approximately 55 kDa (high molecular weight band) 
which is homogeneous, and the light chains, resolved into two principal bands in the 
proximity of 25 kDa (Yoshikawa and Pardridge, 1992). All other lanes of reduced 
samples present these bands equally with additional signals which will be discussed in 
the section “results”. Lane V (reduced peak I) and land VII (unpurified reaction mix) 
exhibit additionally a slight band around 60 kDa and a blurred signal around 250 kDa. 
As expected, not denaturized samples (lanes I-III) all aggregate in the upper part of the 
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gel, indicating high molecular weight of the proteins or complexes of protein. Lane II 
(not reduced peak II) and low concentration of reaction mix before gel filtration in lane III 
show roughly bands at about 200 kDa. 
 
Figure 10: Tris-Glycine-Gel electrophoresis under non-reducing (left side, lanes I-III) 
and reducing (right side, lanes IV-VII) conditions, for identification of samples containing 
the conjugate OX26-streptavidin, before and after purification by the gel 
chromatography depicted in Figure 9 B (peak I and II). Lanes: I: two concentrations of 
peak I; II: high concentration of peak II; III: two concentrations of reaction mix before gel 
filtration; middle: molecular weight marker SeeBlue® Plus2, Invitrogen; IV: OX26 mAb; 
V: two concentrations of peak I; VI: two concentrations of peak II; VII two concentrations 
of reaction mix before gel filtration. 
 
4.1.3 Biotin binding assay 
The binding capacity of the OX26-streptavidin conjugate for [3H]biotin was determined 
by an ultrafiltration method (Figure 11). Analysis of the biotin binding curve indicates 
that biotin binding is only partially impaired as a consequence of the coupling of 
streptavidin with the OX26 mAb. Using 32 nM OX26-streptavidin conjugate, saturation 
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of biotin binding is observed between 64 and 100 nM biotin, indicating the presence of 
two to three biotin-binding sites on each OX26-streptavidin conjugate. There are 
normally four biotin-binding sites on the tetrameric streptavidin (Hermanson, 1996).  
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Figure 11: Concentration-dependent binding of [3H]biotin to a streptavidin-OX26 
conjugate. Unbound [3H]biotin was separated from streptavidin-OX26 by ultrafiltration 
using a filter membrane wit a molecular-mass cut-off of 30 kDa. Saturation of total 
[3H]biotin binding in the presence of 32 nM streptavidin-OX26 was observed at biotin 
concentrations of 64 - 100 nM. 
 
4.1.4 Loading of immunoliposomes by pH gradient 
Encapsulation of daunomycin into liposomes was achieved using a pH gradient across 
the liposome bilayer. The pH gradient was established by preparing liposomes in 
presence of an acidic buffer with substantial buffering capacity, such as 0.1 M citrate pH 4.0, 
and adjustment of the external buffer by addition of NaOH to a pH between 7.1 and 7.7. 
Daunomycin was spiked with 5 µCi [3H]daunomycin as radioactive tracer. Labeled drug 
was added to external buffer and mixed with liposomes at a drug-to-lipid ratio of 0.2 
(wt/wt). Not incorporated drug was separated from liposomal drug by SEC with 0.001 M 
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PBS pH 7.4. Using this method, external buffer is exchanged with a low phosphate PBS 
buffer (0.001 M) and liposomes are eluted in a physiological environment. The 
percentage of encapsulated daunomycin was determined by scintillation counting and is 
shown in Figure 12 to be approximately 90 %. This figure is representative for all 
experiments where daunomycin was encapsulated into liposomes using a pH gradient. 
Loading efficiencies were high throughout all experiments, i.e. in Figure 12 it was 95 %. 
In general, the range of pH gradient loading efficiencies was between 89 and 95 %.  
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Figure 12: Loading of OX26-immunoliposomes with [3H]daunomycin by pH-gradient. 
Loading efficiencies were calculated by scintillation counting of eluates after purification 
by size exclusion chromatography. Loading efficiencies were 89 - 95 %.  
 
 
Stability of entrapment of biotinylated PEG-liposomes was analyzed after storage at 
4°C during four days. Liposomes were purified from leaked drug by gel 
chromatography. The leakage after this time was 2.6 % (data not shown).  
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4.1.5 Passive loading of immunoliposomes 
Substances to be incorporated by the pH gradient method have to fulfill two 
requirements. First, this technique necessitates a certain pK of the compound to be 
incorporated. Thereby, active uptake into the liposomes follows an existing 
electrochemical transmembrane gradient (i.e. daunomycin). Second, the substance has 
to be insensitive towards changes in pH and high temperatures (incorporation by pH 
gradient is done at 50 - 60°C). In the present work, ESR spin labels, fluorescent 
markers (i.e. carboxyfluorescein and propidium iodide), expression plasmids and 
oligonucleotides have been entrapped into liposomes by an alternative passive method. 
As passive loading presents a fast and simple approach, it is the method of choice for 
low priced substances (i.e. used ESR spin labels and fluorescent dyes), because 
entrapment efficiency is poor.  
pH-sensitive liposomes do not tolerate low pH and can thereby not be loaded by the 
more efficient pH gradient method. Manufactured pH-sensitive liposomes contained 
dioleoylphosphatidylethanolamine (DOPE), a lipid that adopts the nonbilayer inverted 
hexagonal (HII) phase in isolation (Cullis and de Kruijff, 1978), and an ionizable acidic 
lipid such as cholesteryl hemisuccinate. Liposomes can only be formed with a mixture 
of both lipids, where CHEMS stabilizes DOPE and allows the adoption of a bilayer 
structure. Protonation of CHEMS at pH below its pK (5.8 (Hafez and Cullis, 2000)) 
diminishes the ability of this component to stabilize DOPE in the bilayer organization 
(Lai et al., 1985) leading to membrane inversion, membrane fusion and thus 
decomposition of liposomal structures. For this reason, we used a passive entrapment 
method in this case, with the disadvantage of a poor efficacy of 6 %. Stability of 
entrapment of pH-sensitive liposomes was analyzed after four days of storage at 4°C. 
These liposomes contained only 2 % of the initial substance (data not shown). 
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4.2 IN VITRO ASSAYS AND RESULTS 
4.2.1 Immunohistochemistry 
By immunostaining experiments using the OX26 mAb, the presence of the transferrin 
receptor in rat skeletal muscle tissue was examined (Figure 13). Tissue sections 
perpendicular to the muscle fibres (Figure 13 A) showed an intense immunostaining at 
the periphery of the myofibres, as well as at the periphery of the enclosed myofibrils. 
The staining of the myofibre surface can also be seen in longitudinal sections (Figure 
13 B). Little or no fluorescent signal was observed in control experiments using 
secondary antibody only (Figure 13 B, inset) or an unspecific mouse IgG2a isotype 
control antibody (results not shown).  
 
 
Figure 13: Analysis of muscle tissue sections by confocal microscopy using the OX26 
mAb (125 µg/ml) and a secondary Cy2-labeled polyclonal antibody. Immunostaining of 
rat muscle tissue which is cryo-sectioned (A) orthogonal or (B) parallel to the muscle 
fibres. The inset to (B) shows the control experiment (incubation with secondary 
antibody only). Scale bars represent 100 µm. 
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4.2.2 Immunocytochemistry and uptake experiments 
Immunocytochemistry was done in parallel with immunohistochemistry. The rat skeletal 
muscle derived L6 cell line was incubated with OX26 mAb at 37°C and analyzed with a 
fluorescent secondary antibody against mouse antibody (Cy2). Figure 14 A and 14 B 
shows a conspicuous fluorescent signal on the cell surface and a particulate staining 
pattern in the cells. Nearly all cells were positive when incubated at 37°C (Figure 14 A). 
The percentage of positive cells in these experiments was not investigated analytically; 
however, the overlay of fluorescence image with phase contrast image allows the 
assumption that more than 90 % of the cells showed a fluorescent signal. At 4°C, 
binding of OX26 accumulates on the cell surface and only the periphery of cells 
appears in fluorescence visualization. Figure 14 C shows one single cell incubated at 
4°C.  
 
 
Figure 14: Immunocytochemistry and uptake experiments using the OX26 mAb and L6 
cells. (A) Cellular uptake of the OX26 mAb (100 µg/ml) by L6 cells at 37°C and 
visualization of internalized antibody using a Cy2-labeled secondary antibody: overlay 
between a phase contrast image of L6 cells and the corresponding fluorescence image. 
The inset shows the negative control, using an unspecific IgG2a isotype antibody. (B) 
Magnification of a single L6 cell (incubation with 30 µg/ml OX26 at 37°C) reveals a 
particulate intracellular staining pattern. The inset shows the control (secondary 
antibody only). (C) Immunolabeling of surface receptors by incubation of L6 cells with 
OX26 mAb (100 µg/ml) at 4°C. The inset shows the control (unspecific IgG2a isotype 
antibody). Scale bars represent 20 µm.  
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Same immunostaining experiments were done with the RG2 rat glioma cell line, 
resulting in similar results (Figure 15). Figure 15 A and B display cellular uptake of the 
OX26 mAb (50 µg/ml) by the RG2 cells at 37°C. The phase contrast image overlaid 
with the corresponding fluorescence image confirms that every cell has taken up the 
OX26 mAb whereas in control experiments (inset, Figure 15 A), little or no fluorescence 
occurs. Similar as in L6 cells, at 4°C, OX26 mAb accumulates in RG2 cells at the 
periphery of the cell, indicating that receptor-mediated endocytosis and thus 
internalization of the labeled antibody is inhibited (Figure 15 C).  
 
 
Figure 15: Immunocytochemistry and uptake experiments using the OX26 mAb and 
RG2 cells. (A) Cellular uptake of the OX26 mAb (50 µg/ml) by RG2 cells at 37°C and 
visualization of internalized antibody using a Cy2-labeled secondary antibody: overlay 
between a phase contrast image of RG2 cells and the corresponding fluorescence 
image. The inset shows the negative control (secondary antibody only). (B) 
Magnification of RG2 cells (incubation with 30 µg/ml OX26 at 37°C) reveals a 
particulate intracellular staining pattern. The inset shows the control (secondary 
antibody only). (C) Immunolabeling of surface receptors by incubation of RG2 cells with 
OX26 mAb (30 µg/ml) at 4°C. The inset shows the control (secondary antibody only). 
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Figure 16: Cellular uptake of fluorescence-labeled OX26-streptavidin (OX26-
streptavidin biotin-fluorescein) and fluorescent OX26 immunoliposomes by cultured L6 
muscle cells. Cells were fixed after 1 h incubation and analyzed by confocal 
microscopy. The concentration of OX26 was always 70 µg/ml. (A) Incubation with 
OX26-streptavidin and biotin-fluorescein; (B) Incubation with OX26 immunoliposomes 
loaded with carboxyfluorescein; (C) Competition of cellular uptake of OX26 
immunoliposomes in presence of 200 µg/ml free OX26; (Control) Background 
fluorescence of L6 cells. Scale bars represent 50 µm. 
 
 
Results of uptake experiments for L6 cells are shown in Figure 16, and for RG2 cells in 
Figure 17. OX26-streptavidin was fluorescence-labeled by adding biotin-fluorescein. 
Intracellular fluorescent signal is presented in either of the cell lines, the muscular L6 
line and the glioma RG2 line. In another set of experiments, liposomes were loaded 
with carboxyfluorescein and subsequently connected to OX26-streptavidin. Figure 16 B 
(L6) and 17 B (RG2) reveal a considerable intracellular staining of the cells, confirming 
previous experiments where OX26-streptavidin was labeled with biotin-fluorescein (A in 
Figure 16 and 17). Pre-incubation of cells with free OX26, in the purpose of occupying 
OX26-binding sites on the transferrin receptor, resulted in a lesser fluorescence 
intensity in both cell lines (C in Figures 16 and 17). 
 70
Results  
 
Figure 17: Cellular uptake of fluorescence-labeled OX26-streptavidin (OX26-
streptavidin biotin-fluorescein) and fluorescent OX26 immunoliposomes by cultured 
RG2 rat glioma cells. Cells were fixed after 1 h incubation and analyzed by confocal 
microscopy. The concentration of OX26 was always 70 µg/ml. (A) Incubation with 
OX26-streptavidin and biotin-fluorescein; (B) Incubation with OX26 immunoliposomes 
loaded with carboxyfluorescein; (C) Competition of cellular uptake of OX26 
immunoliposomes in presence of 200 µg/ml free OX26; (Control) Background 
fluorescence of RG2 cells. Scale bars represent 20 µm apart from control (50 µm). 
 
4.2.3 Endosomal release of propidium iodide 
Endosomal release of OX26-immunoliposomes was visualized by confocal 
fluorescence microscopy as described by Cerletti et al. (Cerletti et al., 2000). For this 
purpose, OX26-immunoliposomes were synthesized and loaded with propidium iodide 
(PI), a fluorescent dye that was shown to be impermeable to both, living cells and 
liposomal membranes. PI has spectral characteristics, changing dramatically upon 
binding to nucleic acids (Vogel et al., 1996). A shift in fluorescence of propidium iodide 
of a factor of 8 in presence of 0.5 mg/ml DNA was shown. This increase was 
accompanied by a shift of the excitation and emission wavelength maxima from 494 nm 
to 544 nm and from 627 nm to 603 nm, respectively, which makes the dye detectable 
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when it is released from liposomes and binds to DNA. RG2 cells were incubated with 
propidium iodide filled OX26-immunoliposomes for 1, 3 or 24 h prior to analysis by 
fluorescent confocal microscopy using settings of the microscope which were optimized 
for detection of propidium iodide associated with DNA (equipment settings Leica, 
installed in instrument). For pH-sensitive immunoliposomes, cells showed particulate 
fluorescence after one hour incubation which after 3 hours was at least of similar 
intensity after 3 hours and diminished after 24 hours incubation (Figure 18). Results 
were the same whether liposomes were removed after 3 hours or left on the cells for 24 
hours (not shown). Different from published data where particularly the nucleus was 
stained (Cerletti et al., 2000), fluorescence in RG2 cells was increased in the cytosol 
and nucleolus. For not pH-sensitive immunoliposomes, fluorescence was most 
significant after 1 hour incubation and clearly less pronounced after 3 and 24 hours 
(Figure 19). However, it was less intensive throughout the experiment than the 
corresponding fluorescence of cells incubated with pH-sensitive immunoliposomes.  
 
 
Figure 18: Uptake and endosomal release of pH-sensitive OX26-immunoliposomes by 
RG2 rat glioma cells. RG2 cells were incubated with propidium iodide loaded 
immunoliposomes and analyzed by confocal microscopy after (A) 1 h, (B) 3 h, or (C) 24 
h. Immunoliposomes were removed after 3 h and cells were washed with normal growth 
medium. 
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Figure 19: Uptake and endosomal release of not pH-sensitive OX26-immunoliposomes 
by RG2 rat glioma cells. RG2 cells were incubated with propidium iodide loaded 
immunoliposomes and analyzed by confocal microscopy after (A) 1 h, (B) 3 h, or (C) 24 
h. Immunoliposomes were removed after 3 h and cells were washed with normal growth 
medium.  
 
4.2.4 Gene uptake and expression using immunoliposomes  
After these promising results we decided to focus on uptake studies with the objective 
of gene uptake and expression. For this purpose, DNA was incorporated into liposomes 
by the freeze-thaw technique, which entails a low efficacy. For the purpose to remove 
external DNA, two different methods were carried out. By DNAse digestion, not 
incorporated DNA is decomposed and can not be expressed by cells. SEC 
chromatography is a mechanic method that separates external DNA from liposomes as 
molecular weight is significantly lower and therefore is retained for a longer time in the 
column than liposomes. To confirm the presence of DNA in the immunoliposomes, 
analysis by agarose gel electrophoresis before and after size exclusion chromatography 
was performed (Figure 20). A plasmid of known molecular mass was examined to 
control experiment. Figure 20 shows the analysis of liposomal plasmid DNA by 
electrophoresis. 25 µl-aliquots of the initial reaction mixture before SEC purification 
(Figure 20, lanes 3 and 4) and 500 µl-aliquots of SEC purified (pooled) fractions (lanes 
5 and 6) were applied on a 0.8 % agarose gel for electrophoresis. As control for the 
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DNAse I digest, pCDNA1.3-lacZ (8.5 kb) was used. The DNA band in lane 1 (after 
digestion) in the proximity of the 8 kb band of the DNA ladder, together with its 
complete absence in lane 2 (with digest), confirms functionality of electrophoresis and 
DNAse digestion. The DNA bands of the original liposome mixture (reaction mixture 
after incorporation process), are in the area of the 5 kb band of the DNA ladder, 
independent of DNAse digestion (lane 4) or not (lane 3). This agrees with 
manufacturer’s molecular mass indication of pGL3 (4.8 kb). Bands of the original 
liposome mixture differ considerably in intensity and dimension when treated with 
DNAse (lanes 3 and 4), the signal becomes narrow-banded and well defined. Analysis 
of liposomal fractions after SEC (lane 6) and post-peak fractions (lane 5) exhibit 
similarly a 5 kb band that is well-defined and exact. Peak-fractions are more intensive 
than post-peak fractions which also contains certain amounts of DNA.  
 
 
Figure 20: Agarose electrophoresis to confirm DNA incorporation into immuno-
liposomes: (liposomal) plasmid DNA before and after purification by size exclusion 
chromatography and optional DNAse I digestion. Lanes: 1: pCDNA3.1-lacZ plasmid 
(8.5 kb) without DNAse; 2: pCDNA3.1-lacZ plasmid with DNAse; 3: Immunoliposomes 
containing pGL3 (4.8 kb) without DNAse, not purified by chromatography; 4: 
Immunoliposomes containing pGL3 with DNAse, not purified by chromatography; 5: 
DNAse treated immunoliposomes after chromatography: post-peak fraction; 6: DNAse 
treated immunoliposomes after chromatography: peak fraction; 7: buffer control; 8: 1 kb 
DNA ladder (Invitrogen Cat. # 15615-024, Carlsbad, CA) 
 74
Results  
4.2.5 Liposomal administration of pGL3 expression vector 
The expression of liposome-incorporated luciferase gene in RG2 rat glioma and L6 rat 
muscle cells was determined by pGL3 Luciferase Reporter Vector under the control of 
the unspecific SV40 promoter (Promega, Madison, WI), using lipofectamine transfection 
as control. Lipofectamine transfections were conducted under standard conditions, as 
recommended by the manufacturer’s protocol. Transcriptional activity was measured 
with a TECAN fluorescence and luminescence plate reader (Spectrafluor plus, TECAN, 
Männedorf, CH), and peak light emission was measured at 20°C and recorded as 
relative light units. Figure 21 shows L6 cells incubated with pGL3 Luciferase Reporter 
Vector for 24 hours. Plasmid DNA was either transfected with lipofectamine (not shown) 
or encapsulated in pegylated immunoliposomes that were conjugated to the OX26 mAb 
or the unspecific IgG2a mAb. OX26-immunoliposomes were examined in normal (1 x) or 
double concentration (2 x). Negative controls (Figure 21, control) were cells without 
plasmid administration, treated the same. Experiments were conducted with n = 6 wells 
per sample. Only double concentrated liposomal plasmids resulted in a luciferase 
expression higher than background (untreated cells). It was not tested whether further 
enhancement of concentration leads to an increase in luciferase expression of 
transfected cells. These results suggest that gene expression of cells transfected with 
liposomal plasmids can be enhanced by the OX26 mAb to a certain extend. However, it 
seems not to be the most adpted targeting vector and better results may be achieved 
with a more adapted antibody. The positive control, cells transfected with lipofectamine, 
exhibited strong luminescence (> 30000 relative light units in the same scale, data not 
shown). Rat glioma RG2 cells did not show differences between negative untreated 
control cells and cells incubated with liposome incorporated DNA (data not shown).  
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Figure 21: The luciferase activity in L6 cells, expressed as relative light units 
(luminescence), is shown for L6 cells after 24 h of administration of the pGL3 plasmid 
DNA encapsulated in pegylated immunoliposomes that were conjugated to the OX26 
mAb or the unspecific IgG2a mAb. Controls are not treated at all. Data are mean ± SEM 
(n = 6). Positive control cells were transfected with lipofectamine (not shown).  
 
4.2.6 Expression of β-galactosidase in RG2 cells 
Additionally to liposomal plasmid delivery of the β-galactosidase vector, gene 
expression experiments were also performed with lipofectamine transfection as positive 
control for the expression plasmid. Lipofectamine transfections were conducted under 
standard conditions, as recommended by the manufacturer’s protocol. In brief, 5 µg of 
the plasmid per well was used for lipofectamine transfection. The initial amount of 
plasmid used for incorporation into liposomes was 400 µg, 6.6 % from pooled liposome 
fractions after purification by SEC were placed per well. Loading efficiency was not 
determined; data from other experiments give efficiencies of about 5 % incorporation by 
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the passive freeze-thaw technique. In samples 24 and 48 hours after transfection, 
positive lipofectamine transfected controls showed intense blue staining (β-
galactosidase expression) at 1 hour after staining with X-gal solution. Cells incubated 
with liposomal β-galactosidase expression vector did not reveal any signals, even after 
a staining treatment of 24 h (pictures not shown).  
4.2.7 Uptake of liposomal, labeled oligonucleotides by RG2 cells 
After this limited success with β-galactosidase expression vector, uptake of fluorescent 
Cy3-labeled phosphorothioate oligonucleotides was examined. The intention was to 
investigate the location and endosomal release of liposomal cargo after cellular uptake. 
Targeted immunoliposomes under control of OX26 mAb were compared to 
unconjugated biotinylated PEG-liposomes and uptake was analyzed after 1, 24 and 40 
hours (Figures 22 and 23). Fluorescent microscopy after one hour didn’t reveal any 
difference, fluorescence was not detected in neither of the two formulations (Figure 22, 
inset A and C). Comparison after 24 h represented a more intensive fluorescence of 
cells incubated with OX26-immunoliposomes (Figure 22 A). However, unconjugated 
liposomes showed also fluorescence, but in a less extent (Figure 22 B). Analysis of 
DAPI staining brings out cell nucleus of stained cells and allows to discern the rate of 
cells that have taken up the labeled liposomal content.  
Visualization of fluorescence after 40 h incubation demonstrates no appreciable 
difference between targeted and unconjugated liposomes (Figure 23). Comparison with 
DAPI staining indicates that approximately every cell exhibits fluorescence and has 
taken up the labeled oligonucleotides. The punctuated staining pattern of fluorescence 
is located rather in the cytosol than in nucleus and is distributed all-over the cell plasma. 
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Figure 22: Uptake of liposomes by RG2 cells: fluorescent microscopy of Cy3-labeled 
oligonucleotides incorporated into OX26-immunoliposomes or into unconjugated 
liposomes after addition to cultured RG2 cells. (A) and (B) RG2 cells were incubated 
with OX26-immunoliposomes for 24 h prior to visualization by fluorescence microscopy 
of Cy3 (A) and DAPI staining (B); Inset (A) identical fluorescence microscopy of Cy3 
after 1 h incubation; (C) and (D) RG2 cells were incubated with unconjugated liposomes 
for 24 hours prior to analysis by fluorescence microscopy of Cy3 (C) and DAPI staining 
(D); Inset (C) fluorescence microscopy of Cy3 after one hour incubation. 
 
 
Figure 23: Uptake of liposomes by RG2 cells: fluorescent microscopy of Cy3-labeled 
oligonucleotides incorporated into OX26-immunoliposomes or into unconjugated 
liposomes after addition to cultured RG2 cells and incubation of 40 h prior to 
visualization by fluorescent microscopy. (A) RG2 cells were incubated with OX26-
immunoliposomes prior to visualization of Cy3 and DAPI staining (inset); (B) RG2 cells 
were incubated with unconjugated liposomes prior to visualization of Cy3 and DAPI 
staining (insert).  
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4.2.8 Cytotoxicity of liposomal daunomycin 
The next sets of experiments were based on something completely different. Drug 
delivery experiments using immunoliposomes were done with the aim to show a 
pharmacological in vitro effect. The cytotoxic substance daunomycin was therefore 
incorporated into OX26-immunoliposomes that were incubated with cells. The 
pharmacological action (i.e. cytotoxicity) and proliferation inhibition of daunomycin was 
determined in either a multidrug-resistant cell line and in a chemosensitive cell line 
using the sulforhodamine B cytotoxicity assay. Immortalized rat brain capillary 
endothelial cells (RBE4) overexpressing P-glycoprotein and the rat glioma RG2 cells 
were used for these experiments. LD50 values of daunomycin cytotoxicity, determined 
for incubation periods of 3, 6 and 24 hours with increasing concentrations of the 
cytotoxic agent, are shown in Table 1 and Figure 24 (RBE4) and 25 (RG2). The 
sensitivity of the multi-drug resistant RBE4 cells (LD50 after 3 hours 10.3 µM) towards 
daunomycin was significantly lower than the chemosensitivity of the RG2 cells, which 
showed a LD50 of 0.5 µM under the same assay conditions (Figures 24 and 25). LD50 
values were not dependent on the duration of the daunomycin incubation: An increase 
of the daunomycin incubation period from 3 to 6 h and 24 h led to similar LD50 values of 
15.5 µM and 13.4 µM for RBE4 cells and 0.2 µM and 0.3 µM for RG2 cells, respectively.  
 
Table 1: LD50 values in µM of RBE4 and RG2 cells. Values are means (n = 3) for 
exposure times of 3 h, 6 h and 24 h.  
 
Cell line RBE4 RG2 
LD50 3h 10.3 0.5 
LD50 6h 15.5 0.2 
LD50 24h 13.4 0.3 
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Figure 24: Dose-dependent cytotoxicity of daunomycin in rat brain endothelial RBE4 
cells: influence of increasing concentrations of daunomycin on proliferation of RBE4 
cells after 3 h (♦), 6 h (■) or 24 h (▲) of daunomycin exposure time. Values are means 
± SEM, n = 6. Solid lines: Regression curves calculated by Michaelis Menten’s 
equitation. 
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Figure 25: Dose-dependent cytotoxicity of daunomycin in rat glioma RG2 cells: 
influence of increasing concentrations of daunomycin on proliferation of RG2 cells after 
3 h (♦), 6 h (■) or 24 h (▲) of daunomycin exposure time. Values are means ± SEM, n = 
6. Solid lines: Regression curves calculated by Michaelis Menten’s equitation.  
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These results indicate that daunomycin effectively inhibits growth in glioma RG2 cells 
and in endothelial RBE4 cells. As shown in Table 1, mean LD50 values for three 
different incubation times were 44 times lower for chemosensitive RG2 cells (0.3 µM) 
than for P-glycoprotein expressing RBE4 cells (13.1 µM). As a consequence of P-
glycoprotein drug efflux pump, RBE4 cells are expected to response more sensitive to 
liposomal formulations than to free daunomycin. By-passing of P-glycoprotein using 
immunoliposomes can enhance the toxicity of a drug in a cell line that overexpresses 
this efflux pump, such as RBE4 cells. All further cytotoxicology experiments were 
therefore performed with chemoresistant REB4 cells.  
4.2.9 Cellular uptake of liposomal [3H]daunomycin 
Cellular uptake of radiolabeled daunomycin by chemoresistant RBE4 cells did increase 
significantly if the drug was incorporated within biotinylated OX26-immunoliposomes 
(Figure 26). There was a more than 2-fold increase in cellular uptake of daunomycin 
during a 1 h incubation. After an incubation of three hours, the uptake was 12.7 % for 
liposomal and 5.2 % for free daunomycin respectively. The observed effect was time-
dependent as longer incubation-times of liposomal daunomycin did result in a further 
and statistically significant increase in cellular accumulation of daunomycin (Figure 26). 
Preliminary incubation of the cells with free OX26 didn’t change the uptake of liposomal 
daunomycin significantly.  
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Figure 26: Cellular uptake of either free [3H]daunomycin or [3H]daunomycin 
incorporated in OX26-immunoliposomes after pre-incubation where indicated, by REB4 
brain endothelial cells. Values  are means ± SEM, n = 5. *: P < 0.005 by Student’s t-test 
as compared to the indicated group. 
 
 
4.2.10 Pharmacological effects of daunomycin loaded immunoliposomes on   
RBE4 cells 
Cellular uptake of liposomal daunomycin was associated with cytotoxic effects of 
daunomycin. Toxicity experiments were performed using the immortalised rat brain 
capillary endothelial cell line (RBE4) and are shown in Figures 27, 28, 29 and 30. Cell 
growth of RBE4 cells was inhibited by liposomal daunomycin.  
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Figure 27: Cytotoxicity of different formulations of daunomycin in RBE4 brain 
endothelial cells: time-dependent inhibition of cell growth after exposure to different 
concentrations of daunomycin either incorporated in OX26-immunoliposomes (IL) or 
applied as free drug (free dauno). Control: 45 min pre-incubation of RBE4 cells with 1 
mg/ml of free OX26 mAb (comp). Values are means ± SEM, n = 8. P < 0.005 (*) by 
Student’s t-test as compared to the indicated group. 
 
 
Cellular toxicity did increase with increasing incubation times (i.e. 1 h versus 3 h). Cell 
growth after 1 h incubation with 1 µM liposomal daunomycin was 78.8 ± 2.5 % of the 
untreated control; prolongation of exposure time to 3 h entailed a reduction of cell 
growth to 44.4 ± 2.5 % of untreated control cells. The observed pharmacological effects 
were dose-dependent (i.e. 1 µM versus 5 µM of daunomycin). Incubation with 5 µM 
provoked even more important reductions in growth (35.2 ± 3.2 % of untreated control 
cells after 1 h and 16.8 ± 1.4 % after 3 h, respectively). Effects were mediated by the 
OX26 monoclonal antibody since competitive inhibition of cellular uptake of liposomal 
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daunomycin by co-incubation with 100 µg/ml of free OX26 decreased cellular toxicity of 
the drug significantly (cell growth 94.2 ± 3.2 % of untreated control for 1 µM 
daunomycin and 67.7 ± 4.3 % for 5 µM, respectively). 
The same experiments were performed on confluent cells (results not shown). Effects 
were notably more obvious on the sub-confluent cell layer. Results were statistically 
significant in both, sub-confluent and confluent cells. 
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Figure 28: Daunomycin response of RBE4 brain endothelial cells: inhibition of cell 
growth after exposure to free or in OX26-immunoliposomes incorporated daunomycin 
for indicated times and concentrations. Values are means ± SEM, n = 8. P < 0.005 (*). 
 
 
Figure 28 presents same experiments in comparison with a formulation of free 
daunomycin. In these experiments, free daunomycin had a surprisingly strong cytotoxic 
effect which was significantly higher than the effect of liposomal daunomycin (Figure 
28). Viability in RBE4 cells was lower throughout all experiments, when incubated with 
free daunomycin. This despite the fact that cellular uptake (and thus intracellular 
concentrations) of daunomycin were lower after incubations with free drug as opposed 
to incubations with liposomal drug (Figure 26). After one-hour incubation at 1 µM 
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daunomycin, cell growth was 78.8 ± 2.5 from untreated control for liposomal 
daunomycin and 30.1 ± 2.3 % for free daunomycin. After 3 h, values were 44.4 ± 2.5 % 
for liposomal and 25 ± 2.1 % for free daunomycin. Maximal toxicity was observed at the 
high concentration (5 µM) after 3 hours incubation with free daunomycin. Viability was 
1.9 ± 0.1 % (16.8 ± 1.4 % for liposomal daunomycin).  
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Figure 29: Time-dependent cytotoxicity of different formulations of daunomycin: RBE4 
cells were incubated with either 15 µM daunomycin incorporated in OX26-
immunoliposomes (□) or 15 µM free drug (●) for the indicated period of time. At 24 h, 
cytotoxicity of daunomycin was determined. Values are means ± SEM, n = 6. 
 
 
Figure 29 displays the time-response curves for 15 µM daunomycin that was free or 
incorporated into OX26-immunoliposomes, for exposure times of 1, 3, 6, 12 and 24 h. 
Again, cells response of free daunomycin was more sensitive than of the OX26 coupled 
liposomal formulation. Differences were more obvious at the earlier time-points and 
approximated over experimentation course. Cell growth after 1 hour incubation was 
77.3 ± 2.6 % of controls for liposomal (OX26 controlled) daunomycin and 51.2 ± 1.8 % 
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for free daunomycin. The importantly higher toxicity of free daunomycin, however, was 
present only in incubations which had a duration of less than 12 hours (Figure 29) as 
prolonged incubations with liposomal daunomycin led to a strong increase in cellular 
toxicity of the immunoliposomes. Values converged after 12 hours of incubation and 
curves even crossed after 24 hours of incubation. 
Inhibition of cell growth in a dose-dependent way is illustrated in Figure 30. Both, 
liposomal (OX26 controlled) and free daunomycin caused a significant reduction of 
protein content measured by the SRB toxicity assay at higher doses for different 
exposure times (which is 3 hours in Figure 30). Again, free daunomycin causes 
significantly more cell growth inhibition than liposomal daunomycin formulations. 
However, values converge at higher concentrations; cell growth after 3 hours exposure 
to 15 µM daunomycin was 66.9 ± 2.7 % of controls for liposomal daunomycin and 46.4       
± 1.0 % for free daunomycin, whereas at 1.5 µM, values divergence more (100 ± 2.7 % 
and 64.2 ± 2.7 % respectively). Daunomycin effect was tested up to 24 hours exposure 
with 15 µM formulations. Under these conditions saturation occurred with both, 
liposomal and free daunomycin, generating very low cell growth values. 
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Figure 30: Daunomycin response of RBE4 brain endothelial cells: Concentration 
dependence of inhibition of cell growth after 3 hours exposure to free or OX26-
immunoliposomes incorporated daunomycin for indicated concentrations. Values are 
means ± SEM, n = 6. 
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Experiments were conducted several times and same trends persisted continuously. 
However, there was a substantial variability between individual values of different sets 
of experiments or cell batches. Broad relations between free and liposomal daunomycin 
were assessed by implementing average values of performed experiments. The 
response of RBE4 brain endothelial cells to daunomycin was compared for 15 µM of 
free and liposomal daunomycin after a 1 hour incubation time throughout 3 independent 
sets of experiments. Toxicity of liposomal (OX26) daunomycin was 50.9 ± 29.4 % 
(mean of n = 3) of toxicity caused by free daunomycin.  
In addition, total percent reversal caused by pre-incubation was analyzed statistically 
throughout all experiments. The reversal by pre-incubation with OX26 (means of n = 4) 
was 20.6 ± 38.2 %. These experiments were carried out at different daunomycin 
concentrations and OX26 competition concentrations. 
 
4.3 IN VIVO ASSAYS AND RESULTS 
4.3.1 Plasma concentrations of free and liposomal daunomycin in rat 
In order to explore the in vivo properties of biotinylated OX26-immunoliposomes, series 
of pharmacokinetic and tissue distribution studies were performed in the rat. Different 
formulations of liposomal radiolabeled daunomycin (equal doses of 20 µCi/kg 
equivalent to 0.6 µg/kg) were applied by jugular vein injection (including free drug). Five 
different types of liposomes were prepared and loaded with radiolabeled daunomycin 
using the pH gradient method. Daunomycin loading was achieved with a high 
reproducible yield (> 95 % entrapment in most cases) (Huwyler et al., 1996). Fabricated 
types of liposomes were (1.) conventional, sterically stabilized (by incorporation of lipid-
conjugated PEG) liposomes and (2.) additionally biotinylated (by incorporation of 
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DSPE-PEG-biotin phospholipids) liposomes that were either (3.) used directly or (4. and 
5.) linked to a streptavidin coupled antibody by means of a biotin-streptavidin bond. In 
doing so, two antibodies were used: the monoclonal mAb OX26 against transferrin 
receptor in order to show a specific targeting, and the IgG2a isotope as an unspecific 
control antibody. Previous studies have shown that uptake of unchanged mouse IgG2a 
solely by rat tissue is minimal and behaves similar to a blood volume marker after i.v. 
injection (Pardridge et al., 1991). Pharmacokinetic parameters (Table 2) were 
calculated by non-compartmental data analysis of the plasma-concentration versus time 
profiles shown in Figure 31.  
 
Table 2: Pharmacokinetics in the rat of different formulations of [3H]daunomycin: Area 
under the plasma concentration curve for the initial 60 min after intravenous bolus 
injection (AUC0-t), steady state volume of distribution (VD) and plasma clearance (Cl) of 
free drug (daunomycin) or drug incorporated within biotinylated PEG-liposomes, 
unspecific IgG2a-immunoliposomes and biotinylated OX26-immunoliposomes. Data are 
means ± SEM, n = 3.  
 
Vehicle AUC(0-1h) T½ VD(SS) Cl 
 
Daunomycin Vehicle PEG biotin IgG %ID*min/ml min l/kg ml/min/kg 
Free drug - - - 3.69 ± 0.4 49.4 ± 7.6 3.85 ± 0.3 55.6 ± 6.4 
PEG-liposomes + - - 299.78 ± 13.0 38.0 ± 1.8 0.05 ± 0.0 0.9 ± 0.0 
Bio-liposomes + + - 210.38 ± 11.0 28.8 ± 1.6 0.05 ± 0.0 1.3 ± 0.0 
OX26 + + + 30.17 ± 2.3 25.7 ± 1.8 0.35 ± 0.0 9.3 ± 0.5 
IgG2a + + + 47.67 ± 3.4 15.9 ± 1.8 0.15 ±0.0 6.8 ± 0.7 
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Free daunomycin is rapidly removed from the circulation. The steady state volume of 
distribution (VD = 3.9 l/kg) and the systemic plasma clearance (CL = 56 ml/min/kg) are 
very high. This is in contrast to the corresponding values for biotinylated PEG-
liposomes (PEG-liposomes; VD = 0.05 l/kg and CL = 1.3 ml/min/kg, Table 2). 
Biotinylation of conventional PEG-liposomes has a negligible impact on their plasma 
concentrations, volume of distribution or plasma clearance: Control experiments using 
non-biotinylated PEG-liposomes revealed a volume of distribution of 0.05 l/kg and a 
plasma clearance of 0.9 ml/min/kg. In view of these minimal differences, we assumed 
that it doesn’t make a substantial difference whether biotinylated or non-biotinylated 
PEG-liposomes were used as a plasma volume marker (V0) for the calculation of organ 
PS products. We therefore decided to focus in our discussion solely on biotinylated 
PEG-liposomes and to use them as V0 for the calculation of PS products (Huwyler et 
al., 1996).  
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Figure 31: Plasma-concentration versus time profiles in the rat of different formulations 
of [3H]daunomycin: Intravenous bolus administration of daunomycin or daunomycin 
incorporated within biotinylated PEG-liposomes (PEG-liposomes), unspecific IgG2a-
immunoliposomes (IgG-IL) and biotinylated OX26-immunoliposomes (OX26-IL). Plasma 
concentrations (%ID/ml) of [3H]daunomycin are plotted versus times. Data are means ± 
SEM, n = 3. 
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The plasma clearance of radiolabeled drug was reduced 62-fold by incorporation into 
liposomes and solely PEG conjugation. An additional biotinylation resulted in a less 
pronounced 43-fold reduction of plasma clearance. These reductions are indicative of a 
long retention of the drug within sterically stabilized liposomes and the plasma 
compartment. The stability of PEG-liposomes in the circulation was investigated in 
previous studies where the presence of intact liposomes in the circulation for at least 6 
hours after injection was evidenced (Huwyler et al., 1997). Conjugation of antibodies to 
pegylated liposomes reversed partially the effect of pegylation and led to an increase of 
the plasma clearance as well as the volume of distribution of these immunoliposomes. 
The plasma clearance of immunoliposomes was 9.3 ml/min/kg (OX26 coupled) and   
6.8 ml/min/kg (IgG2a coupled). The effect of pegylation on the area under the plasma 
concentration curve after one hour (AUC0-t) was most conspicuous. Steric stabilized 
liposomes increased the daunomycin AUC0-t by a factor of 81 when compared to the 
free drug and additional biotinylation by a factor of 57 (Table 2).  
4.3.2 Tissue distribution of free daunomycin and daunomycin loaded 
liposomes or immunoliposomes  
Several tissues (brain, liver, heart, kidney, lung, spleen, testes and muscle tissue) were 
analyzed for tissue clearance (PS product) and tissue uptake (%ID/g tissue) of different 
daunomycin formulations (Figure 32 and Table 3). Analysis revealed a very low volume 
of distribution of sterically stabilized and biotinylated liposomes which were used as a 
plasma volume marker (V0), leading per definition to a PS of zero (since VD – V0 is 
zero) for this formulation (‘BIO’ in Figure 32). In sharp contrast to brain, no superiority of 
OX26-immunoliposomes could be shown with respect to %ID/g tissue for spleen, liver, 
heart, muscle or kidney. Spleen and liver are the two organs where substantially higher 
amounts of immunoliposomes accumulate as compared to free daunomycin (Figure 32 
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A and B). The high tissue clearance (PS product) of immunoliposomes is indicative of 
an active and unspecific sequestration of these particulate drug carriers by spleen and 
liver. In contrast, immunoliposomes are poorly retained by muscle tissue or the kidney. 
In these organs, free daunomycin had a 20- to 30-fold higher tissue clearance (Figure 
32 F). The highest PS product was reached for free daunomycin in the kidney with a 
value for 120 µl/min/g tissue (Figure 32 H).  
 
Table 3: Tissue distribution in the rat after intravenous injection of different formulations 
of [3H]daunomycin: Tissue clearance (PS) and tissue uptake (%ID/g tissue) were 
determined 60 min after intravenous bolus administration of [3H]daunomycin or 
[3H]daunomycin incorporated within immunoliposomes (conjugated to the OX26 mAb or 
an unspecific IgG2a control). Biotinylated PEG-liposomes are used as plasma volume 
marker and have both a PS product and %ID/g value of zero. Data are means ± SEM, n = 3.  
 
Tissue Formulation 
PS 
(µl/min/g tissue) 
%ID/g tissue 
Spleen free daunomycin 39.5 ± 6.5 0.15 ± 0.04 
 OX26-liposomes 171.1 ± 42.3 5.21 ± 1.46 
 IgG-liposomes 228.0 ± 47.3 10.10 ± 1.45 
Liver free daunomycin 54.3 ± 7.2 0.19 ± 0.01 
 OX26-liposomes 47.3 ± 6.9 1.42 ± 0.22 
 IgG-liposomes 49.9 ± 8.9 2.22 ± 0.24 
    
Heart free daunomycin 48.2 ± 1.1 0.177 ± 0.017 
 OX26-liposomes 2.66 ± 0.19 0.079 ± 0.001 
 IgG-liposomes 4.19 ± 0.67 0.188 ± 0.021 
Muscle free daunomycin 15.7 ± 1.3 0.058 ± 0.010 
 OX26-liposomes 0.55 ± 0.14 0.016 ± 0.004 
 IgG-liposomes 0.52 ± 0.05 0.023 ± 0.002 
    
Kidney free daunomycin 120.3 ± 5.0 0.444 ± 0.054 
 OX26-liposomes 4.41 ± 1.40 0.139 ± 0.053 
 IgG-liposomes 5.00 ± 0.62 0.227 ± 0.024 
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Figure 32: Tissue distribution in the rat after intravenous injection of different 
formulations of [3H]daunomycin: free daunomycin (DAU), biotinylated PEG-liposomes 
(BIO), OX26-immunoliposomes (OX26) and IgG2a-immunoliposomes (IgG2a). Tissue 
clearance (PS) and uptake (%ID/g tissue) were determined 60 min after intravenous 
bolus administration of the relative [3H]daunomycin formulation. Data are means ± 
SEM, n = 3. 
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Interestingly, only in brain, PS product of OX26-immunoliposomes was higher than of 
IgG2a-immunoliposomes (Figure 32 G and Figure 33). All other organs showed a 
resembling pattern for PS products: free daunomycin >> IgG2a-immunoliposomes ≥ 
OX26-immunoliposomes > biotinylated PEG-liposomes (> PEG-liposomes) (Figure 32, 
C, D and H). Analysis of brain tissue at 60 min after intravenous administration of these 
different formulations of daunomycin revealed a permeability surface area (PS) product 
of free daunomycin of 1.7 µl/min/g brain. This in contrast to daunomycin incorporated 
within OX26-immunoliposomes which had a tissue clearance (i.e. PS product) of 0.4 
µl/min/g brain. However, the area under the plasma concentration curve of daunomycin 
is very low (Table 2) resulting in a brain accumulation (%ID/g brain = 0.006) which is 
only half of the one of OX26-immunoliposomes (%ID/g brain = 0.01). The PS product of 
unspecific control IgG2a-immunoliposomes is 0.1 µl/min/g brain leading to a %ID/g brain 
value of 0.006. The difference between brain accumulation of OX26-immunoliposomes 
and IgG2a-immunoliposomes represents thereby the effect mediated specifically by the 
OX26 monoclonal antibody. It is important to note that the use of pegylated liposomes 
reduced the PS product to zero. As a consequence, no brain uptake of such PEG-
liposomes was observed despite the high plasma AUC for this liposomal formulation.  
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Figure 33: Brain delivery of [3H]daunomycin or [3H]daunomycin incorporated within 
OX26-immunoliposomes or control IgG2a-immunoliposomes: Brain tissue clearance (PS 
product, left panel) and brain uptake (%ID/g brain tissue, right panel) were determined 
60 min after intravenous bolus administration in the rat. Data are means ± SEM, n = 3. 
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5 DISCUSSION AND FUTURE PERSPECTIVES 
5.1 CHARACTERIZATION AND OPTIMIZATION OF A NOVEL 
LIPOSOMAL CARRIER SYSTEM  
 
Sterically stabilized liposomes have some significant advantages over conventional 
liposomes, including decreased uptake by macrophages of the reticuloendothelial 
system, increased blood residence times, increased stability to contents leakage, 
increased flexibility in lipid composition and dose-independent pharmacokinetics. 
Ganglioside GM1 appears to be unique among the glycolipids in conveying these 
properties to liposomes, and polyethylene glycolipid derivatives appear, so far at least, 
to be superior to other polymers in this regard (Allen, 1994b). The distinctive properties 
of stabilized liposomes or PEG-liposomes, makes them excellent candidates for many 
therapeutic applications including drug targeting (Maruyama et al., 1990b; Schnyder et 
al., 2004; Torchilin et al., 1992) as well as its use as a slow release formulation (Allen et 
al., 1992; Mayhew et al., 1992; Papahadjopoulos et al., 1991).   
 
In the present thesis, a novel design of biotinylated PEG-immunoliposomes is 
presented, where a streptavidin-conjugated targeting vector (i.e. the OX26 mAb raised 
against the rat transferrin receptor) is attached to the surface of the liposome using a 
PEG spacer (Figure 5). Biotin was thereby coupled to the tip of the pegylated 
phospholipid PEG-DSPE, and subsequently incorporated into sterically stabilized 
liposomes (PEG-liposomes). A biotinylated PEG-liposome carries approximately 5500 
strands of 2000 Da PEG and 30 strands of the linker lipid biotin-PEG-DSPE, and has a 
measured particulate size of 150 nm. The use of PEG as a flexible tether allows the 
biotin, and thereby the attached OX26 mAb, to extend away from the liposome surface, 
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which minimizes steric hindrance by unconjugated PEG moieties. Previous studies 
(Laverman et al., 2000) have indeed demonstrated that biotinylation of PEG-liposomes 
does not affect their in vivo pharmacokinetics in control rats, but promotes their 
accumulation in subcutaneous Staphylococcus aureus abscesses in the rabbit. 
Furthermore, direct measurement of the ligand-receptor interaction potential using 
biotinylated PEG-liposomes and streptavidin on a supported lipid bilayer indicated a 
markedly extended range of the interaction (Wong et al., 1997).  
 
Biotinylated PEG-liposomes can be used for the non-covalent conjugation of any avidin- 
or streptavidin-conjugated ligand. Such ligands could include genetically engineered 
single chain antibody-streptavidin fusion proteins, such as the OX26 single chain Fv 
antibody-streptavidin fusion protein (Li et al., 1999), which can be produced on large 
scale in procaryotic or eucaryotic expression systems (Morrison and Shin, 1995). In the 
present work, streptavidin was chemically linked to the hybridoma-generated OX26 
mAb. MBS was used as a hetero-bifunctional cross-linker reactive for primary amines in 
streptavidin and a single thiol group introduced into the OX26 mAb by thiolation with 
Traut's reagent (2-iminothiolane). This procedure has been shown previously to retain 
both, the antigen affinity of the OX26 mAb (Huwyler et al., 1996) and the biotin binding 
site of streptavidin (Zhang et al., 2002a). The OX26-streptavidin conjugate was purified 
and analyzed by gel-filtration chromatography (Figure 9). The conjugate was identified 
by a shift in molecular mass as compared with unconjugated OX26 mAb, and its ability 
to bind the fluorescent label biotin-fluorescein (Figure 9 A). A separation was achieved 
between cross-linked precipitates OX26-streptavidin (Figure 9 B, peak I) and unbound 
OX26 mAb (Figure 9 B, peak II), and this was confirmed by Tris-Glycine gel 
electrophoresis (Figure 10). Fractions containing the reaction product OX26 mAb 
conjugated to streptavidin were identified comparing electrophoresis pattern with the 
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molecular weight marker SeeBlue® Plus2 (Invitrogen) and bands of OX26 mAb (lane 
IV). The characteristic pattern of two light chain bands and one heavy chain band 
(Yoshikawa and Pardridge, 1992) have been confirmed. Except from lane II (peak II), 
samples analysed under non-reducing conditions (lanes I-III) show accumulation of 
signals above 250 kDa. Lane II exhibits the most intensive band at about 150 kDa, 
indicating free OX26 mAb (molecular weight of 150 kDa). Lane I (not reduced peak I) 
shows a band in the region of 200 kDa what corresponds to OX26-streptavidin by 
adding together molecular weights (molecular weight of streptavidin is 60 kDa). This 
peak is also present in the reaction mix before SEC purification (lane III). In addition, 
the band at approximately 150 kDa corresponds to the band (free OX26) in lane II. 
Cross-linking of OX26-streptavidin is supposed, considering the blurred signal above 
250 kDa. Possible molecular weight of cross-linked conjugates are n * 150 kDa + n * 60 
kDa, i.e. 270 kDa (1 OX26 linked to 2 streptavidin molecules), 360 kDa (2 OX26, 1 
streptavidin), 420 kDa (2 and 2) and so on. Lower weights can be assumed but later on 
end in a inseparable blur of bands. Under reducing conditions, the interchain disulfide 
bonds of the antibody are cleaved, resulting in separation in heavy and light chains of 
the antibody. Conjugated streptavidin is not cleaved from the antibody, since it is 
connected by a stable thioether binding. Again, there are multiple weights possible, as a 
consequence of cross-linking with multiple streptavidin molecules bound per antibody. 
Starting with total molecular weights of 25, 50, 85 (light chain and streptavidin), 110 
(heavy chain and streptavidin), 145 (two streptavidin molecules), continuation results in 
a blurred band likewise as it is possible to have inter-cross-linkages of two chains per 
streptavidin. These assumptions are confirmed in Figure 10, by the indefinite signals up 
from approximately 150 kDa in lane I (peak I) and III (reaction mix before purification) 
and it’s absence in lane II (peak II). These findings confirm the presence of OX26-
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streptavidin, cross-linked to a certain extent in pooled peak I and the occurrence of 
unconjugated OX26 in peak II.  
The approximate yield of streptavidin-conjugated OX26 recovered after purification was 
40 %. The binding capacity of the OX26-streptavidin conjugate for [3H]biotin was 
determined by an ultrafiltration method (Figure 11). There are normally four biotin-
binding sites on the tetrameric streptavidin (Hermanson, 1996). Analysis of the biotin 
binding curve indicates that biotin binding is only partially impaired as a consequence of 
the coupling of streptavidin with the OX26 mAb. Owing to the extremely high affinity of 
biotin binding to streptavidin, with a KD approximating 10-15 M (Hermanson, 1996), the 
affinity constant of the OX26-streptavidin conjugate in itself cannot be determined. 
However, using 32 nM of OX26-streptavidin conjugate, saturation of biotin binding is 
observed between 64 and 100 nM biotin, indicating the presence of two to three biotin-
binding sites on each OX26-streptavidin conjugate. The presence of multiple biotin-
binding sites on each OX26-streptavidin conjugate may potentially lead to cross-linking 
of biotinylated liposomes, and thus to the formation of liposomal aggregates. To 
minimize this risk and to block excess biotin-binding sites, free biotin was added to 
OX26-streptavidin in a molar ratio of 1:1 prior to coupling of the OX26-streptavidin 
conjugate to biotinylated liposomes.  
 
A vast number of different methods to synthesize liposomes are described. 
Phospholipids form spontaneously vesicles when transferred to water. The challenge is 
to produce liposomes which have the right size and structure and to entrap materials 
with high efficiency and in such a way that they do not leak out (New, 1990). The main 
difference between the various methods of production is in the way in which the 
membrane components are dispersed in aqueous media, before being allowed to 
coalescence in the form of bilayer sheets. In the present work, liposomes were 
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prepared after the simple physical dispersion method by drying down lipids and 
disperse them by addition of an aqueous medium, followed by shaking (New, 1990). 
Other methods, such as two-phase dispersion or detergent solubilization, are more 
complex or require more sophisticated equipment and components. The applied 
dispersion method is easy and fast, necessary facilities are a rotary evaporator 
apparatus for removing organic solvents (Figure 34) and an extruder to bring the 
liposomes to a defined size.  
 
 
Figure 34: Rotary evaporator apparatus for evaporating off organic solvents. The 
evaporator consists of a heating bath with a rotating flask, in which the liquid is 
distributed as a thin film over the hot wall surfaces and can evaporate easily. The 
evaporation rate is regulated by the heating bath temperature, the size of flask, the 
pressure of distillation and the speed of rotation. (New, R. (1990) in The practical 
approach series (Rickwood, D. and Hames, B.D., eds.), pp. 301, Oxford University 
Press, Oxford)(New, 1990). 
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Figure 35: Hand-driven extrusion apparatus with a capacity of 1 ml (LiposoFast-Basic, 
Avestin, Ottawa, Canada). A 50 - 400 nm pore-size polycarbonate membrane is placed 
in the filter holder (middle). Back-and-forth passages of the sample between the two 
syringes result in a defined size of extruded liposomes. 
 
 
We used for our studies a hand-driven extrusion apparatus with a capacity of 1 ml 
(LiposoFast-Basic, Avestin, Ottawa, Canada), which is easily made at low cost and 
meets the needs for our experiments (Figure 35). Alternatively, we had the possibility to 
use a Lipex™ high-pressure extruder (Northern lipids inc., Vancouver, Canada). 
However, the disadvantage of this device was a frequent congestion of the filter pores 
in consequence of the high pressure on the system. 
The main difficulty is to develop liposomal systems that feature certain flexibility in 
composition, no drug leakage and long circulation half-lives. Therefore, efficient loading 
of material into the liposome and prevention of leakage presents a fundamental issue. 
Most of the water-soluble materials, such as carboxyfluorescein and propidium iodide, 
will be entrapped into liposomes by introducing aqueous solutions of these materials 
before or at some stage during the manufacture of the liposomes. However, this 
method is highly inefficient due to the fact that concentration is equal inside and outside 
the liposomes. As shown theoretical in Figure 6, the captured volume of liposomes is 
related to the liposome diameter, the surface area of the vesicles (which is proportional 
to the square of the radius), lipid weight and number of vesicles. It represents a small 
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percentage of the whole suspension only, explaining the inefficiency of passive 
entrapment. Some materials can not be incorporated by another, more efficient (active) 
loading method. Oligonucleotides and plasmids, for example, require a gentle working 
method at physiologic pH and temperatures. For inexpensive and simply available 
substances, though, losses can be accepted and it is not necessary to develop a 
specific drug incorporation procedure.  
Certain types of compounds with ionizable groups and those that display both, lipid and 
water solubility, can also be introduced into liposomes after formation of the intact 
membranes (New, 1990). A substantial challenge with such substances is to retain 
them inside the liposomes and to circumvent leakage. Achieving equilibration between 
the liposome interior and exterior is a driving force in every system. If a lipophilic 
substance can pass the membrane and get inside the liposome, it is not hampered to 
go the same way back out again. However, there are substances that precipitate in a 
special form upon loading and pH change, respectively. Such compounds are the 
anticancer drugs daunomycin and doxorubicin that precipitate in the liposome interior in 
a form of gel with low solubility product. They practically do not leak out in the scale of 
days (Lasic et al., 1995). This is confirmed by the high loading efficiencies achieved in 
experiments with daunomycin in the present work. Furthermore, leakage was not 
excessive in the length of time, even after four days of storage at 4°C.  
On the other hand, a too high stability of liposomes is rather disadvantageous than 
desired. Remaining inside of stable liposomes, entrapped materials are not delivered to 
the target tissue, organs or cells. The objective is, to find the right balance between 
stability in the circulation and rapid endosomal release when vesicles are taken up by 
the target cells. An approach to resolve this problem is the development of (sterically 
stabilized) pH-sensitive liposomes (Simoes et al., 2004). Such liposomes are stable at 
physiological pH 7.4 but undergo destabilization and acquire fusogenic properties under 
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acidic conditions, thus leading to the release of their aqueous contents. Liposomes 
encounter such changes in pH during the process of receptor mediated endocytosis as 
the pH in the endosomal compartment is characterized to be around 5.5 (Tycko et al., 
1983). Destabilization of the liposomal membrane can also be induced by bound 
amphiphilic peptides that adopt an α-helical conformation in an acidic environment 
(Vogel et al., 1996) or the use of mixtures of cationic and ionizable anionic lipids 
(Duezguenes and Nir, 1999). Such pH-sensitive liposomes are typically prepared from 
mixtures of dioleoylphosphatidylethanolamine (DOPE), which adopts a non-bilayer 
inverted hexagonal (HII) phase in isolation, and an ionizable anionic lipid such as 
cholesterolhemisuccinate (CHEMS). In its negatively charged form at elevated pH 
values, CHEMS stabilizes DOPE in its bilayer organization. Protonation of CHEMS at 
pH values below its pK abolishes its stabilizing effect, leading to membrane inversion, 
membrane fusion and the release of entrapped substances into the liposome-
surrounding compartment (Hafez et al., 2000). This technology can be applied both to 
conventional liposomes as well as long-circulating, sterically stabilized liposomes 
(Slepushkin et al., 1997). Such pH-sensitive liposomes consisting of DOPE and 
CHEMS were produced and filled with propidium iodide in order to enhance endosomal 
drug release in the present work. It has been shown on Figure 18 that cells showed 
fluorescent signal one hour after incubation with pH-sensitive liposomes. However, 
despite this advantage of fast drug release, such liposomes were not sufficiently stable 
and incorporated substances leaked out when stored longer than 24 hours.  
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5.2 IN VITRO ASSAYS  
 
Antibody conjugated liposomes can be used for targeting of organs and tissues in vivo. 
In order to study cellular uptake of OX26-immunoliposomes, rat glioma RG2 cells, 
which acquire transferrin by receptor mediated endocytosis, were used. This cell line 
was previously shown to take up OX26 mAb connected covalently to liposomes 
(Huwyler et al., 1999; Huwyler et al., 1997). The question rises if the developed novel 
design of biotinylated immunoliposomes, linked via a non-covalent streptavidin-biotin 
binding to the OX26-streptavidin conjugate, is taken up the same way by this cell line. 
Immunostaining of RG2 cells with free OX26 mAb and visualization by a secondary 
antibody against mouse antibody, confirmed the presence of transferrin receptor. It was 
expressed on cellular surface, as well as in the intracellular compartment when fixed 
cells were permeabilized prior to immunostaining (Figure 15). Examination by confocal 
microscopy showed a fluorescent staining pattern of the cell plasma whereas incubation 
at 4°C inhibited cellular uptake. Under these conditions, fluorescence signal was 
restricted to the cellular surface, since receptor-mediated endocytosis is inhibited at low 
temperatures.  
 
Incubation at 37°C of RG2 cells with fluorescent-labeled OX26-streptavidin (Figure 17 A) 
resulted in accumulation of fluorescence within the cell, similarly. Furthermore, rat 
glioma RG2 cells incubated with biotinylated OX26-streptavidin immunoliposomes, 
which were filled with carboxyfluorescein to represent the liposomal cargo, exhibited a 
similar staining pattern (Figure 17 B). Fluorescent OX26-immunoliposomes were taken 
up by RG2 cells and did accumulate in distinct intracellular compartments, probably 
endosomes or lysosomes. After one hour of incubation, the entire cytoplasm showed a 
well-defined, particulate staining pattern. Background fluorescence of cells examined in 
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control experiments was not or only weakly fluorescent. This confirms that the signal 
originates from fluorescent immunoliposomes. This was further shown by competition 
experiments with free OX26 mAb, with the aim of occupying OX26 mAb binding-sites 
on the transferrin receptor (Figure 17 C). Fluorescence intensity was considerably 
diminished by this competition. In the face of the fact that it is hardly possible to achieve 
complete inhibition by competition, there is always some residual fluorescence present. 
Additionally, transferrin receptor does not disappear after mediating cellular (iron) 
uptake. The receptor is recycled after endocytosis with bound iron and release of the 
latter into the cell. Reoccurring on the cellular surface, the receptor is ready for the next 
endocytosis cycle. All these observations suggest that OX26-streptavidin conjugated 
biotinylated immunoliposomes penetrate RG2 cells by means of endocytosis as it was 
shown for other OX26-immunoliposomes.  
 
The question arises of whether targeting of skeletal muscle could be achieved using 
OX26-streptavidin as a vector directed against the transferrin receptor. The transferrin 
receptor is expressed by different organs, such as the liver, spleen, general vascular 
endothelium and the blood-brain barrier. In skeletal muscle, transferrin has been shown 
to have an important role in muscle growth, i.e. the process of myoblast and satellite 
cell proliferation, their fusion to myotubes and their further differentiation into muscle 
fibers (Ozawa, 1989). Studies with, for example, primary cultures of chick muscle cells 
(Sorokin et al., 1987) have clearly demonstrated high expression levels of functional 
transferrin receptors regardless of the state of growth or differentiation of these cells. 
We confirmed, by immunostaining experiments using the OX26 mAb, the presence of 
the transferrin receptor in rat skeletal muscle tissue (Figure 13). Tissue sections 
perpendicular to the muscle fibers show an intense immunostaining at the periphery of 
the myofibers (which have a diameter of 50 - 100 µm), as well as at the periphery of the 
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enclosed myofibrils. The staining of the myofiber surface can also be seen in 
longitudinal sections. These findings were yet endorsed by the little or no fluorescence 
in control experiments using secondary antibody only or an unspecific mouse IgG2a 
isotype control antibody. Incubation of L6 cells, a cell line derived from rat skeletal 
muscle, with OX26 mAb at 37°C followed by visualization of the OX26 mAb using a 
fluorescent secondary antibody (Figure 14) reveals a fluorescent signal on the cell 
surface as well as a particulate intracellular staining pattern. This observation suggests 
that the OX26 mAb is internalized by L6 cells under cell-culture conditions, and 
subsequently accumulates within the endosomal compartment of these cells. At 4°C, 
binding of OX26 mAb to the cell surface only was observed (Figure 14 C) because of 
inhibition of receptor-mediated endocytosis at low temperature. Our findings are in line 
with previous reports on expression levels of the transferrin receptor in L6 cells, which 
indicated a receptor density of approximately 200000 receptors per L6 myocyte (Fava 
et al., 1981). We conclude from these experiments that the L6 cell line can be 
considered to be a representative cell-culture model of skeletal muscle that may be 
used to study transferrin receptor-mediated transport processes in vitro.  
Uptake experiments in L6 cells (Figure 16) and RG2 cells (Figure 17) demonstrated that 
the functionality of the OX26 mAb is retained after chemical modification and coupling 
to streptavidin. Incubation of OX26-streptavidin, which was fluorescence-labeled using 
biotin-fluorescein, resulted in a strong intracellular accumulation of fluorescence in L6 
cells (Figure 16 A). Similar results were obtained using carboxyfluorescein loaded 
OX26-immunoliposomes (Figure 16 B). The observed effects were mediated 
specifically by the OX26 mAb, since competitive inhibition of cellular uptake was 
observed in presence of free OX26 mAb (Figure 16 C). The percentage of positive cells 
in these experiments was estimated to be over 90 %. We conclude that biotinylated 
OX26-immunoliposomes, despite their big particulate size of 150 nm, are transported 
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across the plasma membrane of L6 muscle cells by means of receptor-mediated 
endocytosis. Experiments with RG2 cells confirmed these results (Figure 17) in rat 
glioma cells. 
 
Recapitulating, these experiments confirm that the developed innovative drug carrier 
system (OX26 conjugated via streptavidin-biotin bond to biotinylated immunoliposomes) 
is taken up by the two transferrin receptor expressing cell lines, glioma RG2 and muscle 
L6 cells, by means of endocytosis. 
 
It was been shown in several studies that liposomal cargo is released in a time-depend 
manner to the cytoplasm. The kinetics of endosomal release (Cerletti et al., 2000) are 
very similar to the one described for other liposomal delivery systems, i.e. folate-
targeted liposomes (Vogel et al., 1996). Among other groups, Vogel et al. also 
demonstrated that the process or drug release can be accelerated by the use of pH-
sensitive liposomes. By taking advantage of the decreased pH within the endosomal 
compartment, drug incorporation into pH-sensitive liposomes can facilitate its release 
after uptake by transferrin receptor expressing cells. Two different liposome formations, 
a pH-sensitive and a conventional formulation, were synthesized and their release of 
incorporated drug in transferrin receptor expressing RG2 cells was compared (Figures 
18 and 19). Findings corresponded broadly to published data. Major differences could 
be manifested only at early time points, with the most notably distinction after 3 hours 
(Figure 18 B and E). Interestingly, comparison after one hour could not point out an 
evident distinction between pH-sensitive and conventional immunoliposomes. 
Propidium fluorescence is detected in the cell only when liposomes have successfully 
released their contents into the cytoplasm. Upon binding to RNA or diffusion into the 
nucleus and association with DNA, a dramatic increase on fluorescence is observed, 
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that is distinguishable from unbound PI (Vogel et al., 1996). However, leakage of 
liposomes and absence of free PI was not controlled and may explain similar results for 
the two formulations after one hour, but a distinctive differentiation after only 3 hours. 
Figures 18 and 19 reveal an outstanding staining pattern with most of the fluorescence 
localized in the nucleoli and the cytoplasm. As nucleoli are the organelles in the nucleus 
where ribosomes are synthesized, they are particularly important and multiplied when 
protein expression is required, hence when cells are in division state. PI is used to 
visualize DNA and RNA. What may explain fluorescence of nucleoli. The peculiar 
nucleolus staining has been shown by Vogel et al. similarly. Fluorescence was less 
pronounced after 24 and 36 hours for both formulations what may be due to a dilution 
effect of dividing cells (liposomes were removed after 3 hours).  
 
We can summarize our preliminary results as follows: OX26-immunoliposomes have 
been taken up by RG2 cells and released their cargo into the cells. Release was time-
dependent and could be accelerated by incorporating the dye into pH-sensitive 
liposomes. Further experiments will be needed to get a quantitative assessment of the 
process of endosomal release.  
  
A variety of gene delivery systems have been tested including viruses and liposomes. 
Because of the risk of infectivity and their possible immunogenic, cytopathic or 
recombinogenic effects, there are potential complications associated with viral vectors 
(Xu et al., 2002). Consequently, a significant amount of attention has been directed at 
nonviral vectors for the delivery of molecular therapeutics. The lack of immunogenicity 
may be the most important advantage of the liposome approach. Gene expression of 
“immunoliposomal” administered expression vectors in vitro was examined using two 
different, commercially available and highly sensitive plasmids: pGL3-Basic Luciferase 
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Vector (Promega) and β-galactosidase plasmid DNA (pcDNA™3.1/myc-His/lacZ, 
Invitrogen, Carlsbad, CA). Luciferase expression vector incorporated into OX26-
immunoliposomes and administered on RG2 and L6 cells, did lead to a marginal 
luciferase expression only (Figure 21). The presence of complete DNA within the 
liposomes was proofed by agarose electrophoresis (Figure 20) and corresponded to the 
indicated molecular weight of the commercial plasmids, controlled by a 1 kb DNA 
ladder. Furthermore, the control experiment of DNA transfection by using a well 
established transfection reagent (lipofectamine) that revealed very high luciferase 
expression on both examined cell lines, confirmed the function of the plasmid. The 
expression level of the positive control was 400 fold higher than the level of OX26-
immunoliposomes. Since incubation time was 24 hours, incubation time was not a 
limiting factor in these experients That should be largely sufficient for endosomal uptake 
(Note: T½ values for transferrin receptor endocytosis in erythroid cells were shown to 
be approximately 1.5 min (Ponka and Lok, 1999)) and gene expression, and does not 
explain the outstanding difference between lipofectamine transfection and gene delivery 
by using immunoliposomes. Gene expression experiments using a β-galactosidase 
expression vector (pcDNA™3.1/myc-His/lacZ), with at least similar sensitivity, did not 
show better results for liposomal gene delivery. Cells transfected with lipofectamine 
likewise expressed β-galactosidase in a pronounced extend, clearly distinguishable 
from liposomal transfected cells that didn’t exhibit the characteristic blue staining of X-
gal, confirming β-galactosidase expression.  
The results of these studies of gene expression via liposomal administration can be 
summarized with the conclusion that RG2 and L6 cells can be used both to study gene 
expression of luciferase and β-galactosidase expression vectors but that gene 
expression could not be achieved by administration plasmids incorporated into 
immunoliposomes.  
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In summary, marginal gene-transfer by immunoliposomes could be achieved only. The 
question arises if incomplete cellular uptake of DNA or intracellular enzymatic 
degradation of the transported DNA might be the reason for this low transfection 
efficiency. To clarify this point, additional DNA uptake experiments were performed. 
 
To investigate endosomal release and location of liposome incorporated DNA, Cy3-
labeled oligonucleotides were encapsulated into immunoliposomes and administered to 
RG2 cells. OX26-immunoliposomes were loaded by the gentle freeze-thaw method and 
as a control, unconjugated liposomes were examined in parallel. Figure 22 confirms the 
uptake of the oligonucleotides incorporated into OX26-immunoliposomes. Furthermore, 
fluorescence signal after 24 h incubation with unconjugated liposomes is apparently 
decreased, compared to immunoliposomes. That confirms a more rapid uptake of 
targeted OX26-immunoliposomes in a directly measurable form. Simultaneously, these 
observations also show an uptake, even if decreased, of “unspecific” liposomes without 
connected targeting vector. Additionally, after an incubation of 40 hours, no difference 
between antibody conjugated OX26-immunoliposomes and unspecific biotinylated 
PEG-liposomes could be recognized. In spite of the more rapid uptake by OX26-
targeted immunoliposomes, signals could not be distinguished from those, obtained 
with bare liposomes after longer incubation times. This extensive unspecific uptake may 
result from interactions of biotin with cell surface structures, such as other receptors or 
uptake mediating proteins. Another possibility could be the fusion of liposomal bilayer 
with cell membranes or unspecific uptake mechanisms via other transporters. An 
explicit location of the fluorescence within the cells was difficult to determine. Figure 23 
evidences a predominantly fluorescence signal in the cytoplasm, but not in the nucleus. 
Thus, neither oligonucleotides delivered by OX26-immunoliposomes, nor by bare 
liposomes reach nucleus within 40 hours and rather remain in the cytoplasm. DNA 
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plasmids containing a (therapeutic) gene need to enter the nuclear compartment for 
transcription and integration into the host cell genome for stable expression (Belting et 
al., 2005). Small inhibitory RNA (siRNA) on the contrary, are processed for specific 
targeting of complementary mRNA sequences in the cytosol and have to escape 
therefore through the liposomal and endosomal membrane into the cytosol. Thus, if 
immunoliposomes are filled with bioactive RNA structures, delivery to the nucleus has 
not to be achieved as protein synthesis takes place in the cytosol. For liposomal DNA 
plasmids, however, delivery to the nucleus is mandatory and may not be reached, 
relating to used immunoliposomes. Moreover, once inside the nucleus, plasmid 
mediated effects will not persist, unless extraneous DNA integration into the host cell 
chromatin structure is attained. Whereas retroviral vectors are capable of integrating 
into the host genome, non-viral delivery systems are restricted to extra chromosomal 
plasmid expression and may even exit the nucleus during cell division (Belting et al., 
2005). Considering all this, a detailed understanding of how bioactive peptides and 
nucleic acids are processed and targeted in the intracellular compartment, is essential 
to develop an eligible gene delivery system.  
Zhang et al. (Zhang et al., 2002b) used a liposomal drug delivery system to bring 
therapeutic genes to the nuclear compartment of implanted cancer cells by conjugating 
two different receptor-specific monoclonal antibodies to the surface of PEG-liposomes. 
Mice were implanted with intracranial human glial brain tumors. The mAb against 
mouse transferrin receptor enabled transport across the tumor vasculature, which is of 
mouse brain origin. The mAb against human insulin receptor, which was simultaneously 
connected to the liposomes, caused transport across the plasma membrane and the 
nuclear membrane of the human brain cancer cell. This study showed that such 
sophisticated liposomal gene delivery systems can produce significant therapeutic 
effects in an experimental brain cancer model. These findings suggest linkage of OX26-
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immunoliposomes with a second antibody that controls transport within the cells. It was 
not examined in the present work and may be the objective of future projects.  
 
We can summarize that liposomal contents passed the cellular plasma membrane and 
were delivered into the cytoplasm, where the exact localization could not be defined.  
Uptake of targeted OX26-immunoliposomes in RG2 cells occurred earlier than uptake 
of biotinylated liposomes; therefore cells should not be incubated longer than 24 hours 
in order to discern specific uptake from unspecific interactions. Overcoming this firs 
barrier of the cellular membrane, delivery to the nucleus seemed to be incomplete. 
Solutions therefore may be coupling liposomes with multiple antibodies, responsible for 
mediating overcoming of the different barriers to optimize gene expression. 
 
Targeting of small molecules to tumour cells using immunoliposomes may enhance 
considerably intracellular accumulation of the transported pharmaceuticals. This 
technique is of special interest when it comes to the treatment of drug-resistant tumours 
(Mamot et al., 2003). In these cells, overexpression of drug-efflux transporters, such as 
the ABC-transporter P-glycoprotein (Eytan and Kuchel, 1999; Roninson, 1992), 
prevents cellular uptake of free drug and thus confers the multidrug resistance 
phenotype to these cells. Previous studies (Goren et al., 2000; Huwyler et al., 2002; 
Suzuki et al., 1997) have indeed demonstrated that by-passing of plasma membrane-
associated P-glycoprotein using liposomal carriers leads to an enhanced intracellular 
accumulation of the transported molecules. However, this did not necessarily translate 
to enhanced pharmacological effects (Goren et al., 2000). In a set of toxicity in vitro 
experiments, the immunoliposome-based drug delivery system was used as a more 
specific strategy in order to promote cellular uptake of liposomal cargo, tritium-labeled 
daunomycin ([3H]daunomycin). Daunomycin was therefore incorporated within 
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biotinylated OX26-immunoliposomes to induce a cytotoxic effect in RBE4 cells. These 
cells express P-glycoprotein (Begley et al., 1996) and are therefore resistant to the 
anthracycline antibiotic: the LD50 dose of 10 µM determined in the sulforhodamine B 
cytotoxicity was 20-fold higher as compared to the corresponding value in the 
chemosensitive RG2 rat glioma cell line (Figures 24 and 25). As observed earlier with 
non-biotinylated immunoliposomes (Huwyler et al., 2002), cellular uptake of 
daunomycin increased significantly (2- to 3-fold) if the drug was incorporated within 
biotinylated OX26-immunoliposomes (Figure 26). Growth inhibition of RBE4 cells was 
analyzed to show that intracellular accumulation of liposomal daunomycin was 
associated with a pharmacological effect, which was both, time- and dose-dependent 
(Figure 27). Since competitive inhibition of cellular uptake with free OX26 mAb led to a 
statistically significant reduction of cytotoxicity, we can assume that the observed 
effects were mediated by the OX26 mAb. Surprisingly, however, the pharmacological 
effect of liposomal daunomycin was lower than the one of the free drug (Figure 28). An 
explanation for this finding could be the observation, that endosomal release of drugs 
incorporated within OX26-immunoliposomes is a rather slow process. Quantitative 
determination of intracellular unloading of liposomal propidium iodide (Cerletti et al., 
2000) indicated that this fluorescent dye was released from the endosomal 
compartment to the cytoplasm with an initial rate of 4 % of total intracellular dose per 
hour only. Data from Figure 29 support this view in that an increase of the incubation 
time has a considerably higher impact on cytotoxicity of liposomal daunomycin as 
compared to the free drug. As opposed to the situation after 1 or 3 hours (Figures 27, 
28 and 29), after incubations longer than 12 hours, both formulations of daunomycin 
showed equivalent pharmacological effects. It is tempting to speculate that 
modifications of the phospholipid composition of the liposomes could be used to adjust 
the rate of intracellular release and thus the kinetics of pharmacological effects. Such a 
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strategy could be based on the principle of pH-sensitive liposomes: The endosomal 
compartment is characterized by a low pH value of 5.0 to 5.5 (Tycko et al., 1983). 
Incorporation of pH-sensitive peptides (which adopt an amphiphilic α–helical 
conformation on a mildly acidic environment) were shown to promote endosomal 
release of a liposomal cargo (Parente et al., 1988; Vogel et al., 1996). pH-sensitive 
liposomes that transform into an inverted hexagonal phase and release the liposomal 
content within shorter times have been mentioned before and will be described 
subsequently in more details (5.5. Future perspectives).  
5.3 IN VIVO ASSAYS  
 
Antibody conjugated liposomes can be used for targeting of organs and tissues in vivo. 
Previous studies have demonstrated that brain drug delivery of small molecules can be 
achieved in vivo using immunoliposomes conjugated to the OX26 mAb to the rat 
transferrin receptor (Huwyler et al., 1996; Huwyler et al., 1997). In previous 
experiments, free OX26 mAb has been shown to permeate across the blood-brain 
barrier (Bickel et al., 1994). Labeled OX26 mAb were detected after internal carotid 
artery infusion at the luminal plasma membrane of brain capillary endothelia, within 
endocytotic vesicles of 50 - 100 nm and beyond the abluminal plasma membrane. 
Studies demonstrated that immunoliposomes with a similar composition to the 
liposomes used in present work had favorable in vivo pharmacokinetic properties, e.g. 
minimal unspecific tissue binding (Huwyler et al., 1996; Huwyler et al., 1997). Tissue 
distribution of the immunoliposomes was mediated by the OX26 mAb with selective 
accumulation in brain tissue.  
The pharmacokinetics and tissue distribution of free daunomycin and different liposomal 
formulations of daunomycin were determined in the rat after intravenous injection 
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(Figure 31). Free daunomycin is rapidly removed from the circulation. The apparent 
volume of distribution (VD) as well as the systemic plasma clearance of the free drug is 
high. The clearance value of 56 ml/min/kg is close to liver blood flow in the awake rat 
(60 to 80 ml/min/kg (Davies and Morris, 1993; Kawasaki et al., 1990)). This is in sharp 
contrast to the situation where daunomycin is incorporated within biotinylated PEG-
liposomes. As expected from literature data (Lasic and Papahadjopoulos, 1995), the 
plasma clearance is very low and reduced 43-fold as compared to free daunomycin. 
Such pegylated liposomes have a very low apparent volume of distribution of 0.05 l/kg, 
which is almost identical to the plasma volume (0.032 l/kg (Davies and Morris, 1993)). 
Biotinylated PEG-liposomes were therefore used as a plasma volume marker for the 
calculation of organ PS products. Both, unspecific control immunoliposomes as well as 
OX26-immunoliposomes, have a higher plasma clearance than PEG-liposomes since 
decoration of the liposome surface with antibodies reverses partially the protective 
effect of PEG. This effect has been described for other particulate targets as well 
(Frank, 1993). It is important to note, however, that liposomes conjugated to the specific 
OX26 mAb are characterized by a higher VD and plasma clearance as compared to 
control IgG2a-immunoliposomes. Analysis of brain tissue at 1 hour after intravenous 
administration (Figure 32) revealed indeed a two-fold higher tissue accumulation (in 
terms of %ID/ g brain tissue) as well as brain permeability (PS product) of OX26-
immunoliposomes as compared to IgG2a-immunoliposomes. OX26-immunoliposomes 
showed also a higher brain accumulation than free daunomycin, this despite the fact 
that the PS product of free daunomycin is very high. The brain delivery of a given drug 
(%ID/g) can be described as the product of its PS product and its plasma AUC at a 
given time after injection (Pardridge, 1995a). Thus, brain delivery of free daunomycin is 
poor due to its rapid clearance from the circulation resulting in a short and low exposure 
of brain tissue. Note that no brain uptake is observed for PEG-liposomes, which results 
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in PS and %ID/g values of zero for this plasma volume marker. Figure 33 shows the 
advantages of OX26-immunoliposomes. The only difference between this formulation 
and OX26-immunoliposomes is the antibody and it shows effects that are not due to the 
OX26 mAb. In summary, these in vivo results obtained with biotinylated OX26-
immunoliposomes are similar to previous results from studies with OX26-
immunoliposomes prepared by covalent chemical coupling (Huwyler et al., 1996) 
indicating a low impact of the used coupling procedure. 
 
Receptor mapping studies in cynomolgous monkey using monoclonal antibodies 
against the human transferrin receptor showed that distribution of such antibodies was 
not confined to brain tissue but that a significant percentage of the injected dose did 
accumulate in other tissues expressing the transferrin receptor such as skeletal muscle 
(Friden et al., 1996). Interestingly, the over-all pattern of tissue distribution was quite 
different for the two monoclonal antibodies which were tested. This may be a 
consequence of binding of the antibodies to different structural motives on the 
transferrin receptor. These results together with our findings suggest that in vivo drug 
targeting to skeletal muscle may be achieved by targeting of the transferrin receptor; 
using the streptavidin-conjugated OX26 mAb directed against the rat transferrin 
receptor, targeting of immunoliposomes to L6 skeletal muscle cells in vitro followed by 
intracellular accumulation was achieved and published (Schnyder et al., 2004). Two 
important questions were therefore if OX26-immunoliposomes, which have a particulate 
size of 100 - 150 nm, could be used for drug targeting to the brain as well as to skeletal 
muscle in vivo.  
Besides brain tissue, skeletal muscle as well as several other tissues such as spleen, 
liver, heart and kidney were therefore analyzed (Table 3). Neither in skeletal muscle nor 
in any other of these tissues (and in sharp contrast to the brain), a superior targeting of 
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OX26-immunoliposomes as compared to IgG2a-immunoliposomes was observed. In 
these tissues, unspecific tissue interactions with antibody-conjugated liposomes 
seemed to mask effects mediated by the OX26 mAb. This can be explained by the fact 
that the brain is the only examined tissue where the OX26 antibody has been shown to 
permeate across the endothelial cell barrier of the vasculature by an active transport 
process (i.e. receptor mediated transcytosis (Pardridge et al., 1991)). Spleen and liver 
were two tissues, where immunoliposomes accumulated to a higher degree than free 
daunomycin. This could be indicative for their clearance by macrophages of the 
reticuloendothelial system. The opposite effect was observed for the kidney: this organ 
showed very high tissue permeability (PS product) for free daunomycin. This is in line 
with the observation that renal excretion of parent drug (25 % of applied dose in man) is 
a major pathway for elimination (Dollery, 1999). However, in muscle tissue, OX26-
immunoliposomes did not mediate specific tissue uptake of daunomycin. This 
observation is in agreement with previous studies in rhesus monkey (Zhang et al., 
2003c), where gene delivery using immunoliposomes directed against the human 
insulin receptor did result in a pronounced expression of the reporter gene (β-
galactosidase) in brain, liver and spleen, but not in heart or skeletal muscle. The latter 
organs are perfused by capillaries with continuous endothelium. The endothelial pore 
system of this vasculature is too small to allow for a passive passage of 100 nm 
liposomes. For targeting of muscle tissue, a second antibody would be needed to 
trigger transport across the muscle capillary endothelial wall prior to OX26-mediated 
endocytosis of the immunoliposomes by muscle cells (Schnyder et al., 2004). Such a 
concept of double antibody targeting was applied recently (Zhang et al., 2002b) to anti-
sense mRNA targeting of tumour tissue: A mouse anti-transferrin receptor antibody was 
used for transport across the tumour vasculature whereas an anti-insulin receptor 
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antibody did mediate transport across the plasma- and nuclear-membranes of the 
target cell.  
 
5.4 FUTURE PERSPECTIVES  
 
One of the most interesting and promising challenges in drug targeting by the use of 
targeted immunoliposomes is the combination with gene targeting. However, this 
potential technology is in the fledging stages and has to be elaborated and optimized 
onward until it can be administered in a large-scale way. As discussed earlier (1.6. gene 
targeting), several groups have shown very promising results of gene expression after 
incorporating expression vectors into immunoliposomes (Shi et al., 2001a; Zhang et al., 
2002a). Further, it has been shown that targeting can be obtained on two different 
stages. First, by the use of a specific targeting vector coupled to the liposome, and 
second, by incorporation of a specific promoter controlling the incorporated DNA 
plasmid (Shi et al., 2001b). We integrated a human alpha-skeletal actin gene into the 
before described pGL3 expression vector, in order to direct the expression of luciferase 
protein in muscle cells. However, this approach of gene expression of a muscle specific 
promoter containing plasmid was of limited success. Skeletal muscle cells transfected 
by lipofectamine with the modificated pGL3 plasmid did not express luciferase in a 
higher extend than glioma cells (results not shown) and no distinction between cells 
originating from muscle or from brain could be demonstrated. Nevertheless, this 
concept will be followed up sure enough, considering the growth of impact over the last 
few years of this subject and further, promising results.  
A basic knowledge about the intracellular processing of any drug delivery system 
remains to be fundamental for the development of future applications. Characterization 
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of intracellular fate, i.e. of immunoliposomes, has to be elucidated therefore in order to 
understand uptake mechanism and liposomal release. In the present work, electron 
spin resonance (ESR) technique was applied to examine intracellular fate of 
immunoliposomes in vitro. We developed a method to monitor in vitro pH-changes of 
the environment of liposomes. Two spin labels were used to be incorporated into 
liposomes or liposomal bilayer (Figure 36).  
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Figure 36: The chemical structure of spin labels. Left panel: 4-Amino-2,2,5,5,-
tetramethyl-3-imidazoline-1-yloxy, pK = 6.1 (hydrophil); Right panel: 2-Heptadecyl-
2,3,4,5,5,-pentamethylimidazolidine-1-yloxy, pK = 4.5 (lipophil). Both purchased from 
Magnettech GmBH (Berlin, FRG). 
 
 
The lipophil spin label 2-Heptadecyl-2,3,4,5,5,-pentamethylimidazolidine-1-yloxy (HP) 
(Magnettech GmbH, Berlin, FRG) possesses in addition to the spin trap (nitroxyl 
radical) a long, saturated hydrocarbon chain (heptadecyl) that can be incorporated 
within the liposomal bilayer. The other used spin label 4-Amino-2,2,5,5,-tetramethyl-3-
imidazoline-1-yloxy (AT) (Magnettech) is water soluble and was incorporated into 
liposomes by the freeze-thaw technique. The molecular structures of the spin probes 
are shown in Figure 36. Nitroxyl radicals are spin labels for electron spin resonance 
(ESR), an investigative tool for the study of radicals (spins) formed in solid and liquid 
materials. Due to charge-dipol interactions, one of the two isomeric forms of a nitroxyl 
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radical is favored in a polar environment and therefore depends also on pH (Bittner et 
al., 2001). Transitions can be induced between spin states by applying a magnetic field 
and then supplying electromagnetic energy. 
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Figure 37: ESR spectra of a freely movable spin label. 2aN (distance between the first 
and the third peak) and H-Values (intersection with baseline) can be read off from the 
spectral shape. 
 
 
The resulting absorption spectra are described as electron spin resonance (ESR) 
spectra (Figure 37). The distance between the first and the third peak in the ESR 
spectrum (2aN) is directly proportional to the spin density on the nitrogen atom of the 
nitroxyl moiety. Thus, 2aN is sensitive to the polarity of the environment of the spin 
probe and depends on pH. Moreover, the ratios between the signal amplitudes are 
indicative for the mobility of the spin probe. Spin labels in an environment where 
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mobility is high, result in an isotropic spectrum characterized by three absorption peaks 
with comparable signal amplitudes. 
 A B C 
Environment pH 7.4, H2O pH 7.4, lipid bilayer pH 4.0, lipid bilayer 
2aN 1 x 1 x ½ x 
Symmetry Yes No Medium 
 
Magnetic field (G)Magnetic field (G) Magnetic field (G)
 
 
 
 
 
 
 
Figure 38: ESR spectra and trends of values of spin labels in different environments. A: 
hydrophil spin label (4-Amino-2,2,5,5,-tetramethyl-3-imidazoline-1-yloxy) dissolved in a 
buffer where it is freely movable; B: lipophil spin label (2-Heptadecyl-2,3,4,5,5,-
pentamethylimidazolidine-1-yloxy ) incorporated in liposomal bilayer at pH 7.4; C: same 
as B at pH 5.0. 
 
 
This is shown in Figure 38 A where the hydrophil spin label AT was dissolved in an 
aqueous buffer pH 7.4, where it is freely movable. Its spectrum presents three identical, 
even peaks. When the lipophil spinlabel HT was incorporated into the bilayer 
membrane of liposomes (by its hydrocarbon chain), its free movement is limited by 
other phospholipid-, cholesterol- and PEG molecules building up the membrane of the 
liposome. Spectra of such spin labels are not symmetric any longer as shown in Figure 
38 B with pH-sensitive liposomes. These pH-sensitive liposomes were structured by 
DOPE, CHEMS and optionally PEG, as described before. Symmetry of the three peaks 
increased with lower pH, indicating more flexibility of the spin. This enhancement of 
freedom may be a consequence of formed HII phase (non-bilayer inverted hexagonal 
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phase), a liquid-crystalline phase allowing freer scope than the bilayer structure of intact 
liposomes at pH 7.4. This is illustrated only in a minor extent in Figure 38 C (primarily 
peak one and two), in the spectrum of the same spin label but at decreased pH of 5.0. 
As HII phase seems to be a highly instable state and liposomes therefore decomposed 
at slightly lower pH, more crucial adjustments of symmetry could not be measured 
anymore. Decomposition of liposomes upon pH decrease was detected by a sudden 
disappearance of the characteristic opalescence of the dispersion and a formulation of 
a fine precipitate. As a consequence of leakage, these pH studies could not be carried 
out with the hydrophil spin label AT incorporated in pH-sensitive liposomes. 
In order to examine behavior of spin labels in dependence of pH in a larger scale, the 
hydrophil spin label AT was titrated and analyzed at different pH. The spin probe was 
therefore dissolved in an appropriate aqueous buffer and ESR spectra were recorded at 
decreasing pH. The overall spectrum width 2aN (distance between first and third peak) 
from unprotonated AT (high pH) was greater than from protonated label (low pH). 2aN 
values and a simulation of a pH-titration-curve crossing the diagram points are shown in 
Figure 39.  
These results suggest that in vitro characterization of intracellular fate of 
immunoliposomes can be done by ESR monitoring to some degree. Phase transition 
from liposomal bilayer to HII phase was detected in liposomal suspension with a lipophil 
spin label. Further experiments with more stable (pH-sensitive) liposomes are required 
for same examinations with a hydrophil spin label that is incorporated into the 
liposomes. ESR is a convenient, rapid and simple method to monitor pH changes and 
drug release in vitro as well as in vivo and has been used by other groups (Bittner et al., 
2001; Mäder et al., 1998). A study was made by Foster et al. (Foster et al., 2003) of the 
in vivo detectability of a pH-sensitive spin probe, and the efficacy of ESR-based 
techniques for pH measurement in vitro and in vivo in rats. Moreover, Mäder et al. 
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(Mäder et al., 1995) monitored in vivo drug release and polymer erosion from 
biodegradable polymers by ESR spectroscopy. A special implant composed of different 
layers was thereby manufactured and the mobility of introduced nitroxides was 
monitored by ESR spectroscopy. Evaluation of spectra gave information about motion 
of spin traps towards the border of the implant.  
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Figure 39: pH dependence of hydrophil spin label AT. 2aN values (distance between 
first and third peak in ESR spectra) of spin label dissolved in aqueous buffer. Spin 
probe was monitored at decreasing pH and a sigmoid pH-titration-curve simulation was 
fitted through the data points. Data are means  SEM (n = 3) 
 
 
We incubated cells wih pH-sensitive immunoliposomes containing spin label in order to 
analyze cellular uptake. No ESR signals could be monitored in harvested cells, neither 
in supernatant medium. pH-sensitive immunoliposomes containing hydrophil spin probe 
AT could not be monitored because of leakage of this liposome formulation. Another 
reason responsible for this limited success is intracellular metabolisation of the spin 
label radical by reduction and thus loss of the ESR signal, leading to sensitivity 
problems. Considering these difficulties, we decided no to go on with ESR projects and 
 122
Discussion and future perspectives  
 
focused on other methods to examine drug delivery and drug release that are described 
earlier in the other chapters.  
The development of pH-sensitive liposomes is a possibility to enhance intracellular 
release of liposomal drug by the use of multifunctional liposomes. Such liposomal 
formulations release their contents spontaneously in an environment with a decreased 
pH. Liposomes encounter such changes in pH during the process of receptor mediated 
endocytosis as the pH in the endosomal compartment is characterized by a pH of ~5.5 
(Tycko et al., 1983). Destabilization of the liposomal membrane can be induced by 
bound amphiphilic peptides which adopt an α-helical conformation in an acidic 
environment (Vogel et al., 1996) or the use of mixtures of cationic and ionizable anionic 
lipids (Duezguenes and Nir, 1999). Such pH-sensitive liposomes are typically prepared 
from mixtures of dioleoylphosphatidylethanolamine (DOPE), which adopts a non-bilayer 
inverted hexagonal (HII) phase in isolation, and a ionizable anionic lipid such as 
cholesterolhemisuccinate (CHEMS). In its negatively charged form at elevated pH 
values, CHEMS stabilizes the DOPE in its bilayer organization. Protonation of the 
CHEMS at pH values below its pK abolishes its stabilizing effect leading to membrane 
inversion, membrane fusion and the release of entrapped substances into the liposome-
surrounding compartment (Hafez et al., 2000). This technology can be applied both to 
conventional liposomes as well as long-circulating, sterically stabilized liposomes 
(Slepushkin et al., 1997). 
 
There are other approaches to develop ‘multifunctional’ liposomes with the aim of 
optimizing liposomal design. Long circulating pegylated liposomes can be seen as a 
starting point for the design of multifunctional drug carrier systems. The properties of 
such targeted liposomes can be modulated and adopted to different needs by the 
combination of different types of vectors and enzymes bound to the liposome surface. 
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Previous reports describe the design of immuno-enzymosomes, i.e. immunoliposomes 
bearing enzymes on their surface that catalyze the conversion of prodrugs into active 
parent compounds (Vingerhoeds et al., 1993). Vingerhoeds et al. (Vingerhoeds et al., 
1996) used a β-glucuronidase bearing enzymosome drug targeting system, directed 
against ovarian carcinoma cells by F(ab‘)2 fragments of the mouse monoclonal 323/A3 
antibody. This antibody recognizes a surface glycoprotein on a variety of carcinomas.  
After binding of immuno-enzymosomes to the target cells, the prodrug is administered 
and converted into the active drug in close proximity of the tumor cell. The density of 
the enzyme is thus increased substantially at the target cell surface using such a 
liposome-based targeting strategy. This is in particular valuable for tumors with little 
antigen expression.  
 In addition to these approaches, liposomes can be decorated with two or even more 
different peptidomimetic antibodies or targeting fragments to increase liposomal 
delivery of an incorporated drug or plasmid DNA to both extracellular epitopes as well 
as intracellular compartments. For example, one vector might be responsible for brain 
tissue targeting and another for inducing cellular uptake or intracellular transport, as 
already discussed. This strategy is based on the observation that some antigens may 
be attractive targets in terms of patterns of expression, yet, they are poor at delivering 
their cargo (i.e. DNA) to the appropriate cellular (i.e. nuclear) compartment (Tan et al., 
2003).  
In another set of experiments (Tan et al., 2003), liposomes were linked to a first 
antibody to the transferrin receptor and a second antibody specific for E-selectin. 
Targeting of the transferrin receptor offers a rapid internalization of the liposomal 
complex by receptor-mediated endocytosis. Tissue selectivity of the immunoliposomes 
is thereby enhanced by the antibody against E-Selectin, which exhibits a distinct and 
endothelial-selective pattern of expression.  
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Besides this promising construction of multifunctional liposomal carrier systems, 
another future perspective is the binding of liposomes to vectors that target structures in 
human, i.e. human insulin receptor. The use of such targeting antibodies and proteins is 
a further step towards development of liposomal delivery systems for clinical 
administration. With the coupling technology described in present study, where a 
streptavidin-biotin binding is used to link antibodies to biotinylated liposomes, such 
exchange of targeting vectors is easy and rapid. We used the mouse mAb OX26 
against the rat transferrin receptor and showed the flexibility of this delivery system by 
the use of streptavidin-coupled IgG2a antibody as control. The basic tool for drug 
delivery to human cells is therefore represented, the only lacking component is an 
appropriate vector with a human target that merely has to be coupled with a streptavidin 
molecule.  
The OX26 mAb targets the transferrin receptor and we consequently studied delivery to 
tissues and organs with above-average expression of transferrin receptor, such as the 
brain. Delivery systems to other organs and tissues have also been developed. Derycke 
et al. (Derycke et al., 2004) examined whether transferrin-mediated liposomal targeting 
of a photosensitizer is an effective strategy to attain tumor-selective accumulation of 
this compound when applied intravesically in rats. Bladder transitional-cell carcinoma 
cells overexpress the transferrin receptor on their surface. They could show a specific 
targeting into carcinoma cells of transferrin-conjugated liposomes, compared to 
unconjugated liposomes and they concluded that transferrin-mediated liposomal 
targeting of photosensitizing drugs is a promising potential tool for photodynamic 
therapy of superficial bladder tumors. Additionally, selective transferrin receptor 
mediated uptake by HeLa cells was shown by the same group (Gijsens et al., 2002).  
A cooperating group in nephrology (Tuffin et al., Inselspital, Bern) used liposomes of the 
same composition as described in the present work, to target rat mesangial cells that 
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are characterized by expression of the Thy1.1 antigen. The OX7 monoclonal antibody 
directed against the Thy1.1 antigen was coupled to the liposomes by a covalent 
binding. Specific targeting of mesangial cells in kidney as well as specific 
pharmacologic effects were shown (publication in preparation).  
Closing this chapter of future perspectives and to-be uses of liposomal delivery 
systems, it must be kept in mind that there are other fields where a drug targeting is 
desirable. In addition to therapeutic applications, a possible future use of 
immunoliposomes might include their use as diagnostic tools to localize, for example, 
tumor tissue (Mamot et al., 2004) or amyloid plaques in Alzheimer’s disease (Kurihara 
and Pardridge, 2000; Lee et al., 2002), as described before.  
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6 CONCLUSIONS  
In summary, this study demonstrates that biotinylated immunoliposomes can be used to 
target incorporated drugs to target cells in vitro or in vivo. The observed 
pharmacokinetics and tissue distribution in the rat confirmed findings from previous 
studies using an alternative design of covalently conjugated immunoliposomes. in vitro, 
cellular uptake of OX26-immunoliposomes by multidrug-resistant target cells expressing 
the transferrin receptor resulted in by-passing of P-glycoprotein and thus to an 
enhanced intracellular accumulation of the cytotoxic agent daunomycin. Intracellular 
accumulation of daunomycin was mediated by the OX26 mAb and associated with a 
pharmacological effect. While the presented data demonstrates the feasibility of 
targeting using biotinylated immunoliposomes, further experimentation will be needed to 
optimize the properties of the liposomal carrier. In particular, modifications of the 
phospholipid membrane composition may be needed to accelerate intracellular release 
of the transported cargo. The target specificity of biotinylated immunolipsomes may be 
tailored to specific needs by substitution of the OX26 mAb for an alternative, 
streptavidin-conjugated targeting vector. Such modifications can be realized with ease 
using the proposed immunoliposome design and may bring the described technology to 
its full potential. 
 127
References 
  
7 REFERENCES 
Allen, T. M. (1994a). "Long-circulating (sterically stabilized) liposomes for targeted drug 
delivery." Trends Pharmacol. Sci., 15, 215-220. 
Allen, T. M. (1994b). "The Use of Glycolipids and Hydrophilic Polymers in Avoiding 
Rapid Uptake of Liposomes by the Mononuclear Phagocyte System." Advanced 
Drug Delivery Reviews, 13(3), 285-309. 
Allen, T. M., Brandeis, E., Hansen, C. B., Kao, G. Y., and Zalipsky, S. (1995). "A new 
strategy for attachment of antibodies to sterically stabilized liposomes resulting 
in efficient targeting to cancer cells." Biochim. Biophys. Acta, 1237(2), 99-108. 
Allen, T. M., and Chonn, A. (1987). "Large unilamellar liposomes with low uptake into 
the reticuloendothelial system." FEBS Lett, 223(1), 42-6. 
Allen, T. M., Mehra, T., Hansen, C., and Chin, Y. C. (1992). "Stealth liposomes: an 
improved sustained release system for 1-beta-D-arabinofuranosylcytosine." 
Cancer Res., 52(9), 2431-2439. 
Allen, T. M., Sapra, P., Moase, E., Moreira, J., and Iden, D. (2002). "Adventures in 
targeting." J. Liposome Res., 12(1-2), 5-12. 
Arnold, D. L., and Matthews, P. M. (2002). "MRI in the diagnosis and management of 
multiple sclerosis." Neurology, 58(8 Suppl 4), S23-31. 
Basanez, G., Goni, F. M., and Alonso, A. (1997). "Poly(ethylene glycol)-lipid conjugates 
inhibit phospholipase C-induced lipid hydrolysis, liposome aggregation and 
fusion through independent mechanisms." FEBS Lett, 411(2-3), 281-6. 
Begley, D. J., Lechardeur, D., Chen, Z. D., Rollinson, C., Bardoul, M., Roux, F., 
Scherman, D., and Abbott, N. J. (1996). "Functional expression of P-
glycoprotein in an immortalised cell line of rat brain endothelial cells, RBE4." J. 
Neurochem., 67(3), 988-995. 
Belting, M., Sandgren, S., and Wittrup, A. (2005). "Nuclear delivery of macromolecules: 
barriers and carriers." Adv Drug Deliv Rev, 57(4), 505-27. 
Bendas, G., Krause, A., Bakowsky, U., Vogel, J., and Rothe, U. (1999). "Targetability of 
novel immunoliposomes prepared by a new antibody conjugation technique." 
Int. J. Pharm., 181(1), 79-93. 
Bickel, U., Kang, Y. S., Yoshikawa, T., and Pardridge, W. M. (1994). "In vivo 
demonstration of subcellular localization of anti-transferrin receptor monoclonal 
antibody-colloidal gold conjugate in brain capillary endothelium." J. Histochem. 
Cytochem., 42(11), 1493-1497. 
 128
References 
  
Bickel, U., Yoshikawa, T., and Pardridge, W. M. (1993). "Delivery of peptides and 
proteins through the blood-brain barrier." Adv. Drug Deliv. Rev., 10, 205-245. 
Bittner, B., Gonzalez, R. C., Walter, I., Kapps, M., and Huwyler, J. (2003). "Impact of 
Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous 
administration to male Wistar rats." Biopharm Drug Dispos, 24(4), 173-81. 
Bittner, B., Isle, H., and Mountfield, R. J. (2001). "The use of election paramagnetic 
resonance spectroscopy in early preformulation experiments: the impact of 
different experimental formulations on the release of a lipophilic spin probe into 
gastric juice." Eur J Pharm Biopharm, 51(2), 159-162. 
Bobo, R. H., Laske, D. W., Akbasak, A., Morrison, P. F., Dedrick, R. L., and Oldfield, E. 
H. (1994). "Convection-enhanced delivery of macromolecules in the brain." 
Proc. Natl. Acad. Sci. U S A, 91(6), 2076-2080. 
Bulte, J. W., Douglas, T., Mann, S., Frankel, R. B., Moskowitz, B. M., Brooks, R. A., 
Baumgarner, C. D., Vymazal, J., Strub, M. P., and Frank, J. A. (1994). 
"Magnetoferritin: characterization of a novel superparamagnetic MR contrast 
agent." J. Magn. Reson. Imaging, 4(3), 497-505. 
Carlsson, J., Kullberg, E. B., Capala, J., Sjoberg, S., Edwards, K., and Gedda, L. 
(2003). "Ligand liposomes and boron neutron capture therapy." J. Neurooncol., 
62(1-2), 47-59. 
Cerletti, A., Drewe, J., Fricker, G., Eberle, A. N., and Huwyler, J. (2000). "Endocytosis 
and transcytosis of an immunoliposome-based brain drug delivery system." J. 
Drug Targeting, 8(6), 435-447. 
Cullis, P. R., and de Kruijff, B. (1978). "The polymorphic phase behaviour of 
phosphatidylethanolamines of natural and synthetic origin. A 31P NMR study." 
Biochim Biophys Acta, 513(1), 31-42. 
Davies, B., and Morris, T. (1993). "Physiological parameters in laboratory animals and 
humans." Pharm Res, 10(7), 1093-5. 
Derycke, A. S., Kamuhabwa, A., Gijsens, A., Roskams, T., De Vos, D., Kasran, A., 
Huwyler, J., Missiaen, L., and de Witte, P. A. (2004). "Transferrin-conjugated 
liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells." J 
Natl Cancer Inst, 96(21), 1620-30. 
Dollery, C. (1999). "Daunorubicin (hydrochloride)." In Dollery, C. (ed). Therapeutic 
drugs (London: Churchill Livingstone), pp. D18-D23. 
Duezguenes, N., and Nir, S. (1999). "Mechanisms and kinetics of liposome-cell 
interactions." Adv. Drug Deliv. Rev., 40(1-2), 3-18. 
Dufresne, I., Desormeaux, A., Bestman-Smith, J., Gourde, P., Tremblay, M. J., and 
Bergeron, M. G. (1999). "Targeting lymph nodes with liposomes bearing anti-
HLA-DR Fab' fragments." Biochim Biophys Acta, 1421(2), 284-94. 
 129
References 
  
Dunnick, J. K., McDougall, I. R., Aragon, S., Goris, M. L., and Kriss, J. P. (1975). 
"Vesicle interactions with polyamino acids and antibody: in vitro and in vivo 
studies." J Nucl Med, 16(6), 483-7. 
Emanuel, N., Kedar, E., Bolotin, E. M., Smorodinsky, N. I., and Barenholz, Y. (1996). 
"Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: 
pharmacokinetics and biodistribution in tumor-bearing mice." Pharm. Res., 
13(6), 861-868. 
Eytan, G. D., and Kuchel, P. W. (1999). "Mechanism of action of P-glycoprotein in 
relation to passive membrane permeation." Int. Rev. Cytol., 190, 175-250. 
Fava, R. A., Comeau, R. D., and Woodworth, R. C. (1981). "Specific membrane 
receptors for diferric-transferrin in cultured rat skeletal myocytes and chick-
embryo cardiac myocytes." Biosci. Rep., 1(5), 377-385. 
Foster, M. A., Grigor'ev, I. A., Lurie, D. J., Khramtsov, V. V., McCallum, S., Panagiotelis, 
I., Hutchison, J. M., Koptioug, A., and Nicholson, I. (2003). "In vivo detection of a 
pH-sensitive nitroxide in the rat stomach by low-field ESR-based techniques." 
Magn Reson Med, 49(3), 558-67. 
Frank, M. M. (1993). "The reticuloendothelial system and bloodstream clearance." J. 
Lab. Clin. Med., 122, 487-488. 
Friden, P. M., Olson, T. S., Obar, R., Walus, L. R., and Putney, S. D. (1996). 
"Characterization, receptor mapping and blood-brain barrier transcytosis of 
antibodies to the human transferrin receptor." J. Pharmacol. Exp. Ther., 278(3), 
1491-1498. 
Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., 
Huang, A., and Barenholz, Y. (1994). "Prolonged circulation time and enhanced 
accumulation in malignant exudates of doxorubicin encapsulated in 
polyethylene-glycol coated liposomes." Cancer Res, 54(4), 987-92. 
Gabizon, A., and Papahadjopoulos, D. (1988). "Liposome formulations with prolonged 
circulation time in blood and enhanced uptake by tumors." Proc. Natl. Acad. Sci. 
U S A, 85(18), 6949-6953. 
Gabizon, A., Shmeeda, H., and Barenholz, Y. (2003). "Pharmacokinetics of pegylated 
liposomal Doxorubicin: review of animal and human studies." Clin. 
Pharmacokinet., 42(5), 419-436. 
Gabizon, A. A. (2001). "Pegylated liposomal doxorubicin: metamorphosis of an old drug 
into a new form of chemotherapy." Cancer Invest., 19(4), 424-436. 
Gagne, J. F., Desormeaux, A., Perron, S., Tremblay, M. J., and Bergeron, M. G. (2002). 
"Targeted delivery of indinavir to HIV-1 primary reservoirs with 
immunoliposomes." Biochim. Biophys. Acta., 1558(2), 198-210. 
 130
References 
  
Gijsens, A., Derycke, A., Missiaen, L., De Vos, D., Huwyler, J., Eberle, A., and de Witte, 
P. (2002). "Targeting of the photocytotoxic compound AlPcS4 to Hela cells by 
transferrin conjugated PEG-liposomes." Int J Cancer, 101(1), 78-85. 
Goren, D., Horowitz, A. T., Tzemach, D., Tarshish, M., Zalipsky, S., and Gabizon, A. 
(2000). "Nuclear delivery of doxorubicin via folate-targeted liposomes with 
bypass of multidrug-resistance efflux pump." Clin. Cancer Res., 6(5), 1949-
1957. 
Gulati, M., Bajad, S., Singh, S., Ferdous, A. J., and Singh, M. (1998). "Development of 
liposomal amphotericin B formulation." J. Microencapsul., 15(2), 137-151. 
Hafez, I. M., Ansell, S., and Cullis, P. R. (2000). "Tunable pH-sensitive liposomes 
composed of mixtures of cationic and anionic lipids." Biophys. J., 79(3), 1438-
1446. 
Hafez, I. M., and Cullis, P. R. (2000). "Cholesteryl hemisuccinate exhibits pH sensitive 
polymorphic phase behavior." Biochim Biophys Acta, 1463(1), 107-14. 
Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S., and Allen, T. M. (1995). 
"Attachment of antibodies to sterically stabilized liposomes: evaluation, 
comparison and optimization of coupling procedures." Biochim Biophys Acta, 
1239(2), 133-44. 
Heath, T. D., Fraley, R. T., and Papahadjopoulos, D. (1980). "Antibody targeting of 
liposomes: cell specificity obtained by conjugation of F(ab')2 to vesicle surface." 
Science, 210, 539-541. 
Heath, T. D., Montgomery, J. A., Piper, J. R., and Papahadjopoulos, D. (1983). 
"Antibody-targeted liposomes: increase in specific toxicity of methotrexate-
gamma-aspartate." Proc Natl Acad Sci U S A, 80(5), 1377-81. 
Hermanson, G. T. (1996). Bioconjugate techniques, Academic Press, San Diego. 
Herrlinger, U., Kramm, C. M., Aboody-Guterman, K. S., Silver, J. S., Ikeda, K., 
Johnston, K. M., Pechan, P. A., Barth, R. F., Finkelstein, D., Chiocca, E. A., 
Louis, D. N., and Breakefield, X. O. (1998). "Pre-existing herpes simplex virus 1 
(HSV-1) immunity decreases, but does not abolish, gene transfer to 
experimental brain tumors by a HSV-1 vector." Gene Ther., 5(6), 809-819. 
Hosokawa, S., Tagawa, T., Niki, H., Hirakawa, Y., Nohga, K., and Nagaike, K. (2003). 
"Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-
density-dependent manner." Br. J. Cancer, 89(8), 1545-51. 
Huwyler, J., Cerletti, A., Fricker, G., Eberle, A. N., and Drewe, J. (2002). "By-passing of 
P-glycoprotein using immunoliposomes." J. Drug Targeting, 10(1), 73-79. 
Huwyler, J., Froidevaux, S., Roux, F., and Eberle, A. N. (1999). "Characterization of 
transferrin receptor in an immortalized cell line of rat brain endothelial cells, 
RBE4." J. Recept. Signal Transduct. Res., 19, 729-739. 
 131
References 
  
Huwyler, J., Wu, D., and Pardridge, W. M. (1996). "Brain drug delivery of small 
molecules using immunoliposomes." Proc Natl Acad Sci U S A, 93(24), 14164-9. 
Huwyler, J., Yang, J., and Pardridge, W. M. (1997). "Receptor mediated delivery of 
daunomycin using immunoliposomes: pharmacokinetics and tissue distribution 
in the rat." J. Pharmacol. Exp. Ther., 282(3), 1541-1546. 
Hwang, S. H., Maitani, Y., Qi, X. R., Takayama, K., and Nagai, T. (1999). "Remote 
loading of diclofenac, insulin and fluorescein isothiocyanate labeled insulin into 
liposomes by pH and acetate gradient methods." Int J Pharm, 179(1), 85-95. 
Hyde, R., Peyrollier, K., and Hundal, H. S. (2002). "Insulin promotes the cell surface 
recruitment of the SAT2/ATA2 system A amino acid transporter from an 
endosomal compartment in skeletal muscle cells." J Biol Chem, 277(16), 13628-
34. 
Iden, D. L., and Allen, T. M. (2001). "In vitro and in vivo comparison of 
immunoliposomes made by conventional coupling techniques with those made 
by a new post-insertion approach." Biochim Biophys Acta, 1513(2), 207-16. 
Jefferies, W. A., Brandon, M. R., Williams, A. F., and Hunt, S. V. (1985). "Analysis of 
lymphopoietic stem cells with a monoclonal antibody to the rat transferrin 
receptor." Immunology, 54(2), 333-341. 
Kaasgaard, T., Mouritsen, O. G., and Jorgensen, K. (2001). "Screening effect of PEG 
on avidin binding to liposome surface receptors." Int. J. Pharm., 214(1-2), 63-65. 
Kajiwara, K., Byrnes, A. P., Ohmoto, Y., Charlton, H. M., Wood, M. J., and Wood, K. J. 
(2000). "Humoral immune responses to adenovirus vectors in the brain." J. 
Neuroimmunol., 103(1), 8-15. 
Kang, Y. S., and Pardridge, W. M. (1994). "Use of neutral avidin improves 
pharmacokinetics and brain delivery of biotin bound to an avidin-monoclonal 
antibody conjugate." J. Pharmacol. Exp. Ther., 269(1), 344-350. 
Kawasaki, T., Carmichael, F. J., Saldivia, V., Roldan, L., and Orrego, H. (1990). 
"Relationship between portal venous and hepatic arterial blood flows: spectrum 
of response." Am J Physiol, 259(6 Pt 1), G1010-8. 
Kirpotin, D., Hong, K., Mullah, N., Papahadjopoulos, D., and Zalipsky, S. (1996). 
"Liposomes with detachable polymer coating: destabilization and fusion of 
dioleoylphosphatidylethanolamine vesicles triggered by cleavage of surface-
grafted poly(ethylene glycol)." FEBS Lett, 388(2-3), 115-8. 
Kirpotin, D., Park, J. W., Hong, K., Zalipsky, S., Li, W. L., Carter, P., Benz, C. C., and 
Papahadjopoulos, D. (1997). "Sterically stabilized anti-HER2 immunoliposomes: 
design and targeting to human breast cancer cells in vitro." Biochemistry, 36(1), 
66-75. 
Klibanov, A. L., Maruyama, K., Beckerleg, A. M., Torchilin, V. P., and Huang, L. (1991). 
"Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time 
 132
References 
  
of liposomes depends on the liposome size and is unfavorable for 
immunoliposome binding to target." Biochim. Biophys. Acta, 1062(2), 142-148. 
Kung, V. T., Vollmer, Y. P., and Martin, F. J. (1986). "Large liposome agglutination 
technique for the serological detection of syphilis." J Immunol Methods, 90(2), 
189-96. 
Kurihara, A., and Pardridge, W. M. (2000). "Abeta(1-40) peptide radiopharmaceuticals 
for brain amyloid imaging: (111)In chelation, conjugation to poly(ethylene 
glycol)-biotin linkers, and autoradiography with Alzheimer's disease brain 
sections." Bioconjug Chem, 11(3), 380-6. 
Laemmli, U. K. (1970). "Cleavage of structural proteins during the assembly of the head 
of bacteriophage T4." Nature, 227(5259), 680-5. 
Lai, M. Z., Vail, W. J., and Szoka, F. C. (1985). "Acid- and calcium-induced structural 
changes in phosphatidylethanolamine membranes stabilized by cholesteryl 
hemisuccinate." Biochemistry, 24(7), 1654-61. 
Lasic, D. D. (1996). "Doxorubicin in sterically stabilized liposomes." Nature, 380, 561-
562. 
Lasic, D. D., Ceh, B., Stuart, M. C. A., Guo, L., Frederik, P. M., and Barenholz, Y. 
(1995). "Transmembrane gradient driven phase transitions within vesicles: 
lessons for drug delivery." Biochimica et Biophysica Acta, 1239, 145-156. 
Lasic, D. D., and Papahadjopoulos, D. (1995). "Liposomes revisited." Science, 
267(5202), 1275-1276. 
Laverman, P., Zalipsky, S., Oyen, W. J., Dams, E. T., Storm, G., Mullah, N., Corstens, 
F. H., and Boerman, O. C. (2000). "Improved imaging of infections by avidin-
induced clearance of 99mTc- biotin-PEG liposomes." J. Nucl. Med., 41(5), 912-
918. 
Lee, H. J., Zhang, Y., Zhu, C., Duff, K., and Pardridge, W. M. (2002). "Imaging brain 
amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide 
radiopharmaceutical." J Cereb Blood Flow Metab, 22(2), 223-31. 
Lee, R. J., and Low, P. S. (1994). "Delivery of liposomes into cultured KB cells via folate 
receptor-mediated endocytosis." J. Biol. Chem., 269, 3198-3204. 
Leserman, L. D., Machy, P., and Barbet, J. (1981). "Cell-specific drug transfer from 
liposomes bearing monoclonal antibodies." Nature, 293(5829), 226-8. 
Li, J. Y., Sugimura, K., Boado, R. J., Lee, H. J., Zhang, C., Duebel, S., and Pardridge, 
W. M. (1999). "Genetically engineered brain drug delivery vectors: cloning, 
expression and in vivo application of an anti-transferrin receptor single chain 
antibody-streptavidin fusion gene and protein." Protein Eng., 12(9), 787-796. 
 133
References 
  
Liu, Y., Mounkes, L. C., Liggitt, H. D., Brown, C. S., Solodin, I., Heath, T. D., and Debs, 
R. J. (1997). "Factors influencing the efficiency of cationic liposome-mediated 
intravenous gene delivery." Nat. Biotechnol., 15(2), 167-173. 
Mäder, K., Bacic, G., Domb, A., Elmalak, O., Langer, R., and Swartz, H. M. (1995). 
"Noninvasive in vivo monitoring of drug release and polymer erosion from 
biodegradable polymers by EPR spectroscopy and NMR imaging." J Pharm Sci, 
86(1), 126-134. 
Mäder, K., Bittner, B., Li, Y., Wohlauf, W., and Kissel, T. (1998). "Monitoring 
microviscosity and microacidity of the albumin microenvironment inside 
degrading microparticles from poly(lactide-co-glycolide) (PLG) or ABA-triblock 
polymers containing hydrophobic poly(lactide-co-glycolide) A blocks and 
hydrophilic poly(ethyleneoxide) B blocks." Pharm Res, 15(5), 787-793. 
Mamot, C., Drummond, D. C., Hong, K., Kirpotin, D. B., and Park, J. W. (2003). 
"Liposome-based approaches to overcome anticancer drug resistance." Drug 
Resist Updat, 6(5), 271-9. 
Mamot, C., Nguyen, J. B., Pourdehnad, M., Hadaczek, P., Saito, R., Bringas, J. R., 
Drummond, D. C., Hong, K., Kirpotin, D. B., McKnight, T., Berger, M. S., Park, J. 
W., and Bankiewicz, K. S. (2004). "Extensive distribution of liposomes in rodent 
brains and brain tumors following convection-enhanced delivery." J. 
Neurooncol., 68(1), 1-9. 
Mandel, J. L., and Pearson, M. L. (1974). "Insulin stimulates myogenesis in a rat 
myoblast line." Nature, 251(5476), 618-620. 
Martin, F. J., and Papahadjopoulos, D. (1982). "Irreversible coupling of immunoglobulin 
fragments to preformed vesicles. An improved method for liposome targeting." J. 
Biol. Chem., 257(1), 286-288. 
Maruyama, K., Holmberg, E., Kennel, S. J., Klibanov, A., Torchilin, V. P., and Huang, L. 
(1990a). "Characterization of in vivo immunoliposome targeting to pulmonary 
endothelium." J Pharm Sci, 79(11), 978-84. 
Maruyama, K., Kennel, S. J., and Huang, L. (1990b). "Lipid composition is important for 
highly efficient target binding and retention of immunoliposomes." Proc Natl 
Acad Sci U S A, 87(15), 5744-8. 
Maruyama, K., Takizawa, T., Yuda, T., Kennel, S. J., Huang, L., and Iwatsuru, M. 
(1995). "Targetability of novel immunoliposomes modified with amphipathic 
poly(ethylene glycol)s conjugated at their distal terminals to monoclonal 
antibodies." Biochim. Biophys. Acta, 1234(1), 74-80. 
Matsumura, Y., Gotoh, M., Muro, K., Yamada, Y., Shirao, K., Shimada, Y., Okuwa, M., 
Matsumoto, S., Miyata, Y., Ohkura, H., Chin, K., Baba, S., Yamao, T., Kannami, 
A., Takamatsu, Y., Ito, K., and Takahashi, K. (2004). "Phase I and 
pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG 
immunoliposome, in patients with metastatic stomach cancer." Ann Oncol, 
15(3), 517-25. 
 134
References 
  
Mayer, L. D., Bally, M. B., and Cullis, P. R. (1986). "Uptake of adriamycin into large 
unilamellar vesicles in response to a pH gradient." Biochim Biophys Acta, 
857(1), 123-6. 
Mayhew, E. G., Lasic, D., Babbar, S., and Martin, F. J. (1992). "Pharmacokinetics and 
antitumor activity of epirubicin encapsulated in long-circulating liposomes 
incorporating a polyethylene glycol- derivatized phospholipid." Int. J. Cancer, 
51(2), 302-309. 
Moghimi, S. M., and Patel, H. M. (1992). "Opsonophagocytosis of liposomes by 
peritoneal macrophages and bone marrow reticuloendothelial cells." Biochim. 
Biophys. Acta, 1135(3), 269-274. 
Moradpour, D., Compagnon, B., Wilson, B. E., Nicolau, C., and Wands, J. R. (1995). 
"Specific targeting of human hepatocellular carcinoma cells by 
immunoliposomes in vitro." Hepatology, 22(5), 1527-1537. 
Mori, A., Klibanov, A. L., Torchilin, V. P., and Huang, L. (1991). "Influence of the steric 
barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the 
circulation time of liposomes and on the target binding of immunoliposomes in 
vivo." Febs Lett, 284(2), 263-6. 
Morrison, S. L., and Shin, S. U. (1995). "Genetically engineered antibodies and their 
application to brain delivery." Adv. Drug Delivery Rev., 15(1-3), 147-175. 
Nakano, S., Matsukado, K., and Black, K. L. (1996). "Increased brain tumor microvessel 
permeability after intracarotid bradykinin infusion is mediated by nitric oxide." 
Cancer Res., 56, 4027-4031. 
Nassander, U. K., Steerenberg, P. A., Poppe, H., Storm, G., Poels, L. G., De, J. W., 
and Crommelin, D. J. (1992). "In vivo targeting of OV-TL 3 immunoliposomes to 
ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice." Cancer Res., 
52(3), 646-653. 
New, R. (1990). "Preparation of liposomes in Liposomes: A Practical Approach." The 
practical approach series, D. Rickwood and B. D. Hames, eds., Oxford 
University Press, Oxford, 301. 
O'Connell, J. P., Campbell, R. L., Fleming, B. M., Mercolino, T. J., Johnson, M. D., and 
McLaurin, D. A. (1985). "A highly sensitive immunoassay system involving 
antibody-coated tubes and liposome-entrapped dye." Clin Chem, 31(9), 1424-6. 
Osaka, G., Carey, K., Cuthbertson, A., Godowski, P., Patapoff, T., Ryan, A., Gadek, T., 
and Mordenti, J. (1996). "Pharmacokinetics, tissue distribution, and expression 
efficiency of plasmid [33P]DNA following intravenous administration of 
DNA/cationic lipid complexes in mice: use of a novel radionuclide approach." J. 
Pharm. Sci., 85(6), 612-618. 
Ozawa, E. (1989). "Transferrin as a muscle trophic factor." Rev. Physiol. Biochem. 
Pharmacol., 113, 89-141. 
 135
References 
  
Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., 
Lee, K. D., Woodle, M. C., Lasic, D. D., Redemann, C., and Martin, F. J. (1991). 
"Sterically stabilized liposomes: improvements in pharmacokinetics and 
antitumor therapeutic efficacy." Proc. Natl. Acad. Sci. USA, 88(24), 11460-
11464. 
Pardridge, W. M. (1993). "Brain drug delivery and blood-brain barrier transport." Drug 
Delivery, 1, 83-101. 
Pardridge, W. M. (1995a). "Transport of small molecules through the blood-brain 
barrier: biology and methodology." Adv. Drug Delivery Rev., 15, 5-36. 
Pardridge, W. M. (1995b). "Vector-mediated peptide drug delivery to the brain." Adv. 
Drug Delivery Rev., 15, 109-146. 
Pardridge, W. M., Buciak, J. L., and Friden, P. M. (1991). "Selective transport of an anti-
transferrin receptor antibody through the blood-brain barrier." J. Pharmacol. Exp. 
Ther., 259, 66-70. 
Pardridge, W. M., Eisenberg, J., and Yang, J. (1987). "Human blood-brain barrier 
transferrin receptor." Metabolism, 36, 892-895. 
Parente, R. A., Nir, S., and Szoka, F. C., Jr. (1988). "pH-dependent fusion of 
phosphatidylcholine small vesicles. Induction by a synthetic amphipathic 
peptide." J Biol Chem, 263(10), 4724-30. 
Ponka, P., and Lok, C. N. (1999). "The transferrin receptor: role in health and disease." 
Int. J. Biochem. Cell Biol., 31(10), 1111-1137. 
Radler, J. O., Koltover, I., Salditt, T., and Safinya, C. R. (1997). "Structure of DNA-
cationic liposome complexes: DNA intercalation in multilamellar membranes in 
distinct interhelical packing regimes." Science, 275(5301), 810-814. 
Richardson, D. R., and Ponka, P. (1997). "The molecular mechanisms of the 
metabolism and transport of iron in normal and neoplastic cells." Biochim 
Biophys Acta, 1331(1), 1-40. 
Roninson, I. B. (1992). "The role of the MDR1 (P-glycoprotein) gene in multidrug 
resistance in vitro and in vivo." Biochem. Pharmacol., 43(1), 95-102. 
Saito, R., Bringas, J. R., McKnight, T. R., Wendland, M. F., Mamot, C., Drummond, D. 
C., Kirpotin, D. B., Park, J. W., Berger, M. S., and Bankiewicz, K. S. (2004). 
"Distribution of liposomes into brain and rat brain tumor models by convection-
enhanced delivery monitored with magnetic resonance imaging." Cancer Res., 
64(7), 2572-2579. 
Schnyder, A., Krahenbuhl, S., Torok, M., Drewe, J., and Huwyler, J. (2004). "Targeting 
of skeletal muscle in vitro using biotinylated immunoliposomes." Biochem J, 
377(Pt 1), 61-7. 
 136
References 
  
Shahinian, S., and Silvius, J. R. (1995). "A novel strategy affords high-yield coupling of 
antibody Fab' fragments to liposomes." Biochim. Biophys. Acta, 1239(2), 157-
167. 
Shek, P. N., and Heath, T. D. (1983). "Immune response mediated by liposome-
associated protein antigens. III. Immunogenicity of bovine serum albumin 
covalently coupled to vesicle surface." Immunology, 50(1), 101-6. 
Shi, N., Boado, R. J., and Pardridge, W. M. (2001a). "Receptor-mediated gene targeting 
to tissues in vivo following intravenous administration of pegylated 
immunoliposomes." Pharm Res, 18(8), 1091-5. 
Shi, N., and Pardridge, W. M. (2000). "Noninvasive gene targeting to the brain." Proc 
Natl Acad Sci U S A, 97(13), 7567-7572. 
Shi, N., Zhang, Y., Zhu, C., Boado, R. J., and Pardridge, W. M. (2001b). "Brain-specific 
expression of an exogenous gene after i.v. administration." Proc Natl Acad Sci U 
S A, 98(22), 12754-9. 
Simoes, S., Moreira, J. N., Fonseca, C., Duzgunes, N., and de Lima, M. C. (2004). "On 
the formulation of pH-sensitive liposomes with long circulation times." Adv Drug 
Deliv Rev, 56(7), 947-65. 
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. 
T., Bokesch, H., Kenney, S., and Boyd, M. R. (1990). "New colorimetric 
cytotoxicity assay for anticancer-drug screening." J Natl Cancer Inst, 82(13), 
1107-12. 
Slepushkin, V. A., Simoes, S., Dazin, P., Newman, M. S., Guo, L. S., Pedroso, d. L. M., 
and Duzgunes, N. (1997). "Sterically stabilized pH-sensitive liposomes. 
Intracellular delivery of aqueous contents and prolonged circulation in vivo." J. 
Biol. Chem., 272(4), 2382-2388. 
Sorokin, L. M., Morgan, E. H., and Yeoh, G. C. (1987). "Transferrin receptor numbers 
and transferrin and iron uptake in cultured chick muscle cells at different stages 
of development." J. Cell Physiol., 131(3), 342-353. 
Stevens, P. J., and Lee, R. J. (2003). "Formulation kit for liposomal doxorubicin 
composed of lyophilized liposomes." Anticancer Res, 23(1A), 439-42. 
Storm, G., and Crommelin, D. J. A. (1998). "Liposomes: quo vadis?" Pharmaceutical 
Science & Technology Today, 1, 19-31. 
Suzuki, S., Inoue, K., Hongoh, A., Hashimoto, Y., and Yamazoe, Y. (1997). "Modulation 
of doxorubicin resistance in a doxorubicin-resistant human leukaemia cell by an 
immunoliposome targeting transferring receptor." Br. J. Cancer, 76(1), 83-89. 
Suzuki, S., Uno, S., Fukuda, Y., Aoki, Y., Masuko, T., and Hashimoto, Y. (1995a). 
"Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on 
human cancer cells." Br. J. Cancer, 72(3), 663-668. 
 137
References 
  
Suzuki, S., Watanabe, S., Masuko, T., and Hashimoto, Y. (1995b). "Preparation of long-
circulating immunoliposomes containing adriamycin by a novel method to coat 
immunoliposomes with poly(ethylene glycol)." Biochim. Biophys. Acta, 1245(1), 
9-16. 
Tan, P. H., Manunta, M., Ardjomand, N., Xue, S. A., Larkin, D. F., Haskard, D. O., 
Taylor, K. M., and George, A. J. (2003). "Antibody targeted gene transfer to 
endothelium." J Gene Med, 5(4), 311-23. 
Torchilin, V. P., Goldmacher, V. S., and Smirnov, V. N. (1978). "Comparative studies on 
covalent and noncovalent immobilization of protein molecules on the surface of 
liposomes." Biochem Biophys Res Commun, 85(3), 983-90. 
Torchilin, V. P., Klibanov, A. L., Huang, L., O'Donnell, S., Nossiff, N. D., and Khaw, B. 
A. (1992). "Targeted accumulation of polyethylene glycol-coated 
immunoliposomes in infarcted rabbit myocardium." Faseb J, 6(9), 2716-9. 
Torchilin, V. P., and Weissig, V. (2003). Liposomes, Oxford University Press, New York. 
Triguero, D., Buciak, J., and Pardridge, W. M. (1990). "Capillary depletion method for 
quantification of blood-brain barrier transport of circulating peptides and plasma 
proteins." J. Neurochem., 54(6), 1882-1888. 
Tycko, B., DiPaola, M., Yamashiro, D. J., Fluss, S., and Maxfield, F. R. (1983). 
"Acidification of endocytic vesicles and the intracellular pathways of ligands and 
receptors." Ann. N Y Acad. Sci., 421, 424-433. 
Uster, P. S., Allen, T. M., Daniel, B. E., Mendez, C. J., Newman, M. S., and Zhu, G. Z. 
(1996). "Insertion of poly(ethylene glycol) derivatized phospholipid into pre-
formed liposomes results in prolonged in vivo circulation time." FEBS Lett, 
386(2-3), 243-6. 
Vingerhoeds, M. H., Haisma, H. J., Belliot, S. O., Smit, R., Crommelin, D., and Storm, 
G. (1996). "Immunoliposomes as enzyme-carriers (immuno-enzymosomes) for 
antibody-directed enzyme prodrug therapy (adept) - optimization of prodrug 
activating capacity." Pharm. Res., 13(4), 604-610. 
Vingerhoeds, M. H., Haisma, H. J., van, M. M., van, de, Rijt, Rb, Crommelin, D. J., and 
Storm, G. (1993). "A new application for liposomes in cancer therapy. 
Immunoliposomes bearing enzymes (immuno-enzymosomes) for site-specific 
activation of prodrugs." FEBS Letters, 336(3), 485-490. 
Vogel, K., Wang, S., Lee, R. J., Chmielewski, J., and Low, P. S. (1996). "Peptide-
mediated release of folate-targeted liposome contents from endosomal 
compartments." J. Am. Chem. Soc., 118, 1581-1586. 
Wang, S., and Low, P. S. (1998). "Folate-mediated targeting of antineoplastic drugs, 
imaging agents, and nucleic acids to cancer cells." J. Control. Release, 53(1-3), 
39-48. 
 138
References 
  
Wong, J. Y., Kuhl, T. L., Israelachvili, J. N., Mullah, N., and Zalipsky, S. (1997). "Direct 
measurement of a tethered ligand-receptor interaction potential." Science, 
275(5301), 820-822. 
Woodle, M. C., Matthay, K. K., Newman, M. S., Hidayat, J. E., Collins, L. R., 
Redemann, C., Martin, F. J., and Papahadjopoulos, D. (1992). "Versatility in lipid 
compositions showing prolonged circulation with sterically stabilized liposomes." 
Biochim. Biophys. Acta, 1105, 193-200. 
Wu, D., Yang, J., and Pardridge, W. M. (1997). "Drug targeting of a peptide 
radiopharmaceutical through the primate blood-brain barrier in vivo with a 
monoclonal antibody to the human insulin receptor." J Clin Invest, 100(7), 1804-
12. 
Xu, L., Huang, C. C., Huang, W., Tang, W. H., Rait, A., Yin, Y. Z., Cruz, I., Xiang, L. M., 
Pirollo, K. F., and Chang, E. H. (2002). "Systemic tumor-targeted gene delivery 
by anti-transferrin receptor scFv-immunoliposomes." Mol Cancer Ther, 1(5), 
337-46. 
Yoshikawa, T., and Pardridge, W. M. (1992). "Biotin delivery to brain with a covalent 
conjugate of avidin and a monoclonal antibody to the transferrin receptor." J. 
Pharmacol. Exp. Ther., 263(2), 897-903. 
Zelphati, O., Zon, G., and Leserman, L. (1993). "Inhibition of HIV-1 replication in 
cultured cells with antisense oligonucleotides encapsulated in 
immunoliposomes." Antisense Res Dev, 3(4), 323-38. 
Zhang, Y., Calon, F., Zhu, C., Boado, R. J., and Pardridge, W. M. (2003a). "Intravenous 
nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and 
reversal of motor impairment in experimental parkinsonism." Hum. Gene Ther., 
14(1), 1-12. 
Zhang, Y., Jeong Lee, H., Boado, R. J., and Pardridge, W. M. (2002a). "Receptor-
mediated delivery of an antisense gene to human brain cancer cells." J Gene 
Med, 4(2), 183-94. 
Zhang, Y., Schlachetzki, F., and Pardridge, W. M. (2003b). "Global non-viral gene 
transfer to the primate brain following intravenous administration." Mol. Ther., 
7(1), 11-18. 
Zhang, Y., Schlachetzki, F., and Pardridge, W. M. (2003c). "Global non-viral gene 
transfer to the primate brain following intravenous administration." Mol Ther, 
7(1), 11-8. 
Zhang, Y., Zhang, Y. F., Bryant, J., Charles, A., Boado, R. J., and Pardridge, W. M. 
(2004). "Intravenous RNA interference gene therapy targeting the human 
epidermal growth factor receptor prolongs survival in intracranial brain cancer." 
Clin. Cancer Res., 10(11), 3667-3677. 
Zhang, Y., Zhu, C., and Pardridge, W. M. (2002b). "Antisense gene therapy of brain 
cancer with an artificial virus gene delivery system." Mol. Ther., 6(1), 67-72. 
 139
Curriculum Vitae  
8 CURRICULUM VITAE 
PERSONAL DATA 
Name:    Anita Schnyder 
Date and place of birth: Solothurn, 25.4.1976 
Nationality:   Swiss 
Marital status:   Single 
Present address:   Nidwaldnerstrasse 47 
    CH-4055 Basel 
EDUCATION 
10/1996-11/2001 University of Basel, Basel, CH 
Master degree in Pharmacy and approbation as Eidg. 
Dipl. Apothekerin 
08/1991-01/1996 Grammar school at Kantonsschule Solothurn, 
examination certificate type C 
PROFESSIONAL TRAINING AND EXPERIENCE 
01/2002-present F. Hoffmann–La Roche Basel, Pharma Research, in 
collaboration with University of Basel, Division of clinical 
pharmacology and toxicology, Basel, CH PhD Student in 
clinical pharmacology under the supervision of Prof. Dr. 
Stephan Krähenbühl, Prof. Dr. Jürgen Drewe and PD Dr. 
Jörg Huwyler  
 140
Curriculum Vitae  
02/2001-07/2001 University of Basel, Departement Forschung, 
Kantonsspital of Basel, CH 
Diploma thesis: “Synchronisation des Zellzyklus von 
Mammakarzinomzellkulturen”  
Mentor: PD Dr. Heinz Müller 
10/1998-10/1999   University of Lausanne and Pharmacie de Chailly, 
Lausanne, CH  
One-year internship to fulfill diploma requirements, 
included three-month-trainee at Hôpital de Samaritain in 
Vevey, CH 
10/1999-present Regular substitutions in different pharmacies in Solothurn, 
Nidau, La Chaux-de-Fonds, Ebnat-Kappel  
SCIENTIFIC PUBLICATIONS, PATENT AND AWARD 
03/2005   Review Article:     
Schnyder, A. and Huwyler, J. (2005): Targeting of 
daunomycin using biotinylated immunoliposomes: 
Pharmacokinetics, tissue distribution and in vitro 
pharmacological effects. (submitted) 
01/2005   Review Article:     
Schnyder, A. and Huwyler, J. (2005): Drug Transport to 
Brain with Targeted Liposomes. NeuroRx 2, 99-107 
01/2004   Paper:     
Schnyder, A., Krähenbühl, S., Török, M., Drewe, J. and 
Huwyler, J. (2004): Targeting of skeletal muscle in vitro 
 141
Curriculum Vitae  
using biotinylated immunoliposomes. Biochem. J. 377, 
61-67 
01/2004 Amedis Award 2003 received for the publication in 
Biochemical Journal (2004, 377: 61-67)  
11/2003   US-Patent:       
A non-covalent coupling method for the preparation of 
pegylated immunoliposomes. Huwyler J. and Schnyder A. 
Patent pending (case No. S-22306) 
ATTENDED CONGRESSES / SYMPOSIA 
BBB 2003 5. Blut-Hirn Schranke Expertentreffen Bad Herrenalb, Germany, 26. – 28. 
May 2003 
BBB 2004 6. Blut-Hirn Schranke Expertentreffen Bad Herrenalb, Germany, 17. – 19. 
May 2003 
Pharma-Day 2004, Center of Pharmaceutical Sciences Basel – Zürich, Switzerland, 5. 
February 2004 (with presentation: Amedis lecture: Drug targeting using 
immunoliposomes)  
Certificate “Key Issues in Drug Discovery and Development”, 7-Day-Graduate-Course, 
Center of Pharmaceutical Sciences Basel-Zürich, CH, November 2004 
LANGUAGE SKILLS 
German   native speaker 
French    fluently spoken and written  
English   fluently spoken and written 
Spanish   basic skills (Spanish language courses) 
 142
